Trial number,Protocol code,Title of the trial,Overall trial status,Location(s) and recruitment status,Age group,Age range secondary identifier,Gender,Number of participants enrolled,Trial region,Medical conditions,Therapeutic area,Trial phase,Product,Primary endpoint,Secondary endpoints,Decision date,Start date,End date,Global end of the trial,Trial results,Sponsor/Co-Sponsors,Sponsor type,Last updated
2024-513193-22-00,N/A,"Efficacy, safety and cost-effectiveness of B cell tailored ocrelizumab versus standard ocrelizumab in relapsing remitting multiple sclerosis (BLOOMS):
a randomized controlled trial","Ongoing, recruiting","Netherlands:Ongoing, recruiting","18-64 years, 65+ years",N/A,"Female, Male",296,EEA only,Multiple Sclerosis,"[""Diseases [C] - Nervous System Diseases [C10]""]",Phase III and phase IV (Integrated),Ocrevus 300 mg concentrate for solution for infusion,The two co-primary end points are the difference of percentage of  confirmed relapse-free patients between the two treatment groups after  96 weeks follow-up and the difference of percentage of patients without  new/enlarging T2 MRI lesions between the two treatment groups after  96 weeks follow-up.,N/A,17/09/2024,16/03/2022,N/A,N/A,No,Amsterdam UMC Stichting,Hospital/Clinic/Other health care facility,17/09/2024
2025-521127-73-00,TG1101-RMS-SC301,"A Phase 3, Non-Inferiority, Randomized, Open-Label, Parallel Group, Multicenter Study To Evaluate The Pharmacokinetics, Pharmacodynamics, Safety, Radiological and Clinical Effects Of Subcutaneous Ublituximab Versus Intravenous Ublituximab In Patients With Multiple Sclerosis","Authorised, recruiting","Croatia:Authorised, recruiting, Bulgaria:Authorised, recruitment pending, Czechia:Authorised, recruitment pending, Hungary:Authorised, recruiting",18-64 years,N/A,"Female, Male",84,In both EEA and non-EEA,Relapsing forms of Multiple Sclerosis,"[""Diseases [C] - Nervous System Diseases [C10]""]",Therapeutic confirmatory  (Phase III),"Ublituximab, ublituximab",Commercially confidential information,"Proportion of participants with CD19+ B- cell (please ref to the protocol for the full information), Incidence of treatment emergent adverse events (TEAE)",19/08/2025,12/09/2025,N/A,N/A,No,Tg Therapeutics Inc.,Pharmaceutical company,21/08/2025
2023-505624-56-00,105MS306,"An Open Label, Randomized, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 in Pediatric Subjects Aged 10 to Less than 18 Years for the Treatment of Relapsing Remitting Multiple Sclerosis, with Optional Open-Label Extension (105MS306)","Ongoing, recruitment ended","Slovakia:Ongoing, recruitment ended, Bulgaria:Ongoing, recruitment ended, Hungary:Ongoing, recruitment ended, Croatia:Ongoing, recruitment ended, Czechia:Ended",0-17 years,"6-11 years, 12-17 years","Female, Male",29,In both EEA and non-EEA,Relapsing Remitting Multiple Sclerosis (RRMS),"[""Diseases [C] - Nervous System Diseases [C10]""]",Therapeutic confirmatory  (Phase III),"Plegridy 125 micrograms solution for injection in pre-filled pen, AVONEX 30 micrograms/0.5ml solution for injection in pre-filled pen., Plegridy 63 micrograms+94 micrograms solution for injection in pre-filled pen, AVONEX 30 micrograms/0.5 ml solution for injection.","Part 1: the annualized relapse rate (ARR) at Week 48., Part 2: Percentage of Participants with Adverse Events (AEs), Serious Adverse Events (SAEs) and AEs leading to Study Treatment Discontinuation. [From Week 96 to week 196]","[Part I] ARR at week 48, [Part I]  Percentage of Participants Free of New or Newly Enlarging T2 Hyperintense Lesions on Brain Magnetic Resonance Imaging (MRI) Scans at Weeks 24, 48, and 96, [Part I] Percentage of Participants Free of New MRI Activity in the Brain (Free of Gadolinium [Gd]-Enhancing Lesions and New or Newly Enlarging T2 Hyperintense Lesions) at Weeks 24, 48, and 96, [Part I] Number of New or Newly Enlarging T2 Hyperintense Lesions on Brain MRI Scans at Weeks 24, 48, and 96, [Part I] Number of Gd-Enhancing Lesions on Brain MRI Scans at Weeks 24, 48, and 96, [Part I] Time to First Relapse (timeframe: Up to week 96)., [Part I] Percentage of Participants Free of Relapse at Weeks 48 and 96., [Part I] Change from Baseline in Cognition at Weeks 24, 48, 72, and 96 as Measured by the Symbol Digit Modality Test (SDMT), [Part I] Change from Baseline in the Expanded Disability Status Scale (EDSS) Score at Weeks 48 and 96, [Part I]  Change from Baseline in the Quality of Life as Measured by the Pediatric Quality of Life Inventory (PedsQL) at Weeks 24, 48, 72 and 96, [Part I] Area Under the Plasma Concentration-Time Curve from Time Zero to End of Dosing Interval (AUCtau) for BIIB017.  [Time Frame: Within 8 hours postdose on Day 1 of Week 1; Within 8 hours, 48 and 120 hours postdose on Day 1 of Week 4; Within 8 hours postdose on Day 1 of Week 24], [Part I] Part 1: Maximum Observed Plasma Concentration (Cmax) at Steady State for BIIB017 Within 8 hours postdose on Day 1 of Week 1; Within 8 hours, 48 and 120 hours postdose on Day 1 of Week 4; Within 8 hours postdose on Day 1 of Week 24, [Part I] Time to Reach Maximum Observed Plasma Concentration (Tmax) at Steady State for BIIB017 Within 8 hours postdose on Day 1 of Week 1; Within 8 hours, 48 and 120 hours postdose on Day 1 of Week 4; Within 8 hours postdose on Day 1 of Week 24, [Part I] Percentage of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), and AEs Leading to Study Treatment Discontinuation (timeframe up to week 100), [Part I] Change from Baseline in Height at Weeks 24, 48, 72, 96, and 100, [Part I] Change from Baseline in Weight at Weeks 24, 48, 72, 96, and 100, [Part I] Number of Participants With Binding and Neutralizing Antibodies to Interferon Beta Type 1a (IFN β-1a) [All Participants] [Time Frame: Up to Week 96], [Part I] Number of Participants With Binding Antibodies to Peginterferon (PEG) [BIIB017-Treated Participants] Anti-PEG binding antibodies in human serum will be determined using an ELISA (Timeframe: Up to Week 96), [Part I] Change from Baseline in Depression as Assessed by Mini International Neuropsychiatric Interview for Children and Adolescents (MINI-KID) at Weeks 12, 24, 36, 48, 60, 72, 84, 96, and 100, [Part I] Change from Baseline in Blood Pressure at Weeks 4, 8, 12, 24, 36, 48, 60, 72, 84, 96, and 10, [Part I] Change from Baseline in Pulse Rate at Weeks 4, 8, 12, 24, 36, 48, 60, 72, 84, 96, and 100, [Part I] Change from Baseline in Body Temperature at Weeks 4, 8, 12, 24, 36, 48, 60, 72, 84, 96, and 100, [Part I] Change from Baseline in Respiratory Rate at Weeks 4, 8, 12, 24, 36, 48, 60, 72, 84, 96, and 100, [Part I] Change from Baseline in 12-Lead Electrocardiogram (ECG) Parameters at Weeks 48, 96, and 100, [Part I] Percentage of Participants with Changes Over Time in Clinical Laboratory Values at Baseline & Weeks 4, 8, 12, 24, 36, 48, 60, 72, 84, 96, and 100, Part 2: ARR at Weeks 144 and 192, Part 2: Change from Baseline in EDSS Score at Weeks 120, 144, 168, 192, and 196, Part 2: Change from Baseline in Height at Weeks 120, 144, 168, 192, and 196, Part 2: Change from Baseline in Weight at Weeks 120, 144, 168, 192, and 196, Part 2: Change from Baseline in Tanner Score at Weeks 120, 144, 168, 192, and 196, Part 2: Number of Participants With Binding and Neutralizing Antibodies to IFN β-1a (All Participants) (Time Frame: Up to week 192), Part 2: Number of Participants With Binding Antibodies to PEG (BIIB017-Treated Participants) (Time Frame: Up to week 192), Part 2: Change from Baseline in Blood Pressure at Weeks 120,144,168, 192, and 196, Part 2: Change from Baseline in Pulse Rate at Weeks 120, 144, 168, 192, and 196, Part 2: Change from Baseline in Body Temperature at Weeks 120, 144, 168, 192, and 196, Part 2: Change from Baseline in Respiratory Rate at Weeks 120, 144, 168, 192, and 196, Part 2: Change from Baseline in 12-Lead ECG Parameters at Weeks 144, 192, and 196, Part 2: Change from Baseline in Depression as Assessed by Mini International Neuropsychiatric Interview for Children and Adolescents (MINI-KID) at Weeks 108, 120, 132, 144,156, 168, 180, 192, and 196, Part 2: Percentage of Participants with Changes Over Time in Clinical Laboratory Values at Baseline & (Week 96), Weeks 108, 120, 132, 144, 156, 168, 180, 192, and 196",04/11/2024,07/08/2019,N/A,N/A,No,Biogen Idec Research Limited,Pharmaceutical company,11/09/2025
2023-506543-41-00,MN39158,"A Single Arm, Open Label Multicentre Extension Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Patients with Multiple Sclerosis Previously Enrolled in A F. Hoffmann-La Roche Sponsored Ocrelizumab Phase IIIb/IV Clinical Trial",Ended,"Hungary:Ended, Norway:Ended, Croatia:Ended, Denmark:Ended, Slovakia:Ended, Belgium:Ended, Netherlands:Ended, Sweden:Ended, Italy:Ended, Portugal:Ended, Slovenia:Ended, France:Ended, Poland:Ended, Bulgaria:Ended",18-64 years,N/A,"Female, Male",645,In both EEA and non-EEA,Multiple sclerosis (MS),"[""Diseases [C] - Nervous System Diseases [C10]""]",Therapeutic confirmatory  (Phase III),"Methylprednisolone 500 mg powder and solvent for solution for injection/infusion, Ocrevus 300 mg concentrate for solution for infusion, Paracetamol Accord 1000 mg comprimate efervescente, Ocrevus 300 mg concentrate for solution for infusion, Diphenhydramine Hydrochloride Tablets 50 mg",1. Evaluate clinical measures related to disease progression over the duration of treatment in MS patients,"1. Related to disability progression: Time to onset of Confirmed disability progression (CDP) sustained for at least 24 weeks and for at least 48 weeks, 2. Related to disability progression: Proportion of patients who have confirmed disability improvement (CDI), CDP for at least 24 weeks and for at least 48 weeks yearly and over the duration of treatment, 3. Related to disability progression: Proportion of patients who have improved, stable or worsened disability compared with baseline (inclusion in the study) measured by expanded disability status scale (EDSS), 4. Related to disability progression: Mean change from inclusion in the parent study in EDSS score over the course of treatment, 5. Related to disability progression: Time to 20% increase in timed 25-foot walk test (T25FWT); time to 20% increase in timed nine-hole peg test (9HPT) sustained for at least 24 weeks and for at least 48 weeks, and proportion of patients achieving a sustained increase assessed yearly and over the duration of treatment, 6. Other clinical measures and composite endpoints: Time to first protocol-defined event of disease activity, 7. Other clinical measures and composite endpoints: Time to first relapse, 8. Other clinical measures and composite endpoints: Annualized relapse rate, 9. Other clinical measures and composite endpoints: Proportion of patient relapse free, yearly and over the course of treatment, 10. Other clinical measures and composite endpoints: Proportion of patients with no evidence of protocol-defined disease activity (NEDA) yearly and over the duration of the treatment, 11. Other clinical measures and composite endpoints: Proportion of patients with no evidence of progression, measured by EDSS, 9HPT and T25FW (if assessments are available), 12. Other clinical measures and composite endpoints: Proportion of patients with no evidence of progression sustained for at least 24 weeks and no active disease (if assessments are available), 13. Other clinical measures and composite endpoints: Change from baseline (parent trial) in cognitive performance as measured by the Symbol digit modalities test (SDMT), 14. Related to MRI: Total number of T1 Gd-enhancing lesions as detected by brain MRI over time, 15. Related to MRI: Total number of new and/or enlarging T2 lesion as detected by brain MRI over time, 16. Related to MRI: Change in total T1 hypointense lesion volume over time, 17. Related to MRI: Total number of fluid-attenuated inversion-recovery (FLAIR) late enhancing lesions as detected by brain MRI over time (pertinent to CASTING/MA30005 patients only), 18. Related to MRI: Total number of FLAIR late enhancing lesions as detected by brain MRI at the end of the treatment period, 19. Related to MRI: Change in brain volume (including white and grey matter fractions) as detected by brain MRI over time, 20. Related to MRI: Presence and evolution of leptomeningeal follicles (pertinent to ENSEMBLE/MA30143 patients with identified FLAIR late enhancing lesions and CASTING /MA30005 patients), 21. Other measures related to MS disease:Time to treatment discontinuation/switch, 22. Patient reported outcomes (PROs):Employment status (Work Productivity and Activity Impairment Questionnaire [WPAI]), 23. Patient reported outcomes (PROs):SymptoMScreen score, 24. Patient reported outcomes (PROs):Quality of life (Multiple Sclerosis Impact Scale [MSIS]-29), 25. Rate and nature of adverse events, 26. Changes in vital signs, neurological examinations, clinical laboratory results, locally reviewed MRI for safety (non-MS CNS pathology) and concomitant medications",15/12/2023,25/07/2018,22/04/2025,17/07/2025,No,F. Hoffmann-La Roche AG,Pharmaceutical company,16/06/2025
2022-502609-14-00,GN41851,"A PHASE III MULTICENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB COMPARED WITH TERIFLUNOMIDE IN ADULT PATIENTS WITH RELAPSING MULTIPLE SCLEROSIS","Ongoing, recruitment ended","Finland:Ongoing, recruitment ended, Portugal:Ongoing, recruitment ended, Hungary:Ongoing, recruitment ended, Italy:Ongoing, recruitment ended, Poland:Ongoing, recruitment ended, Germany:Ongoing, recruitment ended, Spain:Ongoing, recruitment ended",18-64 years,N/A,"Female, Male",214,In both EEA and non-EEA,Relapsing multiple sclerosis (RMS),"[""Diseases [C] - Nervous System Diseases [C10]""]",Therapeutic confirmatory  (Phase III),"Fenebrutinib Placebo, Fenebrutinib, AUBAGIO 14 mg film-coated tablets, Fenebrutinib, Aubagio Placebo",1.Annualized relapse rate,"1. Time to onset of cCDP12, 2. Time to onset of CDP12, 3. Time to onset of cCDP24, 4. Time to onset of CDP24, 5. Total number of gadolinium-enhancing lesions on T1-weighted MRI lesions as detected by MRI, 6. Total number of new and/or enlarging T2-weighted lesions as detected by MRI, 7. Rate of percent change in total brain volume from Week 24 as assessed by MRI, 8. Rate of change from baseline in patient-reported physical impacts of MS, as measured by the Multiple Sclerosis Impact Scale (29-Item), Version 2 (MSIS-29 v2) physical scale, 9. Time to onset of 12-week confirmed 4-point worsening in SDMT score, 10. Change from baseline to Week 48 in the concentration of serum neurofilament light chain (NfL), 11. The nature, frequency, timing, and severity of adverse events; serious adverse events; and adverse events leading to study treatment discontinuation or dose interruptions, 12. Change from baseline in targeted vital signs, 13. Change from baseline in targeted ECG parameters, 14. Change from baseline in clinical laboratory results, 15. Proportion of patients with suicidal ideation or behavior, 16. Plasma concentration of fenebrutinib at specified timepoints",18/07/2024,09/12/2020,N/A,N/A,No,F. Hoffmann-La Roche AG,Pharmaceutical company,26/05/2025
2023-506516-40-00,WN42086,"A Phase III Multicenter, Randomized, Double-Blind, Double-Dummy Study to Evaluate Safety and Efficacy of Ocrelizumab in Comparison with Fingolimod in Children and Adolescents with Relapsing-Remitting Multiple Sclerosis","Ongoing, recruitment ended","Belgium:Ongoing, recruitment ended, Romania:Ongoing, recruitment ended, Poland:Ongoing, recruitment ended, Portugal:Ongoing, recruitment ended, Netherlands:Ended, Denmark:Ended, Estonia:Ongoing, recruitment ended, Austria:Ongoing, recruitment ended, Croatia:Ended, Hungary:Ongoing, recruitment ended, Italy:Ongoing, recruitment ended, France:Ongoing, recruitment ended, Greece:Ongoing, recruitment ended, Bulgaria:Ended, Spain:Ongoing, recruitment ended, Latvia:Ongoing, recruitment ended, Germany:Ongoing, recruitment ended",0-17 years,N/A,"Female, Male",94,In both EEA and non-EEA,Relapsing-Remitting Multiple Sclerosis,"[""Diseases [C] - Nervous System Diseases [C10]""]",Therapeutic confirmatory  (Phase III),"Ocrevus 300 mg concentrate for solution for infusion, Reisetabletten AL
Dimenhydrinat 50 mg pro Tablette, Gilenya 0.5 mg hard capsules, Gilenya 0.25 mg hard capsules, Placebo for FINGOLIMOD, Gilenya 0.25 mg hard capsules, Placebo for Ocrelizumab, Gilenya 0.25 mg hard capsules, Methylprednisolon acis 1000 mg Pulver und Lösungsmittel zur Herstellung einer Injektions- bzw. Infusionslösung, Methylprednisolon acis 250 mg Pulver und Lösungsmittel zur Herstellung einer Injektions- bzw. Infusionslösung",1. Protocol-defined annualized relapse rate (ARR) (non-inferiority),"1. Number of new or enlarging T2 lesions as detected by brain MRI during the double-blind period, 2. Number of T1 gadolinium (Gd) lesions at Week 12, 3. Protocol-defined ARR during the double-blind period (superiority), 4. Incidence and severity of adverse events, with severity determined according to National Cancer Institute Common Terminology Criteria for Adverse Events, Version 5.0 (NCI CTCAE v5.0), 5. Change from baseline in targeted vital signs and clinical significant abnormalities in electrocardiogram (ECG) parameters, 6. Change from baseline in targeted clinical laboratory test results, 7. Concentrations of ocrelizumab at indicated time points, 8. Levels of CD19 B-cell count in blood, 9. Prevalence of anti-drug antibodies (ADAs) against ocrelizumab at baseline, 10. Incidence of ADAs against ocrelizumab during the study",07/02/2024,11/02/2022,N/A,N/A,No,F. Hoffmann-La Roche AG,Pharmaceutical company,11/06/2025
2024-517601-82-00,M-2024-424,MB-CART2019.1 in refractory MS,"Authorised, recruitment pending","Germany:Authorised, recruitment pending","65+ years, 18-64 years",N/A,"Female, Male",25,EEA only,refractory Multiple Sclerosis,"[""Diseases [C] - Nervous System Diseases [C10]""]",Phase I and Phase II (Integrated)- Other,N/A,N/A,N/A,30/06/2025,N/A,N/A,N/A,No,Miltenyi Biomedicine GmbH,Pharmaceutical company,30/06/2025
2023-503190-38-00,MACSiMiSE-BRAIN_v1.0,Metformin add-on clinical study in multiple sclerosis to evaluate brain remyelination and neurodegeneration: a phase IIb triple-blind placebo-controlled randomized clinical trial (MACSiMiSE-BRAIN),"Ongoing, recruitment ended","Belgium:Ongoing, recruitment ended","65+ years, 18-64 years",N/A,"Female, Male",120,EEA only,Progressive Multiple Sclerosis,"[""Diseases [C] - Nervous System Diseases [C10]""]",Therapeutic exploratory (Phase II),"AVONEX 30 micrograms/0.5 ml solution for injection., Tecfidera 240 mg gastro-resistant hard capsules, Glatiramyl 40 mg/ml, oplossing voor injectie in een voorgevulde spuit, Zeposia 0.92 mg hard capsules, Glatiramyl 20 mg/ml oplossing voor injectie in een voorgevulde spuit, Mayzent 2 mg film-coated tablets, The placebo will be manufactured based on the Metformin Hydrochloride 850 mg (Metformin STADA® 850 mg) specifications to match the characteristics (appearance, size) of the IMP, without containing the active ingredient (see IMPD)., Ponvory 20 mg film-coated tablets, Rebif 22 micrograms solution for injection in pre-filled syringe, Gilenya 0.5 mg hard capsules, Kesimpta 20 mg solution for injection in pre-filled syringe, Mayzent 1 mg film-coated tablets, Copaxone 40 mg/ml oplossing voor injectie in een voorgevulde spuit., Plegridy 125 micrograms solution for injection in pre-filled syringe, Betaferon 250 microgram/ml, powder and solvent for solution for injection, Copaxone 20 mg/ml oplossing voor injectie in een voorgevulde spuit., TYSABRI 300 mg concentrate for solution for infusion, Ocrevus 300 mg concentrate for solution for infusion, Metformin STADA® 850 mg Filmtabletten, AUBAGIO 14 mg film-coated tablets","Change in walking speed, measured by T25FW, between baseline and 96 weeks of treatment.","Change in Expanded Disability Status Scale (EDSS) between baseline and after 96 weeks of treatment., Change in cognitive function as measured by Symbol Digit Modalities Test (SDMT) between baseline and 96 weeks of treatment., Change in hand function as measured by Nine-Hole Peg Test (9HPT) between baseline and 96 weeks of treatment., Change in the Compisite endpoint as measured by Overall Disability Response Score (ODRS) between baseline and 96 weeks of treatment., Change in 2 minute walk test between baseline and 96 weeks of treatment., Change in brain volume (whole brain volume and gray matter volume) as measured by MRI from baseline to 48 weeks, from baseline to 96 weeks and from 48 to 96 weeks., Change in brain MRI-DTI metrics (fractional anisotropy (FA), mean diffusivity (MD) and radial diffusivity (RD)) from baseline to 48 weeks, from baseline to 96 weeks and from 48 to 96 weeks, Change in quality of life as measured by EQ-5D-5L between baseline and 96 weeks of treatment., Change in quality of life as measured by Multiple Sclerosis Impact Scale-29 between baseline and 96 weeks of treatment., Change in number of SWI lesions from baseline to 48 weeks, from baseline to 96 weeks and from 48 to 96 weeks., Change in Modified Caregiver strain index (MCSI) from baseline to 96 weeks., Average total costs between baseline and 96 weeks of treatment and incremental cost-effectiveness ratio",24/04/2023,23/11/2023,N/A,N/A,No,Antwerp University Hospital,Hospital/Clinic/Other health care facility,26/08/2025
2025-521754-41-00,P1-IMU838–DDI-CYP2C8,"A Phase 1, Single-Center, Open-Label, Fixed-Sequence, 2-Part Adaptive Design Study to Assess the Pharmacokinetics of IMU-838 Administered Alone and in Combination with Multiple Doses of Gemfibrozil as CYP2C8 Inhibitor, or Rifampicin as CYP2C8 Inducer, in Healthy Subjects","Ongoing, recruiting","Netherlands:Ongoing, recruiting",18-64 years,N/A,"Female, Male",24,EEA only,Multiple sclerosis,"[""Diseases [C] - Nervous System Diseases [C10]""]",Human Pharmacology (Phase I)-  Other,N/A,N/A,N/A,10/07/2025,15/08/2025,N/A,N/A,No,Immunic AG,Pharmaceutical company,10/07/2025
2023-509357-31-00,BP42230,"A Study to Investigate the Safety, Tolerability, Immunogenicity, Pharmacokinetics, and Pharmacodynamics of RO7121932 following Intravenous and Subcutaneous Administration in Participants with Multiple Sclerosis","Ongoing, recruiting","Germany:Ongoing, recruiting, Poland:Ongoing, recruiting, Romania:Ongoing, recruiting, Portugal:Ongoing, recruiting, Italy:Ongoing, recruiting, Belgium:Ongoing, recruiting, Spain:Authorised, recruitment pending","65+ years, 18-64 years",65-84 years,"Female, Male",47,In both EEA and non-EEA,Multiple Sclerosis (MS),"[""Diseases [C] - Nervous System Diseases [C10]""]",Human Pharmacology (Phase I)- First administration to humans,N/A,N/A,N/A,15/03/2024,01/06/2021,N/A,N/A,No,F. Hoffmann-La Roche AG,Pharmaceutical company,18/08/2025
2024-510630-40-00,N/A,"Randomized Autologous heMatopoietic stem cell transplantation versus alemtuzumab,  cladribine or ocrelizumab
for patients with relapsing remitting Multiple Sclerosis (RAM-MS)","Ongoing, recruitment ended","Netherlands:Ongoing, recruitment ended, Norway:Ongoing, recruitment ended, Sweden:Ongoing, recruitment ended, Denmark:Ongoing, recruitment ended",18-64 years,N/A,"Female, Male",100,EEA only,Multiple sclerosis,"[""Diseases [C] - Immune System Diseases [C20]"",""Diseases [C] - Nervous System Diseases [C10]""]",Therapeutic confirmatory  (Phase III),"MAVENCLAD 10 mg tablets, Thymoglobuline 25 mg powder for solution for infusion, Sendoxan 1000 mg pulver til injeksjonsvæske, oppløsning, Ocrevus 300 mg concentrate for solution for infusion, LEMTRADA 12 mg concentrate for solution for infusion","The primary efficacy endpoint of this prospective, randomized study is to determine differences between patients in the 2 treatment arms according to the following criteria: Proportion of patients with no evidence of disease activity after a 2 year (96 week) and 5 year (240 week) period. NEDA is the absence of a protocol defined disease activity event.","Proportion of patients with no evidence of disease activity, including atrophy (NEDA 4), as per protocol defined disease activity events (as defined in section 2.2) plus atrophy (measured yearly atrophy above threshold of 0, 4 %) during a 2 year (96 week) and a 5 year (240 week)  period4, with re-baseline for brain athrophy at 48 weeks., Time to first protocol-defined disease activity event as defined in section 2.2, Change in EQ-5D-5L from baseline to Week 96, and from baseline to Week 240, Change in Fatigue Severity Scale (FSS) from baseline to Week 96, and from baseline to Week 240, Change in Multiple Sclerosis Impact Scale (MSIS)-29  from baseline to Week 96, and from baseline to Week 240, Change in EDSS from baseline (Visit 4.1) to Week 96 , and from baseline to Week 240, The proportion of patients who, at Week 96 and at Week 240, have protocol-defined Confirmed Disability Improvement (CDI) , confirmed stable EDSS or Confirmed Disability Progression (CDP) compared to baseline, Annualized rate of protocol-defined relapses during 96 weeks and 240 weeks from start of study treatment, Time to onset of first protocol-defined relapse from start of study treatment, Change in MRI T2-weighted hyperintense lesion volume from baseline to Weeks 48 and 96, and from baseline to Week 144, 192 and 240, Change in MRI T1-weighted hypointense lesion volume from baseline to Weeks 48 and 96, and from baseline to Week 144, 192 and 240, Change in brain volume from re-baseline at week 48, to week 96, from re-baseline at week 48, to Week 144, 192 and 240, Time to detection of a new MRI T2 lesion, Total number of MRI T1-weighted Gd-enhanced lesions at weeks 24, 48, 96, 144, 192 and 240, Proportion of patients free from T1 Gd-enhancing lesions at weeks 24, 48, 96, 144, 192 and 240, Change in Nine-hole-peg test (9-HPT) score from baseline to week 48, 96 and 240, Change in Timed 25 foot walk (T25FW) score from baseline to week 48, 96 and 240, Change in The Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS) score from  baseline to week 96 and 240, Overall survival rate at week 96 and 240, Work productivity and activity impairment at week 96, 144, 192 and 240",06/06/2024,12/02/2018,N/A,N/A,No,Helse Bergen HF,Hospital/Clinic/Other health care facility,12/06/2024
2023-509275-17-00,CLOU064C12306,"A randomized, open-label, parallel-group, non-inferiority study comparing efficacy, safety, and tolerability of remibrutinib after switching from ocrelizumab in participants living with relapsing multiple sclerosis, followed by open-label treatment with remibrutinib","Authorised, recruitment pending","Portugal:Authorised, recruitment pending, France:Authorised, recruitment pending, Italy:Authorised, recruitment pending, Belgium:Authorised, recruitment pending, Greece:Authorised, recruitment pending, Slovakia:Authorised, recruitment pending, Denmark:Authorised, recruitment pending, Spain:Authorised, recruitment pending","65+ years, 18-64 years",65-84 years,"Female, Male",158,In both EEA and non-EEA,Relapsing multiple sclerosis,"[""Diseases [C] - Nervous System Diseases [C10]""]",Therapeutic confirmatory  (Phase III),"LOU064, OCRELIZUMAB, OCRELIZUMAB",Annualized rate of new or enlarging T2 lesions (AR-NELT2) on MRI at Month 24 (relative to baseline MRI scan).,"Percentage of participants with no evidence of disease activity-3 (NEDA-3), as assessed by absence of confirmed MS relapses, 6-month confirmed disability progression (6mCDP) and new/enlarging T2 lesions on MRI between baseline and Month 24., Adverse events, laboratory data, vital signs, electrocardiograms (ECGs), (Commercially confidential information)., Extension Part: Adverse events, laboratory data, vital signs, electrocardiogram (ECG), (Commercially confidential information)., Extension Part:  - Annualized rate of new or enlarging T2 lesions on MRI  - Percentage of participants with NEDA-3.",01/08/2025,N/A,N/A,N/A,No,Novartis Pharma AG,Pharmaceutical company,20/08/2025
2022-502611-10-00,GN41791,"A Phase III Multicenter, Randomized, Double-Blind, Double-Dummy, Parallel-Group Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared with Ocrelizumab in Adult Patients with Primary Progressive Multiple Sclerosis","Ongoing, recruitment ended","Portugal:Ongoing, recruitment ended, Greece:Ongoing, recruitment ended, Poland:Ongoing, recruitment ended, France:Ongoing, recruitment ended, Bulgaria:Ongoing, recruitment ended, Italy:Ongoing, recruitment ended, Hungary:Ongoing, recruitment ended, Austria:Ongoing, recruitment ended, Denmark:Ongoing, recruitment ended, Germany:Ongoing, recruitment ended, Spain:Ongoing, recruitment ended","18-64 years, 65+ years",65-84 years,"Female, Male",297,In both EEA and non-EEA,Primary Progressive Multiple Sclerosis (PPMS),"[""Diseases [C] - Nervous System Diseases [C10]""]",Therapeutic confirmatory  (Phase III),N/A,1. Time to onset of composite 12-week confirmed disability progression (cCDP12),"1. Time to onset of composite 24 week CDP (cCDP24), 2. Time to onset of 12-week CDP (CDP12), 3. Time to onset of 24 week CDP (CDP24), 4. Percent change in total brain volume from Week 24 as assessed by MRI scan, 5. Percent change from screening to Week 120 in serum neurofilament light chain (NfL) levels, 6. Change patient-reported physical impacts of MS (as measured by Multiple Sclerosis Impact Scale, 29-Item [MSIS-29] physical scale), 7. Time to onset of 12 week confirmed 4 point worsening in Symbol Digit Modality Test (SDMT) score, 8. The nature, frequency, timing, and severity of adverse events; serious adverse events; and adverse events leading to study treatment withdrawal, 9. Change from baseline in targeted vital signs, 10. Change from baseline in targeted ECG parameters, 11. Change from baseline in clinical laboratory results following study treatment administration, 12. Change from baseline in the proportion of patients with suicidal ideation or behavior, as assessed by Columbia Suicide Severity Rating Scale (C-SSRS), 13. Plasma concentration of fenebrutinib at specified timepoints",21/08/2024,24/11/2020,N/A,N/A,No,F. Hoffmann-La Roche AG,Pharmaceutical company,20/06/2025
2023-504358-36-00,EFC17919A,"Randomized, double-blind, Phase 3 study comparing efficacy and safety of frexalimab (SAR441344) to teriflunomide in adult participants with relapsing forms of multiple sclerosis","Authorised, recruiting","Poland:Ongoing, recruiting, Belgium:Authorised, recruitment pending, Czechia:Ongoing, recruiting, Lithuania:Ended, Slovakia:Ongoing, recruiting, Austria:Authorised, recruitment pending, Bulgaria:Ongoing, recruiting, Germany:Ongoing, recruiting, Hungary:Ongoing, recruiting, Italy:Ongoing, recruiting, Croatia:Ended, Greece:Authorised, recruitment pending, Romania:Authorised, recruitment pending, Netherlands:Authorised, recruitment pending, France:Ended, Spain:Ongoing, recruiting, Denmark:Ended, Portugal:Ongoing, recruiting",18-64 years,N/A,"Female, Male",430,In both EEA and non-EEA,multiple sclerosis,"[""Diseases [C] - Nervous System Diseases [C10]""]",Therapeutic confirmatory  (Phase III),"Frexalimab, Paramagnetic contrast media, Matched placebo for comparator teriflunomide, AUBAGIO 14 mg film-coated tablets, AUBAGIO 14 mg film-coated tablets, Matched placebo for test product Frexalimab, COLESTYRAMINE, AUBAGIO 14 mg film-coated tablets, AUBAGIO 14 mg film-coated tablets, -, AUBAGIO 14 mg film-coated tablets",Annualized relapse rate (ARR) during the study period assessed by protocol defined adjudicated relapses,"Time to onset of composite confirmed disability worsening (cCDW), Time to onset of cCDW, confirmed over 3 months, Time to onset of individual components of the composite, confirmed over 3-months or 6- months, Time to onset of confirmed disability improvement (CDI), Progression independent of relapse activity defined as the time to onset of 6-month cCDW, Total number of new and/or enlarging T2-hyperintense lesions as detected by MRI, Total number of new Gd-enhancing T1-hyperintense lesions per scan as detected by MRI, Percent change in brain volume loss as detected by brain MRI scans at the EOS compared to Month 6, Change in cognitive function at the EOS compared to baseline as assessed by the symbol digit modalities test (SDMT), Change from baseline in multiple sclerosis impact scale 29 version 2 (MSIS-29v2) questionnaire scores over time, Change from baseline in patient reported outcome measurement information system (PROMIS) Fatigue MS-8 over time, Adverse events, SAEs, AEs leading to permanent study intervention discontinuation, AESIs, safety scales, and potentially clinically significant abnormality (PCSAs) in laboratory tests, ECG, and vital signs during the study period, Antidrug antibodies (ADAs) over time, Change from baseline in plasma neurofilament light chain (NfL) levels over time, Frexalimab plasma concentration over time",26/04/2024,17/10/2024,N/A,N/A,No,Sanofi-Aventis Recherche & Developpement,Pharmaceutical company,01/08/2025
2023-504359-29-01,EFC17504,"A randomized, double-blind, Phase 3 study comparing efficacy and safety of frexalimab (SAR441344) to placebo in adult participants with nonrelapsing secondary progressive multiple sclerosis","Ongoing, recruiting","Italy:Ongoing, recruiting, Netherlands:Ongoing, recruiting, Belgium:Ongoing, recruiting, Bulgaria:Ongoing, recruiting, Spain:Ongoing, recruiting, Hungary:Ongoing, recruiting, Portugal:Ongoing, recruiting, Czechia:Ongoing, recruiting, Germany:Ongoing, recruiting, Poland:Ongoing, recruiting, Sweden:Ongoing, recruiting, Greece:Ongoing, recruiting, France:Ongoing, recruiting",18-64 years,N/A,"Female, Male",591,In both EEA and non-EEA,Multiple sclerosis,"[""Diseases [C] - Nervous System Diseases [C10]""]",Therapeutic confirmatory  (Phase III),"Matched placebo for product, Frexalimab",Time to onset of composite confirmed disability progression (cCDP) confirmed over 6 months,"Time to onset of composite cCDP confirmed over 3 months in the double-blind treatment period, Time to onset of CDP confirmed over 3-months or 6 months in the double-blind treatment period, Time to onset of confirmed disability improvement (CDI) in the double-blind treatment period, Number of new and/or enlarging T2 hyperintense lesions per scan as detected by MRI, Percent change in brain volume loss as detected by MRI scans at the end of double-blind treatment period compared to Month 6, Change in cognitive function at the end of double-blind treatment period compared to baseline as assessed by symbol digit modalities test (SDMT), Change from baseline in multiple sclerosis impact scale 29 version 2 (MSIS-29v2) questionnaire scores over time in the double-blind treatment period, Change from baseline in patient reported outcome measurement information system (PROMIS) Fatigue multiple sclerosis (MS)-8a  over time in the double-blind treatment period, Annualized relapse rate during the double-blind treatment period assessed by protocol defined adjudicated relapses, Adverse events, SAEs, AEs leading to permanent study intervention discontinuation, AESIs, and PCSAs in laboratory tests, ECG, and vital signs during the study period, Antidrug antibody over time, Change from baseline in serum Ig levels over time, Change from baseline in plasma neurofilament light chain (NfL) levels over time in the double-blind treatment period, Frexalimab plasma concentration over time in the double-blind treatment period",25/11/2024,11/12/2024,N/A,N/A,No,Sanofi-Aventis Recherche & Developpement,Pharmaceutical company,27/08/2025
2024-514343-29-00,EFC17919B,"Randomized, double-blind, Phase 3 study comparing efficacy and safety of frexalimab (SAR441344) to teriflunomide in adult participants with relapsing forms of multiple sclerosis","Authorised, recruiting","Germany:Authorised, recruitment pending, Bulgaria:Ongoing, recruiting, Czechia:Ongoing, recruiting, Hungary:Ongoing, recruiting, Italy:Ongoing, recruiting, Romania:Ongoing, recruiting, Greece:Ongoing, recruiting, Slovakia:Authorised, recruitment pending, Austria:Ongoing, recruiting, France:Ongoing, recruiting, Lithuania:Ongoing, recruiting, Poland:Ongoing, recruiting, Portugal:Ongoing, recruiting, Denmark:Ongoing, recruiting, Croatia:Authorised, recruitment pending, Spain:Ongoing, recruiting",18-64 years,N/A,"Female, Male",389,In both EEA and non-EEA,multiple sclerosis,"[""Diseases [C] - Nervous System Diseases [C10]""]",Therapeutic confirmatory  (Phase III),"AUBAGIO 14 mg film-coated tablets, AUBAGIO 14 mg film-coated tablets, AUBAGIO 14 mg film-coated tablets, AUBAGIO 14 mg film-coated tablets, Matched placebo for test product frexalimab, Frexalimab, Matched placebo for comparator teriflunomide, COLESTYRAMINE, AUBAGIO 14 mg film-coated tablets",Annualized relapse rate (ARR) during the study period assessed by protocol defined adjudicated relapses,"Time to onset of composite confirmed disability worsening (cCDW), Time to onset of cCDW, confirmed over 3 months, Time to onset of individual components of the composite, confirmed over 3-months or 6-months, Time to onset of confirmed disability improvement (CDI), Progression independent of relapse activity defined as the time to onset of 6-month cCDW, Total number of new and/or enlarging T2 hyperintense lesions as detected by MRI, Total number of new Gd-enhancing T1 hyperintense lesions per scan as detected by MRI, Percent change in brain volume loss as detected by brain MRI scans at the EOS compared to Month 6, Change in cognitive function at the EOS compared to baseline as assessed by the symbol digit modalities test (SDMT), Change from baseline in multiple sclerosis impact scale 29 version 2 (MSIS-29v2) questionnaire scores over time, Change from baseline in patient reported outcome measurement information system (PROMIS) Fatigue MS-8 over time, Adverse events, SAEs, AEs leading to permanent study intervention discontinuation, AESIs, safety scales, and potentially clinically significant abnormality (PCSAs) in laboratory tests, ECG, and vital signs during the study period, Antidrug antibodies (ADAs) over time, Change from baseline in plasma neurofilament light chain (NfL) levels over time, Frexalimab plasma concentration over time",22/10/2024,19/11/2024,N/A,N/A,No,Sanofi-Aventis Recherche & Developpement,Pharmaceutical company,01/08/2025
2023-506467-34-00,BN42082,"A Phase IIIb Multicenter, Randomized, Double-Blind, Controlled Study to Evaluate the Efficacy, Safety and Pharmacokinetics of a Higher Dose of Ocrelizumab in Adults With Relapsing Multiple Sclerosis","Ongoing, recruitment ended","Hungary:Ongoing, recruitment ended, Poland:Ongoing, recruitment ended, Belgium:Ongoing, recruitment ended, Italy:Ongoing, recruitment ended, Denmark:Ongoing, recruitment ended, Portugal:Ongoing, recruitment ended, Germany:Ongoing, recruitment ended, Greece:Ongoing, recruitment ended, France:Ongoing, recruitment ended, Spain:Ongoing, recruitment ended",18-64 years,N/A,"Female, Male",357,In both EEA and non-EEA,Relapsing Multiple Sclerosis (MS),"[""Diseases [C] - Nervous System Diseases [C10]""]",Therapeutic confirmatory  (Phase III),"Diphenhydramine Hydrochloride Tablets 50 mg, Ocrevus 300 mg concentrate for solution for infusion, Paracetamol 500mg Tablets, Ocrevus 300 mg concentrate for solution for infusion, Placebo ocrelizumab, Methylprednisolone 500 mg powder and solvent for solution for injection/infusion","1. Time to onset of cCDP sustained for at least 12 weeks. Time to onset of cCDP is defined as the first occurrence of a predefined confirmed progression event measured by EDSS, T25FWT or 9-HPT","1. Time to onset of 24 week cCDP (cCDP24), 2. Time to onset of 48-week cCDP (cCDP48), 3. Time to onset of cCDP12 independent of protocol-defined relapses (PDR), also termed progression independent of relapse activity (PIRA) as per Kappos et al 2020, 4. Time to ≥ 20% increase in 12 week confirmed T25FWT, 5. Time to ≥ 20% increase in 24 week confirmed T25FWT, 6. Annual rate of percent change from baseline in total brain volume, 7. Time to 12-week confirmed 4-point worsening in Symbol Digit Modalities test (SDMT), 8. Time to 12-week confirmed 8-point increase in 12-Item Multiple Sclerosis Walking Scale (MSWS-12), 9. Change in NfL (i.e. ratio to baseline) at Week 48 for patients assigned to the higher dose ocrelizumab group, 10. Change in NfL (i.e ratio to baseline) at Week 48 for patients assigned to the approved dose ocrelizumab group, 11. Incidence and severity of adverse events, with severity determined according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 5.0, 12. Change from baseline in clinical laboratory test results (including hematology, chemistry, and Ig levels), 13. Change from baseline in vital signs (including systolic and diastolic blood pressure, and pulse rate) following study treatment administration, 14. Serum concentration of ocrelizumab at specified timepoints, 15. B-cell levels in blood (including comparing the degree of B-cell depletion between the doses), 16. Proportion of participant achieving 5 or less B-cells per microliter of blood, 17. Proportion of participants achieving 5 or less B-cells per microliter of blood in participants with the high versus low affinity Fcgamma Receptor 3A (FcγR3A) genotype per arm, 18. Change from Baseline in the anti-drug antibodies (ADAs) levels, 19. Levels of Neurofilament Light Chain (NfL) in blood, 20. Levels of interleukin-6 (IL-6) in blood, 21. Levels of blood B cells, 22. Levels of Lymphocytes in blood, 23. Proportion of participants with different DNA genotypes",08/02/2024,20/10/2020,N/A,N/A,No,F. Hoffmann-La Roche AG,Pharmaceutical company,18/06/2025
2024-513099-17-00,N/A,Clemastine fumarate as remyelinating treatment in internuclear ophthalmoparesis and multiple sclerosis (RESTORE),Ended,Netherlands:Ended,"65+ years, 18-64 years",N/A,"Female, Male",80,EEA only,"Internuclear ophthalmoparesis, Multiple sclerosis","[""Diseases [C] - Nervous System Diseases [C10]""]",Therapeutic confirmatory  (Phase III),"Capsules for oral use otherwise identical to IMP clemastine, Clemastine Milstein 1 mg, tabletten, Fampyra 10 mg prolonged-release tablets","The relative change in Versional Dysconjugacy Index (VDI) of Area under the Curve (AUC) from baseline will be compared between the treatment and control group at the end of treatment (6 months) and multiple follow-up periods (12, 24 and 36 months)",N/A,14/08/2024,30/08/2022,15/08/2025,N/A,No,Amsterdam UMC Stichting,Hospital/Clinic/Other health care facility,30/01/2025
2023-509345-12-00,CLOU064C12301,"A randomized, double-blind, double-dummy, parallel-group study, comparing the efficacy and safety of remibrutinib versus teriflunomide in participants with relapsing multiple sclerosis, followed by extended treatment with open-label remibrutinib","Ongoing, recruiting","Austria:Ongoing, recruiting, Belgium:Ongoing, recruiting, Poland:Ongoing, recruiting, Croatia:Ongoing, recruiting, Slovakia:Ongoing, recruiting, Bulgaria:Ongoing, recruiting, Lithuania:Ongoing, recruiting, Denmark:Ended, Netherlands:Ongoing, recruiting, Ireland:Ongoing, recruiting, Spain:Ongoing, recruiting, Italy:Ongoing, recruiting, Latvia:Ongoing, recruiting",18-64 years,N/A,"Female, Male",444,In both EEA and non-EEA,Multiple Sclerosis,"[""Diseases [C] - Nervous System Diseases [C10]""]",Therapeutic confirmatory  (Phase III),"MEDICINAL CHARCOAL, Placebo to Remibrutinib (LOU064) 100 mg film-coated tablet, LOU064, Placebo to teriflunomide 14 mg capsule, hard, COLESTYRAMINE, TERIFLUNOMIDE",Annualized relapse rate (ARR) of confirmed relapses,"Time to 3-month confirmed disability progression (3mCDP) on Expanded Disability Status Scale (EDSS), Time to 6-month confirmed disability progression (6mCDP) on EDSS, Number of new or enlarging T2 lesions on MRI per year (annualized T2 lesion rate), Total number of Gd-enhancing T1 lesions per MRI scan, Neurofilament light chain (NfL) concentration in serum, Percentage of participants with No Evidence of Disease Activity-3 (NEDA-3), as assessed by absence of confirmed MS relapses, 6mCDP and new/enlarging T2 lesions on MRI, Time to first confirmed relapse, Time to 6-month confirmed disability improvement (6mCDI) on EDSS (pooled data), Time to 3mCDP and 6mCDP independent of relapse activity (PIRA, pooled data), Change from baseline in the Symbol Digit Modalities Test (SDMT) (pooled data), Time to 6-month confirmed worsening by at least 20% in the:  ● Timed 25-foot walk test (T25FW) (pooled data)  ● Timed 9-hole peg test (9HPT) (pooled data), Time to composite 6-month confirmed disability progression, as evaluated by 6mCDP or 6-month confirmed worsening by at least 20% in T25FW or 9HPT (pooled data), Change from baseline in T2 lesion volume, Multiple Sclerosis Impact Scale (MSIS-29), Adverse events, laboratory data, vital signs, electrocardiogram (ECG), Columbia Suicide Severity Rating, Remibrutinib blood concentrations, Extension Part: ● Adverse events, laboratory data, vital signs, electrocardiogram (ECG), Columbia Suicide Severity Rating ● ARR, number of new or enlarging T2 lesions on MRI per year (annualized T2 lesion rate), time to 6mCDP (EDSS), change in SDMT, NfL, Patient Reported Outcomes scores",20/06/2024,22/06/2022,N/A,N/A,No,Novartis Pharma AG,Pharmaceutical company,24/06/2025
2023-505974-14-00,MN43964,"A Multicenter, Single-arm, Open-label, Extension, Rollover Study To Evaluate The Long-term Safety And Efficacy Of Ocrelizumab In Patients With Multiple Sclerosis","Ongoing, recruitment ended","Finland:Ongoing, recruitment ended, Netherlands:Ongoing, recruitment ended, Spain:Ongoing, recruitment ended, Poland:Ongoing, recruitment ended, Slovakia:Ongoing, recruitment ended, Bulgaria:Ongoing, recruitment ended, Sweden:Ongoing, recruitment ended, Czechia:Ongoing, recruitment ended, Belgium:Ongoing, recruitment ended, Romania:Ongoing, recruitment ended, Hungary:Ongoing, recruitment ended, Italy:Ongoing, recruitment ended, Croatia:Ongoing, recruitment ended, Latvia:Ongoing, recruitment ended, Germany:Ongoing, recruitment ended, Lithuania:Ongoing, recruitment ended, Estonia:Ongoing, recruitment ended, France:Ongoing, recruitment ended, Austria:Ongoing, recruitment ended, Portugal:Ongoing, recruitment ended",18-64 years,N/A,"Female, Male",809,In both EEA and non-EEA,Multiple Sclerosis (MS),"[""Diseases [C] - Musculoskeletal Diseases [C05]"",""Diseases [C] - Nervous System Diseases [C10]""]",Therapeutic confirmatory  (Phase III),Ocrevus 300 mg concentrate for solution for infusion,"1. Incidence and severity of adverse events, with severity determined according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0 (NCI CTCAE v5.0)","1. Change in Expanded Disability Status Scale (EDSS) score over time, 2. Change in 9-Hole Peg Test (9HPT) and Timed 25-Foot Walk Test (T25FWT) over time, 3. The number of new, hypointense T1 lesions and number of new or enlarging T2 lesions, 4. The change in total volume of T2 lesions and in total T1 lesion volume",08/07/2024,23/06/2022,N/A,N/A,No,F. Hoffmann-La Roche AG,Pharmaceutical company,04/08/2025
2023-507906-15-00,COMB157G2399,"An open-label, single arm, multi-center extension study evaluating long-term safety, tolerability and effectiveness of ofatumumab in subjects with relapsing multiple sclerosis (RMS)","Ongoing, recruitment ended","Germany:Ongoing, recruitment ended, Latvia:Ongoing, recruitment ended, Norway:Ongoing, recruitment ended, Belgium:Ongoing, recruitment ended, Netherlands:Ongoing, recruitment ended, Hungary:Ongoing, recruitment ended, Portugal:Ongoing, recruitment ended, Poland:Ongoing, recruitment ended, Spain:Ongoing, recruitment ended, Lithuania:Ongoing, recruitment ended, Slovakia:Ongoing, recruitment ended, Austria:Ongoing, recruitment ended, Sweden:Ongoing, recruitment ended, Czechia:Ongoing, recruitment ended, Bulgaria:Ongoing, recruitment ended, Finland:Ongoing, recruitment ended, Croatia:Ongoing, recruitment ended, France:Ongoing, recruitment ended, Denmark:Ongoing, recruitment ended, Estonia:Ongoing, recruitment ended, Greece:Ongoing, recruitment ended",18-64 years,N/A,"Female, Male",963,In both EEA and non-EEA,Relapsing multiple sclerosis (RMS),"[""Diseases [C] - Nervous System Diseases [C10]""]",Therapeutic confirmatory  (Phase III),"BOOSTRIX, suspension injectable en seringue préremplie Vaccin diphtérique, tétanique et coquelucheux (acellulaire multicomposé), (adsorbé, à teneur réduite en antigènes), Pneumovax 23 oldatos injekció Pneumococcus-poliszacharid vakcina, PNEUMOVAX solution injectable en flacon Vaccin pneumococcique polyosidique, Boostrix suspensión inyectable en jeringa precargada Vacuna antidiftérica, antitetánica y antitos ferina (componente acelular) (adsorbida, contenido antigénico reducido), BOOSTRIX, suspension injectable en seringue préremplie Vaccin diphtérique, tétanique et coquelucheux (acellulaire multicomposé), (adsorbé, à teneur réduite en antigènes), Pneumovax 23 oldatos injekció előretöltött fecskendőben Pneumococcus-poliszacharid vakcina, Pneumovax 23 oldatos injekció előretöltött fecskendőben Pneumococcus-poliszacharid vakcina, PNEUMOVAX 23 Injektionslösung in einer Durchstechflasche Pneumokokken-Polysaccharid-Impfstoff, Boostrix* Diphtherie-Tetanus-Pertussis (azellular)-Kombinationsimpfstoff zur Auffrischimpfung, Pneumovax 23 oldatos injekció előretöltött fecskendőben Pneumococcus-poliszacharid vakcina, Boostrix, suspenzija za injekciju u napunjenoj štrcaljki, cjepivo protiv difterije, tetanusa i pertusisa (nestanicno, komponentno), adsorbirano, smanjenog(ih) sadržaja antigena, Flucelvax Tetra - suspension for injection in pre-filled syringe Influenza vaccine (surface antigen, inactivated, prepared in cell cultures), Pneumovax 23 oldatos injekció előretöltött fecskendőben Pneumococcus-poliszacharid vakcina, Kesimpta 20 mg solution for injection in pre-filled pen, PNEUMOVAX 23 Solución inyectable en vial Vacuna antineumocócica de polisacáridos, Flucelvax Tetra - suspension for injection in pre-filled syringe
Influenza vaccine (surface antigen, inactivated, prepared in cell cultures), PNEUMOVAX 23 Szczepionka przeciw pneumokokom, polisacharydowa, roztwór do wstrzykiwań, PNEUMOVAX solution injectable en flacon Vaccin pneumococcique polyosidique, Kesimpta 20 mg solution for injection in pre-filled pen, Pneumovax 23 oldatos injekció előretöltött fecskendőben Pneumococcus-poliszacharid vakcina, Boostrix Injektionssuspension in einer Fertigspritze Diphtherie-, Tetanus- und Pertussis (azellulär, aus Komponenten)-Adsorbatimpfstoff (mit reduziertem Antigengehalt), Boostrix zawiesina do wstrzykiwań w ampułko-strzykawce|Szczepionka przeciw błonicy, tężcowi i krztuścowi (bezkomórkowa, złożona), adsorbowana, o|zmniejszonej zawartości antygenów, Boostrix szuszpenziós injekció előretöltött fecskendőben diphtheria, tetanus és pertussis (acelluláris összetevő) vakcina (adszorbeált, csökkentett antigén tartalmú), Pneumovax 23 otopina za injekciju u napunjenoj štrcaljki Cjepivo protiv pneumokoka, polisaharidno, Boostrix szuszpenziós injekció eloretöltött fecskendoben diphtheria, tetanus és pertussis (acelluláris összetevo) vakcina (adszorbeált, csökkentett antigén tartalmú), Prevenar 13 suspension for injection in single dose vial pneumococcal polysaccharide conjugate vaccine (13-valent, adsorbed), PNEUMOVAX solution injectable en flacon Vaccin pneumococcique polyosidique, Pneumovax 23 oldatos injekció előretöltött fecskendőben Pneumococcus-poliszacharid vakcina, Boostrix szuszpenziós injekció előretöltött fecskendőben diphtheria, tetanus és pertussis (acelluláris összetevő) vakcina (adszorbeált, csökkentett antigén tartalmú), Pneumovax 23 oldatos injekció Pneumococcus-poliszacharid vakcina, BOOSTRIX, suspension injectable en seringue préremplie Vaccin diphtérique, tétanique et coquelucheux (acellulaire multicomposé), (adsorbé, à teneur réduite en antigènes)","Proportion of subjects with adverse events, Proportion of subjects with laboratory, or vital signs results meeting abnormal criteria, Proportion of subjects with electrocardiogram (ECG) meeting abnormal criteria [through Week 240 (EOS)], Proportion of subjects meeting predefined criteria in Columbia Suicide Severity Rating Scale (C SSRS) [through Week 240/EOS]","Through Week 240/EOS: • Annualized Relapse Rate (ARR), Through Week 240/EOS: • Time to first relapse, Through Week 240/EOS: • Time to 3-month Confirmed Disability Worsening (3mCDW), Through Week 240/EOS: • Time to 6-month Confirmed Disability Worsening (6mCDW), Through Week 240/EOS: • Time to 6-month Confirmed Disability Improvement (6mCDI), Through Week 240/EOS: • Time to 12-month Confirmed Disability Improvement (12mCDI), Through Week 240/EOS: • Time to 24-month Confirmed Disability Improvement (24mCDI), Through Week 240/EOS: • Time to 6-month Confirmed Disability Improvement (6mCDI) sustained until End of Study (EOS), Through Week 240/EOS: • Change in Expanded Disability Status Scale (EDSS), Through Week 240/EOS: • Time to 6-month confirmed 4-point worsening on Symbol Digit Modalities Test (SDMT), Through Week 240/EOS: • Change in SDMT, Through Week 240/EOS: • Annualized T2 lesion rate, Through Week 240/EOS: • Number of T1 Gd-enhancing lesions per Magnetic Resonance Image (MRI) scan, Through Week 240/EOS: • Annual rate of change in brain volume, Through Week 240/EOS: • Change in neurofilament light chain (NfL) concentration in serum, Through Week 240/EOS: • Relationship between NFL and disease activity, disease course and treatment response, Through Week 240/EOS: • Patient Reported Outcomes (PRO)",19/07/2024,30/01/2019,N/A,N/A,No,Novartis Pharma AG,Pharmaceutical company,19/09/2025
2023-503289-22-00,J3K-MC-KIAB,"An Adaptive Phase 2a/2b, Randomized, Double-Blind, Parallel-Group Study to Investigate the Safety and Efficacy of LY3541860 Compared to Placebo in  Slowing the Occurrence of New T1 Gadolinium-Enhancing Lesions in Adult Participants with Relapsing Multiple Sclerosis","Ongoing, recruiting","Italy:Ongoing, recruiting, Lithuania:Ongoing, recruiting, Germany:Ongoing, recruiting, Poland:Ongoing, recruiting, France:Ongoing, recruiting, Latvia:Ongoing, recruiting, Slovakia:Ongoing, recruiting",18-64 years,N/A,"Female, Male",57,In both EEA and non-EEA,Relapsing Multiple Sclerosis,"[""Diseases [C] - Nervous System Diseases [C10]""]",Therapeutic exploratory (Phase II),"0.9% sodium chloride, GADOTERIC ACID",Cumulative Number of New T1 Gadolinium-Enhancing (GdE) Lesions  Cumulative number will be measured by magnetic resonance imaging (MRI) scans,N/A,13/05/2024,05/07/2024,N/A,N/A,No,Eli Lilly & Co.,Pharmaceutical company,12/05/2025
2023-506429-13-00,MN39159,"An Open-Label, Single-Arm 4-Year Study to Evaluate Effectiveness and Safety of Ocrelizumab Treatment in Patients with Progressive Multiple Sclerosis","Ongoing, recruitment ended","Netherlands:Ongoing, recruitment ended, Germany:Ongoing, recruitment ended, Denmark:Ongoing, recruitment ended, Poland:Ongoing, recruitment ended, Czechia:Ended, France:Ongoing, recruitment ended, Italy:Ongoing, recruitment ended","18-64 years, 65+ years",65-84 years,"Female, Male",520,In both EEA and non-EEA,Progressive multiple sclerosis (PMS),"[""Diseases [C] - Nervous System Diseases [C10]""]",Therapeutic confirmatory  (Phase III),"Ocrevus 300 mg concentrate for solution for infusion, Diphenhydramine Hydrochloride Tablets 50 mg, Paracetamol Accord 1000 mg comprimate efervescente, Ocrevus 300 mg concentrate for solution for infusion, Methylprednisolone 500 mg powder and solvent for solution for injection/infusion","1. Proportion of patients with no evidence of progression (NEP) sustained for at least 24 weeks, 2. Proportion of patients with NEP and no active disease (NEPAD) sustained for at least 24 weeks","1. Change from baseline in cognitive function as measured by the Symbol Digit Modalities Test (SDMT) and the Brief Visuospatial Memory Test – Revised (BVMT-R), 2. Change from baseline in the patient-reported outcomes including Multiple Sclerosis Impact Scale -29, Multiple Sclerosis Walking scale -12 items, ABILHAND-56 Questionnaire, Fatigue Scale for Motor and Cognitive (FSMC) function, SymptoMScreen, 88-item Multiple Sclerosis Spasticity Scale, Numerical Pain Rating Scale, Patient Global Impression of Severity (PGIS) for upper limb, lower limb and cognitive functions, 3. Mean change from baseline in the EDSS score over the course of the study, 4. Time to onset of first confirmed disability progression (as measured by EDSS) sustained for at least 24 and 48 weeks, 5. Time to onset of first >=20% increase in timed 25-foot walk test sustained for at least 24 weeks, 6. Time to onset of first >=20% increase in 9-hole peg test sustained for at least 24 weeks, 7. Proportion of patients with NEP, 8. Proportion of patients with NEPAD, 9. Proportion of patients with confirmed disability improvement (CDI) sustained for at least 24 weeks, 10. Change in the following MRI volumetric measures: whole brain volume, cerebral white matter volume change, cortical gray matter volume, deep grey matter volume, thalamic volumes, whole and regional cerebellar volume, 11. Change in the following lesion and tissue integrity parameters: - Number of new/enlarging T2 lesions and total T2 lesion volume - Number of T1 Gd+ lesions and total volume - Number of T1 lesions and total volume - Gd-enhancing fluid-attenuated inversion-recovery (FLAIR) meningeal lesions, 12. Rate and nature of adverse events, 13. Changes in clinical laboratory results, 14. Rates of study treatment discontinuation due to adverse events, 15. Change in the number of falls and near-falls",18/03/2024,02/05/2018,N/A,N/A,No,F. Hoffmann-La Roche AG,Pharmaceutical company,25/08/2025
2024-514617-35-00,P2-IMU-838-PMS,"P2-IMU-838-PMS - Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate Efficacy, Safety, and Tolerability of IMU-838 in Patients with Progressive Multiple Sclerosis (Calliper)","Authorised, recruiting","Germany:Authorised, recruiting, Czechia:Authorised, recruiting, Netherlands:Authorised, recruiting, Bulgaria:Authorised, recruiting, Romania:Authorised, recruiting, Poland:Authorised, recruiting",18-64 years,N/A,"Female, Male",230,In both EEA and non-EEA,Progressive forms of Multiple Sclerosis,"[""Diseases [C] - Nervous System Diseases [C10]""]",Therapeutic exploratory (Phase II),"IMU-838 22.5 mg tablet, IMU-838 45 mg tablet, Placebo for IMU-838 Tablets",Annualized rate of percent brain volume change (PBVC) during MT period.,"Time to 24-week confirmed disability worsening as assessed on a composite of EDSS, 9-Hole Peg Test (9-HPT), or Timed 25-foot Walk (T25-FW) (24wCDW-Comp) during the MT period",12/09/2024,20/12/2021,N/A,N/A,No,Immunic AG,Pharmaceutical company,03/04/2025
2022-501027-25-01,35RC20_9812,TRIO: A prospective randomized Trial of non-inferiority comparing RItuximab versus Ocrelizumab in relapsing-remitting multiple sclerosis.,"Ongoing, recruiting","France:Ongoing, recruiting",18-64 years,N/A,"Female, Male",430,EEA only,"Multiple Sclerosis, Multiple Sclerosis","[""Diseases [C] - Nervous System Diseases [C10]""]",Phase III and phase IV (Integrated),"Rituximab, -, Ocrevus 300 mg concentrate for solution for infusion",% of patients without disease activity at 2 years.  Disease activity is defined as: -	 At least one relapse between baseline and M24 -	OR MRI activity defined as Gd enhancing lesions at M6 or as the appearance of at least one new T2 lesion between M6 and M24,"Clinical criteria - Relapses: annualized relapse rate, mean time of onset of the first relapse, % of patients without relapse at M24, - Disability progression: % of patients without disability progression at M24 Disability progression will be defined as an increase of 1.5 pt if baseline EDSS=0, 1pt EDSS (if baseline 1 ≤ EDSS<6), or an increase of 0.5pt if baseline EDSS is ≥ 6; confirmed at 6 months.  MRI Criteria -	Mean number of Gd enhancing lesions at M6;  -	% of patients with at least one Gd, MRI Criteria -	Mean number of Gd enhancing lesions at M6;  -	% of patients with at least one Gd enhancing lesion(s) at M6; -	Mean number of new or enlarging brain T2 lesion from M6 to M24; % of patients with one or more new or enlarging brain T2 lesions from M6 to M24;, Quality of life  - Change in the EQ5D-5L score from baseline to  every six month of follow up until M24 - Change in the MusiQOL score from baseline to M12 and baseline to M24., Patients experience - Change in the Musicare score from baseline to M12 and baseline to M24., Medico-economic  Incremental Cost-Effectiveness Ratio (ICER) defined as the cost for QALY gained in “ocrelizumab group” versus “rituximab group” at 24 months., Safety - The number of each adverse event and number of severe adverse events will be compared between the two groups.",02/12/2022,01/06/2023,N/A,N/A,No,CHU De Rennes,Hospital/Clinic/Other health care facility,22/04/2024
2024-511168-10-00,KYV101-007,"A Phase 2, Open-Label, Randomized, Multicenter Study of KYV101, an Autologous Fully Human Anti-CD19 Chimeric Antigen Receptor T Cell (CD19 CAR T) Therapy, in Subjects with Refractory Primary and Secondary Progressive Multiple Sclerosis (KYSA-7)","Authorised, recruitment pending","Germany:Authorised, recruitment pending, Italy:Authorised, recruitment pending, Belgium:Authorised, recruitment pending, Austria:Authorised, recruitment pending",18-64 years,N/A,"Female, Male",88,In both EEA and non-EEA,Primary or Secondary Progressive Multiple Sclerosis,"[""Diseases [C] - Immune System Diseases [C20]"",""Diseases [C] - Nervous System Diseases [C10]""]",Therapeutic exploratory (Phase II),"Kesimpta 20 mg solution for injection in pre-filled pen, Ocrevus 300 mg concentrate for solution for infusion, MabThera 500 mg concentrate for solution for infusion, MabThera 100 mg concentrate for solution for infusion, MabThera 100 mg concentrate for solution for infusion, Kesimpta 20 mg solution for injection in pre-filled syringe, Ocrevus 300 mg concentrate for solution for infusion, Kesimpta 20 mg solution for injection in pre-filled syringe, Ocrevus 300 mg concentrate for solution for infusion, MabThera 100 mg concentrate for solution for infusion, Kesimpta 20 mg solution for injection in pre-filled syringe, Kesimpta 20 mg solution for injection in pre-filled pen, KYV-101, Briumvi 150 mg concentrate for solution for infusion, Kesimpta 20 mg solution for injection in pre-filled pen, Kesimpta 20 mg solution for injection in pre-filled syringe, Kesimpta 20 mg solution for injection in pre-filled pen, Kesimpta 20 mg solution for injection in pre-filled pen, Ocrevus 300 mg concentrate for solution for infusion, Ocrevus 300 mg concentrate for solution for infusion, Kesimpta 20 mg solution for injection in pre-filled syringe, Ocrevus 300 mg concentrate for solution for infusion, MabThera 500 mg concentrate for solution for infusion, Briumvi 150 mg concentrate for solution for infusion, Briumvi 150 mg concentrate for solution for infusion, Briumvi 150 mg concentrate for solution for infusion, Ocrevus 300 mg concentrate for solution for infusion, Kesimpta 20 mg solution for injection in pre-filled pen, Ocrevus 300 mg concentrate for solution for infusion, Briumvi 150 mg concentrate for solution for infusion, Kesimpta 20 mg solution for injection in pre-filled syringe, Kesimpta 20 mg solution for injection in pre-filled syringe, Briumvi 150 mg concentrate for solution for infusion, Kesimpta 20 mg solution for injection in pre-filled syringe, MabThera 100 mg concentrate for solution for infusion, Briumvi 150 mg concentrate for solution for infusion, Kesimpta 20 mg solution for injection in pre-filled pen, MabThera 500 mg concentrate for solution for infusion, MabThera 500 mg concentrate for solution for infusion, Kesimpta 20 mg solution for injection in pre-filled pen, Briumvi 150 mg concentrate for solution for infusion","1. Confirmed disability progression, defined as an increase in the EDSS","2a. Incidence and severity of AEs, AESIs, and SAEs, 2b1. Composite Confirmed Disability Progression (CCPD) defined as disability progression measured by EDSS, 2b2. Impact on clinical disability as defined by the number of  days from randomization to the primary outcome., 2b3. Disability as measured by EDSS change from pretreatment baseline to end of study., 2b4. Annualized relapse rate (ARR) in patients with active SPMS (relapse in the past 2 years or active lesions on MRI), 2b5. Comparison of end-of-study brain MRI compared to baseline scan in T2 burden of demyelinating disease, baseline to end of study, including whole brain volume and grey matter volume changes from treatment baseline to end of study., 2b6. For the CSF consenting subset, comparison of interval changes in unmatched intrathecal oligoclonal bands treatment from baseline to end of study., 2c. CAR-positive T-cell counts, CAR transgene level, B-cell counts over time, systemic cytokine concentrations., 2d. Presence of anti-KYV-101 antibodies.",01/10/2024,N/A,N/A,N/A,No,Kyverna Therapeutics Inc.,Pharmaceutical company,07/10/2024
2024-514495-41-00,EFC16035,"A Phase 3, randomized, double-blind, efficacy and safety study comparing SAR442168 to placebo in participants with primary progressive multiple sclerosis (PERSEUS)","Ongoing, recruitment ended","Belgium:Ongoing, recruitment ended, France:Ongoing, recruitment ended, Austria:Ongoing, recruitment ended, Croatia:Ongoing, recruitment ended, Portugal:Ongoing, recruitment ended, Hungary:Ongoing, recruitment ended, Poland:Ongoing, recruitment ended, Netherlands:Ongoing, recruitment ended, Italy:Ongoing, recruitment ended, Bulgaria:Ongoing, recruitment ended, Denmark:Ongoing, recruitment ended, Estonia:Ongoing, recruitment ended, Spain:Ongoing, recruitment ended, Germany:Ongoing, recruitment ended, Czechia:Ongoing, recruitment ended, Greece:Ongoing, recruitment ended, Sweden:Ongoing, recruitment ended, Norway:Ongoing, recruitment ended, Romania:Ongoing, recruitment ended",18-64 years,N/A,"Female, Male",487,In both EEA and non-EEA,Primary Progressive Multiple Sclerosis,"[""Diseases [C] - Nervous System Diseases [C10]""]",Therapeutic confirmatory  (Phase III),"Tolebrutinib, mannitol and microcrystalline cellulose",6-month composite Confirmed Disability Progression (cCDP),"6-month Confirmed Disability Progression  (CDP), 3-month composite Confirmed Disability  Progression (cCDP), Change in T2 hyperintense lesions by MRI, Time to onset of confirmed disability  improvement (CDI), Percent change in Brain volume (BV), Change in cognitive function as assessed by  SDMT, Change in cognitive function as assessed by  CVLT-II, Change in Multiple Sclerosis Quality of Life, Safety and Tolerability, Population pharmacokinetics, Change in plasma neurofilament light chain  (NfL), Change in lymphocyte phenotype subsets, Changes in serum Immunoglobulin level, Change in serum chitinase-3 like protein 1  (Chi3L1)",17/07/2024,04/11/2020,N/A,N/A,No,Genzyme Corp.,Pharmaceutical company,22/09/2025
2024-511686-11-00,CBAF312D2301,"A 2-year randomized, 3-arm, double-blind, non-inferiority study comparing the efficacy and safety of ofatumumab and siponimod versus fingolimod in pediatric patients with multiple sclerosis followed by an open-label extension","Ongoing, recruitment ended","Croatia:Ongoing, recruitment ended, Romania:Ended, Austria:Ongoing, recruitment ended, Estonia:Ongoing, recruitment ended, Latvia:Ongoing, recruitment ended, Spain:Ongoing, recruitment ended, Portugal:Ongoing, recruitment ended, Poland:Ongoing, recruitment ended, Slovakia:Ongoing, recruitment ended, Italy:Ongoing, recruitment ended, Germany:Ongoing, recruitment ended, Belgium:Ongoing, recruitment ended, France:Ongoing, recruitment ended",0-17 years,"2-5 years, 6-11 years, 12-17 years","Female, Male",62,In both EEA and non-EEA,Multiple Sclerosis in pediatric patients,"[""Diseases [C] - Nervous System Diseases [C10]""]",Therapeutic confirmatory  (Phase III),"FINGOLIMOD HYDROCHLORIDE, BAF312, OFATUMUMAB, BAF312, Placebo to Ofatumumab (OMB157) [Kesimpta], BAF312, BAF312, Placebo to Siponimod (BAF312) [Mayzent] film-coated tablets, BAF312, FINGOLIMOD HYDROCHLORIDE, Placebo to Fingolimod (FTY720) [Gilenya] 0.25mg & 0.5mg",Annualized relapse rate (ARR of confirmed relapses),"Annualized relapse rate (ARR of confirmed relapses), Number of new or newly enlarging T2 lesions on MRI per year (annualized T2 lesion rate), Neurofilament light chain (NfL) concentration in serum, Ofatumumab and siponimod and (metabolite M17) plasma concentrations, Proportion of participants with anti-ofatumumab antibodies, Adverse events, Columbia Suicide Severity Rating Scale (C-SSRS), ECG, laboratory and ophthalmological data, pulmonary function tests and vital signs",09/07/2024,05/10/2021,N/A,N/A,No,Novartis Pharma AG,Pharmaceutical company,26/05/2025
2024-514287-84-00,DanNORMS,"Danish non-inferiority study of ocrelizumab and rituximab in MS: A randomized study comparing the efficacy of ocrelizumab
and rituximab in active multiple sclerosis","Ongoing, recruitment ended","Denmark:Ongoing, recruitment ended","65+ years, 18-64 years",65-84 years,"Female, Male",600,EEA only,Multiple sclerosis,"[""Diseases [C] - Nervous System Diseases [C10]""]",Therapeutic confirmatory  (Phase III),"Rixathon 500 mg concentrate for solution for infusion, Ocrevus 300 mg concentrate for solution for infusion, Ruxience 500 mg concentrate for solution for infusion",Percentage of patients with no new or enlarging T2 white matter lesions from month 6 to month 24,"Percentage of patients with 6-month confirmed disease worsening (CDW) in EDSS from baseline to month 24 (m24) • ARR based on cumulative number of confirmed relapses from baseline to m24 • Percentage of patients with 6-months CDW in T25FW, 9HPT and SDMT from baseline to m24 • Change in MSIS-29, FSMC, EQ-5D from baseline to m24 • Percentage of patients without GdEL on m6 and m24 scans • Change in T2 and T1 white matter lesion volume from m6 to m24 •  Difference in serum NFL from baseline to m24",05/08/2024,28/04/2021,N/A,N/A,No,Rigshospitalet,Hospital/Clinic/Other health care facility,05/08/2024
2024-516628-32-00,35RC17_8842_STOPISEP,STOP-I-SEP_Disease modifying therapies withdrawal in inactive Secondary Progressive Multiple Sclerosis patients older than 50 years,"Ongoing, recruitment ended","France:Ongoing, recruitment ended","18-64 years, 65+ years",N/A,"Female, Male",250,EEA only,Multiple Sclerosis,"[""Diseases [C] - Nervous System Diseases [C10]""]",Therapeutic confirmatory  (Phase III),"TERIFLUNOMIDE, INTERFERON BETA-1A, CYCLOPHOSPHAMIDE, METHOTREXATE, INTERFERON BETA-1A, INTERFERON BETA-1B, DIMETHYL FUMARATE, MYCOPHENOLATE MOFETIL, RITUXIMAB, PEGINTERFERON BETA-1A, CYCLOPHOSPHAMIDE, MYCOPHENOLATE MOFETIL, INTERFERON BETA-1A, METHOTREXATE, AZATHIOPRINE, OCRELIZUMAB, GLATIRAMER ACETATE, GLATIRAMER ACETATE, CYCLOPHOSPHAMIDE","Percentage of patients experiencing disability progression (confirmed at 6 months) at 2 years.   Disability progression will be defined as an increase in the EDSS of at least 1 point if the baseline EDSS was 5.5 or less, or 0.5 point if the Baseline EDSS was more than 5.5.","Disability - Time from DMT withdrawal to disability progression confirmed at 6 months;   - Change in a composite disability progression score (increase in the EDSS score, or an increase in the time to perform the timed 25-foot walk ≥ 20%, or an increase in the time to complete the 9-hole peg test ≥ 20%) confirmed at 6 months; - Change in the SDMT score from baseline to 2-year;, Relapses - Percentage of patients with at least one relapse from baseline to 2-year; - Annualized relapse rate during 2-year; - Time from DMT withdrawal to first relapse;, MRI -	 Percentage of patients with one or more new or enlarging brain MRI lesions from baseline to 2-year; -	 Percentage of patients with at least one gadolinium enhancing lesion(s) at 6 months, and/or 1 year,and/or 2-year; -	 Change in brain volume from baseline to 2-year;, Disease free survival -	 Percentage of patients with no evidence of disease activity (NEDA 3: no clinical relapse, no MRI activity, no disability progression) at 2-year; -	 Percentage of patients who resume DMT in the treatment withdrawal group at 2-year, Quality of life -	 Change in the SEP-59 score from baseline to 2-year; -	Change in the EuroQOL EQ-5D from baseline to 2-year;, Medico economic impact -	 Incremental Cost Effectiveness Ratio (ICER) defined as the cost for QALY gained in “treatment withdrawal group” versus “treatment continued group”.",10/10/2024,24/01/2019,N/A,N/A,No,Centre Hospitalier Universitaire De Rennes,Hospital/Clinic/Other health care facility,23/05/2025
2023-507541-29-00,CAMINA,EFFICACY AND SAFETY OF CROMOGLYCATE AS A NEW SYMPTOMATIC TREATMENT IN PATIENTS WITH MULTIPLE SCLEROSIS,"Ongoing, recruiting","Spain:Ongoing, recruiting",18-64 years,N/A,"Female, Male",120,EEA only,Multiple sclerosis,"[""Diseases [C] - Nervous System Diseases [C10]""]",Therapeutic exploratory (Phase II),"CROMOGLICIC ACID, Placebo","Modified Fatigue Impact Scale (MFIS) at the end-of-treatment visit (V4) with respect to baseline., Fatigue Severity Scale (FSS)., Patient-reported outcome measurement information system for fatigue in multiple sclerosis (PROMIS-SF-Fatigue).","Actionable Bladder Symptom Screening Tool (ABSST)., Urinary incontinence questionnaire (ICIQ-SF)., Sandvik incontinence severity test., Bladder Control Scale (BLCS)., International Prostate Symptom Scale (IPSS)., Questionnaire on the specific impact of urinary problems on quality of life (Qualiveen), SF-36 quality of life questionnaires., EQ-5D quality of life questionnaire., Hospital Anxiety and Depression Scale (HADS)., Beck Depression Inventory (BDI)., Expanded Disability Status Scale (EDSS)., Test of the 25 steps., Test of the 9 sticks., Time of multiple sclerosis progression., New lesions evaluated by magnetic resonance imaging, Presence of global cerebral atrophy, thalamic atrophy and cortical atrophy, and correlation with changes in fatigue., Presence of mutation 816V c-kit gene, cytokine levels and activation of lymphocyte populations and correlation with changes in fatigue., Axonal damage and macular volume assessed by optical coherence tomography., Modified ASHWORTH scale., Bowel Control Scale (BWCS)., Questionnaire on intimacy and sexuality in MS (MSISQ-19)., Work Productivity and Activity Impairment Scale (WPAI)., Patient symptom scales., Symbols and Digits Test (SDMT)., Perineal and perianal sensitivity., Bulbocavernosus reflex., Anal sphincter tone., In women: presence of prolapses., Postvoid residue., Peak flow in uroflowmetry., Detrusor contractions in cistonanometry., Urination difficulty assessed by flow pressure test (maximum flow)., PAD test value in 24 hours., Voiding diary: Urinated volume, urgency, urine leakage, urge incontinence, stress incontinence, moulting, and drinking., Treatment-related adverse events, Analytical values ​​of complete blood count, biochemistry, hepatorenal and thyroid profile, serum tryptase, urine strip, systematic and urine sediment and pregnancy test., Concomitant medication., Modifying treatment., Modified fatigue impact scale (MFIS) at each treatment visit with respect to baseline.",13/12/2023,01/10/2024,N/A,N/A,No,Fundacion Para La Investigacion Biomedica Del Hospital Clinico San Carlos,Laboratory/Research/Testing facility,30/06/2025
2023-509372-41-00,CLOU064C12302,"A randomized, double-blind, double-dummy, parallel-group study, comparing the efficacy and safety of remibrutinib versus teriflunomide in participants with relapsing multiple sclerosis, followed by extended treatment with open-label remibrutinib","Ongoing, recruiting","Bulgaria:Ongoing, recruiting, Slovakia:Ongoing, recruiting, Italy:Ongoing, recruiting, Spain:Ongoing, recruiting, Romania:Ongoing, recruiting, Estonia:Ongoing, recruiting, Croatia:Ongoing, recruiting, France:Ongoing, recruiting, Sweden:Ongoing, recruiting, Greece:Ongoing, recruiting, Portugal:Ongoing, recruiting, Slovenia:Ongoing, recruiting, Poland:Ongoing, recruiting, Germany:Ongoing, recruiting, Czechia:Authorised, recruitment pending",18-64 years,N/A,"Female, Male",525,In both EEA and non-EEA,Multiple Sclerosis,"[""Diseases [C] - Nervous System Diseases [C10]""]",Therapeutic confirmatory  (Phase III),"LOU064, TERIFLUNOMIDE, Placebo to teriflunomide 14 mg capsule, hard, COLESTYRAMINE, MEDICINAL CHARCOAL, Placebo to Remibrutinib (LOU064) 100 mg film-coated tablet",Annualized relapse rate (ARR) of confirmed relapses,"Time to 3-month confirmed disability progression (3mCDP) on Expanded Disability Status Scale (EDSS), Time to 6-month confirmed disability progression (6mCDP) on EDSS, Number of new or enlarging T2 lesions on MRI per year (annualized T2 lesion rate), Total number of Gd-enhancing T1 lesions per MRI scan, Neurofilament light chain (NfL) concentration in serum, Percentage of participants with No Evidence of Disease Activity-3 (NEDA-3), as assessed by absence of confirmed MS relapses, 6mCDP and new/enlarging T2 lesions on MRI, Time to first confirmed relapse, Time to 6-month confirmed disability improvement (6mCDI) on EDSS (pooled data), Time to 3mCDP and 6mCDP independent of relapse activity (PIRA, pooled data), Change from baseline in the Symbol Digit Modalities Test (SDMT) (pooled data), Time to 6-month confirmed worsening by at least 20% in the:  ● Timed 25-foot walk test (T25FW) (pooled data)  ● Timed 9-hole peg test (9HPT) (pooled data), Time to composite 6-month confirmed disability progression, as evaluated by 6mCDP or 6-month confirmed worsening by at least 20% in T25FW or 9HPT (pooled data), Change from baseline in T2 lesion volume, Multiple Sclerosis Impact Scale (MSIS-29), Adverse events, laboratory data, vital signs, electrocardiogram (ECG), Columbia Suicide Severity Rating, Remibrutinib blood concentrations, Extension Part: ● Adverse events, laboratory data, vital signs, electrocardiogram (ECG), Columbia Suicide Severity Rating ● ARR, number of new or enlarging T2 lesions on MRI per year (annualized T2 lesion rate), time to 6mCDP (EDSS), change in SDMT, NfL, Patient Reported Outcomes scores",03/07/2024,30/01/2022,N/A,N/A,No,Novartis Pharma AG,Pharmaceutical company,11/08/2025
2024-513105-31-00,N/A,Personalized extended interval dosing of natalizumab in relapsing remitting multiple sclerosis (NEXT-MS),"Authorised, recruitment pending","Netherlands:Authorised, recruitment pending","18-64 years, 65+ years",N/A,"Female, Male",440,EEA only,Multiple Sclerosis,"[""Diseases [C] - Nervous System Diseases [C10]""]",Therapeutic use (Phase IV),"Tysabri 300 mg concentrate for solution for infusion, Tyruko 300 mg concentrate for solution for infusion, Tysabri 150 mg solution for injection in pre-filled syringe",Radiological disease activity (new/enlarging T2 lesions on brain MRI) after two years,N/A,30/07/2024,N/A,N/A,N/A,No,Amsterdam UMC Stichting,Hospital/Clinic/Other health care facility,30/07/2024
2023-510304-53-00,N/A,INFLANET - A French Network for PET imaging of neuroinflammation in MS,"Authorised, recruitment pending","France:Authorised, recruitment pending",18-64 years,N/A,"Female, Male",41,EEA only,Multiple sclerosis,"[""Diseases [C] - Nervous System Diseases [C10]""]",Phase II and Phase III (Integrated),"18F-DPA-714, DOTAREM 0,5 mmol/mL, solution injectable","The respective proportion of lesions classified as homogeneously active, rim active and inactive for every single patient with MS. Classification of lesions will be based on predefined data-driven threshold of activity in lesions subareas (Hamzaoui et al, 2023).","- Regional mean and voxel wise individual maps of innate immune cells activation derived from baseline [18F]-DPA-714 PET : they will be expressed as mean DVR values and as percentage of voxel classified as “DPA+”, for each region of interest: whole brain, NAWM, grey matter, cortex, thalami, deep grey matter, white matter T2 lesions, white matter T1 lesions. - Clinical and neuropsychological scores collected at baseline - An accessible pipeline for the processing of DPA-714 data - MRI data",30/05/2024,N/A,N/A,N/A,No,Assistance Publique Hopitaux De Paris,Hospital/Clinic/Other health care facility,30/05/2024
2023-509078-45-00,ACT16753,"A Phase 2 double blind, randomized, placebo controlled study evaluating the effect of SAR443820 on serum neurofilament levels in participants with multiple sclerosis, followed by an open-label long-term extension period",Ended,"Spain:Ended, Belgium:Ended, Germany:Ended, Italy:Ended, Bulgaria:Ended, Poland:Ended, France:Ended",18-64 years,N/A,"Female, Male",157,In both EEA and non-EEA,Multiple sclerosis,"[""Diseases [C] - Nervous System Diseases [C10]""]",Therapeutic exploratory (Phase II),"Matched placebo for product, GADOBUTROL, SAR443820","Part A: Week 48 sNfL levels relative to baseline, Part B: Week 96 sNfL levels relative to baseline","Part A: Cumulative number of new gadolinium (Gd)-enhancing T1 hyperintense lesions as detected by magnetic resonance imaging (MRI), Part A: Cumulative number of new and/or enlarging T2 hyperintense lesions as detected by MRI, Part A: Time to onset of 12 weeks confirmed disability progression (CDP) from baseline as assessed by the Expanded Disability Status Scale (EDSS) score, Part A: Time to onset of sustained 20% increase in 9-Hole Peg Test (9-HPT) confirmed over at least 12 weeks, Part A: Time to onset of sustained 20% increase in timed 25-foot walk test (T25-FW) confirmed over at least 12 weeks, Part A: Change from baseline in EDSS Plus, Part A: Annualized relapse rate (ARR) of RMS population (relapsing SPMS and RRMS), Part A: Percent change from baseline in brain volume loss (BVL) as detected by brain MRI, Part A: Change from baseline in the volume of slowly expanding lesions (SELs), Part A: Change from baseline in the number of SELs, Part A: Change from baseline in the intensity (T1) of SELs, Part A: Change from baseline in the normalized T1 intensity in lesions, Part A: Change from baseline in the total number of non-enhancing lesions, Part A: Change from baseline in the volume of non-enhancing lesions, Part A: Change from baseline in the number of phase rim lesions (PRL) will be conducted at 3 Tesla (3T) capable sites, Part A: Incidence of adverse event (AE), Part A: Incidence of serious adverse event (SAE), Part A: Incidence of treatment emergent adverse event (TEAE), Part A: Incidence of potentially clinically significant abnormality (PCSA) in laboratory tests, Part A: Plasma concentration of SAR443820, Part B: Percent change from baseline in BVL as detected by brain MRI, Part B: Change from baseline in the volume of slowly expanding lesions (SELs), Part B: Change from baseline in the number of SELs, Part B: Change from baseline in the intensity (T1) of SELs, Part B: Change from baseline in the normalized T1 intensity in lesions, Part B: Change from baseline in the total number of non-enhancing lesions, Part B: Change from baseline in the volume of non-enhancing lesions, Part B: Change from baseline in the number of PRLs (same participants/centers from Part A with 3T capability), Part B: Incidence of AE, Part B: Incidence of SAE, Part B: Incidence of TEAE, Part B: Incidence of potentially clinically significant abnormality (PCSA) in laboratory tests, Part B: Incidence of PCSA in ECG, Part B: Incidence of PCSA in vital signs, Part B: Cumulative number of new Gd-enhancing lesions as detected by T1-weighted MRI, Part B: number of new or enlarging T2-hyperintense lesions on MRI, Part B: ARR of RMS population (relapsing SPMS and RRMS), Part B: Time to onset of composite CDP (CCDP), confirmed over at least 12 weeks (3-month CCDP), by the EDSS Plus composite (EDSS score increase, OR 20% increase in the T25-FW test, OR 20% increase in the 9-HPT), Part B: Time to onset of 12 weeks CDP as assessed by the EDSS score, Part B: Time to onset of sustained 20% increase in 9-HPT confirmed over at least 12 weeks, Part B: Time to onset of sustained 20% increase T25-FW test confirmed over at least 12 weeks, Part B: Change from baseline in EDSS Plus, Part B: Change in Multiple Sclerosis Impact Scale -29 version 2 (MSIS-29v2) physical and psychological domains scoring, Part B: Change in Multiple Sclerosis Walking Scale 12 items (MSWS-12)",24/04/2024,19/12/2022,11/10/2024,21/11/2024,Yes,Sanofi-Aventis Recherche & Developpement,Pharmaceutical company,18/10/2024
2022-501414-53-00,MODAFIMS,"MODAFIMS: An open-label, single-center clinical trial to evaluate predictors of response to MODAFinil in the treatment of cognitive deficits in patients with Multiple Sclerosis","Ongoing, recruiting","Portugal:Ongoing, recruiting",18-64 years,N/A,"Female, Male",64,EEA only,Multiple sclerosis,"[""Diseases [C] - Nervous System Diseases [C10]""]",Therapeutic exploratory (Phase II),Modafinil Generis 100 mg comprimidos,"Changes in brain function and connectivity measured using resting state fMRI (at baseline and after 3 months of treatment with Modafinil). Functional MRI will be performed at baseline, before and 3h (±30 min) after Modafinil administration, and at the end of treatment (3-month visit).","Changes in brain function and connectivity measured using a Go/no-Go task fMRI., Changes in patient reported outcomes (PROs) and neuropsychological tests - Perceived Deficits Questionnaire (PDQ), Symbol Digit Modalities Test (SDMT), Stroop test measured as interference index, MS-specific QoL questionnaire, Work Productivity and Activity Impairment Questionnaire for MS (WPAI:MS) and Modified Fatigue Impact Scale (MFIS). These assessments will occur in the screening or baseline visits and at the end of treatment (3-month visit).",07/06/2024,21/08/2024,N/A,N/A,No,CCAB Centro Clinico Academico Braga Associacao,Pharmaceutical company,18/03/2025
2024-513475-41-00,N/A,"DISEASE MODIFYING THERAPIES WITHDRAWAL IN INACTIVE RELAPSING-REMITTING MULTIPLE SCLEROSIS PATIENTS AGED 55 AND OVER: A MULTICENTRIC, RANDOMIZED, CONTROLLED, OPEN-LABEL CLINICAL TRIAL - TWINS","Ongoing, recruiting","France:Ongoing, recruiting","65+ years, 18-64 years",N/A,"Female, Male",200,EEA only,Multiple Sclerosis,"[""Diseases [C] - Nervous System Diseases [C10]""]",Therapeutic confirmatory  (Phase III),"Tecfidera 240 mg gastro-resistant hard capsules, AVONEX 30 micrograms/0.5ml solution for injection in pre-filled pen., AUBAGIO 14 mg film-coated tablets, Plegridy 63 micrograms + 94 micrograms solution for injection in pre-filled syringe, Betaferon 250 microgram/ml, powder and solvent for solution for injection, Copaxone 20 mg/ml, solution injectable en seringue préremplie, Rebif 44 micrograms solution for injection in pre-filled syringe, Vumerity 231 mg gastro-resistant hard capsules, Extavia 250 microgram/ml powder and solvent for solution for injection",Time to first clinical and/or radiological disease activity during a period of 2 years.,"Secondary endpoints will be measured by comparing baseline scores/evaluations (M0) with the scores/evaluations at M6, M12, M18, and M24: 1.	Kaplan Meier analysis of time to relapse, 2.	Annual relapse rate (ARR), 3.	Transition to secondary progressive multiple sclerosis according to revised McDonald 2017 criteria, 4.	Scores at EDSS, 25Foot/Walk, 9-HPT tests, 5.	Scores at CSCT questionnaire, 6.	Scores at SEP-59, EQ-5D, Hospital Anxiety and Depression (HAD) and Burden of Treatment (TBQ) Questionnaires, 7.	Safety of treatments will be followed by the number and type of adverse or severe adverse events (AE/SAE) throughout the protocol ; Clinical examination, patient questioning; biological analysis in the case of suspected infection, 8.	MS comorbidities questionnaire, 9.	Average annual cost, incremental ratio cost/effectiveness and cost/utility ratios",27/08/2024,03/02/2025,N/A,N/A,No,Les Hopitaux Universitaires De Strasbourg,Hospital/Clinic/Other health care facility,08/11/2024
2024-513527-17-00,ACT16877,"A Phase 2, double-blind, randomized, placebo-controlled study assessing efficacy and safety of SAR441344, a CD40L-antagonist monoclonal antibody, in participants with relapsing multiple sclerosis.","Ongoing, recruitment ended","Spain:Ongoing, recruitment ended, Bulgaria:Ongoing, recruitment ended, France:Ongoing, recruitment ended, Germany:Ongoing, recruitment ended, Czechia:Ongoing, recruitment ended",18-64 years,N/A,"Female, Male",72,In both EEA and non-EEA,Multiple Sclerosis,"[""Diseases [C] - Nervous System Diseases [C10]""]",Therapeutic exploratory (Phase II),"Matched Placebo for test product Frexalimab, Frexalimab",Number of new Gadolinium (Gd)-enhancing T1hyperintense (GdE T1) lesions at week 12,"Total number of GdE T1 lesions at week 12, Adverse events (AEs) and serious adverse events (SAEs) until week 316, Antidrug antibodies (ADA) until week 316, Pharmacokinetic (PK) parameters: Cmax until week 316, PK parameter: tmax until week 316, PK parameter: AUC0-tau until week 316, PK parameter: t1/2z until week 316",08/08/2024,07/06/2021,N/A,N/A,No,Sanofi-Aventis Recherche & Developpement,Pharmaceutical company,31/07/2025
2022-502664-21-00,N/A,Noisy Rebels; Non-inferiority study of rituximab compared to ocrelizumab in relapsing MS,"Ongoing, recruiting","Netherlands:Ongoing, recruiting",18-64 years,N/A,"Female, Male",200,EEA only,multiple sclerosis,"[""Diseases [C] - Nervous System Diseases [C10]""]",Therapeutic use (Phase IV),"MabThera 100 mg concentrate for solution for infusion, Rixathon 100 mg concentrate for solution for infusion, Truxima 100 mg concentrate for solution for infusion, Ocrevus 300 mg concentrate for solution for infusion, MabThera 500 mg concentrate for solution for infusion, Truxima 500 mg concentrate for solution for infusion, Rixathon 500 mg concentrate for solution for infusion, Rixathon 100 mg concentrate for solution for infusion, Ruxience 100 mg concentrate for solution for infusion, Ocrevus 300 mg concentrate for solution for infusion, Ruxience 500 mg concentrate for solution for infusion, Rixathon 100 mg concentrate for solution for infusion, Rixathon 500 mg concentrate for solution for infusion",•	The proportion of patients with no new or enlarged T2  lesions  on brain MRI between month 6 and month 24 of treatment in each arm.,•	The annual relapse rate between baseline to month 24 •	The annual relapse rate between month 6 to month 24 •	Proportion of patients with no relapses from baseline to month 24 •	Proportion of patients with no relapses from month 6 to month 24 •	Time to first relapse •	Proportion of patients with no contrast enhancing lesions between baseline and month 24 •	Proportion of patients with no contrast enhancing lesions between month 6 and month 24 •	The average number of new/enlarged T2 lesions betwe,03/03/2023,01/05/2023,N/A,N/A,No,"Amsterdam UMC, Amsterdam UMC","Hospital/Clinic/Other health care facility, Hospital/Clinic/Other health care facility",10/02/2025
2023-510228-63-00,N/A,"Study of Mesenchymal Autologous stem cells as 
Regenerative Treatment for Multiple Sclerosis (SMART-MS)","Authorised, recruitment pending","Norway:Authorised, recruitment pending",18-64 years,N/A,"Female, Male",18,EEA only,Multiple sclerosis,"[""Diseases [C] - Nervous System Diseases [C10]""]",Therapeutic exploratory (Phase II),"Sodium Chloride 0.9 % w/v Intravenous Infusion BP, Mesenchymal stem cells",Difference in CEP (VEP+SEP+MEP) at 6 months as compared to baseline between MSCs treatment vs. placebo (arm A vs. arm B),"Difference in CEP at 12 months (study treatment 1 vs. study treatment 2), Difference in VEP at 6 months (arm A vs. arm B), Difference in VEP at 12 months (study treatment 1 vs. study treatment 2), Difference in SEP at 6 months (arm A vs. arm B), Difference in SEP at 12 months (study treatment 1 vs. study treatment 2), Difference in MEP at 6 months (arm A vs. arm B), Difference in MEP at 12 months (study treatment 1 vs. study treatment 2), Difference in EDSS at 6 months (arm A vs. arm B), Difference in EDSS at 12 months (study treatment 1 vs. study treatment 2), Difference in MRI T2-weighted hyperintense lesion volume at 6 months (arm A vs. arm B), Difference in MRI T2-weighted hyperintense lesion volume at 12 months (study treatment 1 vs. study treatment 2), Difference in MRI T1-weighted hypointense lesion volume at 6 months (arm A vs. arm B), Difference in MRI T1-weighted hypointense lesion volume at 12 months (study treatment 1 vs. study treatment 2), Difference in brain volume at 6 months (arm A vs. arm B), Difference in brain volume at 12 months (study treatment 1 vs. study treatment 2), Difference in visual function (visual acuity, visual field, color vision and contrast sensitivity) at 6 months (arm A vs. arm B), Difference in visual function (visual acuity, visual field, color vision and contrast sensitivity) at 12 months (study treatment 1 vs. study treatment 2), Difference in retinal thickness measured with OCT at 6 months (arm A vs. arm B), Difference in retinal thickness measured with OCT at 12 months (study treatment 1 vs study treatment 2), Difference in Nine-Hole-Peg Test (9-HPT) score at 6 months (arm A vs. arm B), Difference in Nine-Hole-Peg Test (9-HPT) score at 12 months (study treatment 1 vs. study treatment 2), Difference in Timed 25 Foot Walk (T25FW) score at 6 months (arm A vs. arm B), Difference in Timed 25 Foot Walk (T25FW) score at 12 months (study treatment 1 vs. study treatment 2), Difference in the Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS), European Quality of Life 5 dimensions (EQ-5D-5L), Multiple Sclerosis Impact Scale (MSIS) and Fatigue severity scale (FSS) score at 6 months (arm A vs. arm B), Difference in the Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS), European Quality of Life 5 dimensions (EQ-5D-5L), Multiple Sclerosis Impact Scale (MSIS) and Fatigue severity scale (FSS) score at 12 months (study treatment 1 vs. study treatment 2), Difference in serum neurofilament light chain and GFAP at 6 months (arm A vs. arm B), Difference in serum neurofilament light chain and GFAP at 12 monhts (study treatment 1 vs. study treatment 2), Intraindividual CEP (longitudinal) between study treatment 1 vs. study treatment 2 in each patient, Rate and nature of adverse- and serious adverse events during 18 months of follow up, Clinical relevant changes in vital signs during 18 months of follow up, Clinical relevant changes on physical examinations during 18 months of follow up, Clinical relevant changes in clinical laboratory results during 18 months of follow up",30/04/2024,N/A,N/A,N/A,No,Helse Bergen HF,Hospital/Clinic/Other health care facility,30/04/2024
2024-512891-37-00,N/A,A controlled phase II clinical trial evaluating the safety and efficacy of myelin peptide-loaded tolDC as treatment for Multiple Sclerosis,"Authorised, recruitment pending","Spain:Authorised, recruitment pending, Belgium:Authorised, recruitment pending",18-64 years,N/A,"Female, Male",48,EEA only,Multiple Sclerosis,"[""Diseases [C] - Immune System Diseases [C20]""]",Therapeutic exploratory (Phase II),tolDC,Efficacy will be determined by evaluating the number of new and enlarging T2 lesions on MRI scans,"The number and severity of adverse events, Proportion of relapse-free patients, Changes in relapse rate (compared with the year before inclusions), Changes from baseline in mean EDDS scores and supplementary ambulatory clinical outcome measures, change from baseline in T1 Gd and T2 lesion load, atrophy, and total brain volume on MRI scans",22/11/2024,N/A,N/A,N/A,No,Antwerp University Hospital,Hospital/Clinic/Other health care facility,25/11/2024
2024-515563-55-00,RC14_0359,"An open single-center, phase I proof of concept trial to assess the safety and feasibility of adoptive cell therapy with autologous EBV-specific cytotoxic T lymphocytes (CTL) in patients with a first clinical episode highly suggestive of multiple sclerosis","Ongoing, recruiting","France:Ongoing, recruiting",18-64 years,N/A,"Female, Male",7,EEA only,Multiple sclerosis,"[""Diseases [C] - Nervous System Diseases [C10]""]",Human Pharmacology (Phase I)-  Other,N/A,N/A,N/A,03/10/2024,17/02/2025,N/A,N/A,No,Centre Hospitalier Universitaire De Nantes,Hospital/Clinic/Other health care facility,12/02/2025
2024-519921-39-00,N/A,Effect of cladribine treatment on microglial activation in the CNS,"Ongoing, recruitment ended","Finland:Ongoing, recruitment ended",18-64 years,N/A,"Female, Male",15,EEA only,Multiple Sclerosis,"[""Diseases [C] - Immune System Diseases [C20]"",""Diseases [C] - Nervous System Diseases [C10]""]",Therapeutic use (Phase IV),MAVENCLAD 10 mg tablets,Change in microglial cell activation in different brain areas (NAWM normal appearing grey matter and the chronic active/ smoldering (slowly expanding) lesions) before and after 18 months of treatment with cladribine evaluated with [11C]PK11195-PET-imaging.,"Change in microglial cell activation in different brain areas (normal appearing white matter (NAWM), normal appearing grey matter (NAGM) and the chronic active/ smoldering lesions) before and after 18 months of treatment with cladribine evaluated with QSM-MRI., Change in the total lesion load of the white matter MS plaques at different time points using MRI, Change in total brain, white matter (WM) and gray matter (GM) volumes using MRI at different time points of the study, Change in MD (mean diffusivity) and FA (fractional anisotropy) using DTI (diffusion tensor imaging at different time points of the study, Correlation of the baseline microglial activation status to the clinical outcome parameters at the end of the study (18 months) to evaluate whether high microglial activation is predictive of higher likelihood of progression and other measures of disability., Correlation of the baseline microglial activation status to the MRI parameters, Different microglial activation at baseline in the study group when compared to microglial activation in a group of age-matched previously imaged healthy controls, Different microglial activation in the study group to microglial activation in an independent group of previously imaged age-matched untreated MS-patients.",19/12/2024,16/08/2019,N/A,N/A,No,Varsinais-Suomen hyvinvointialue,Hospital/Clinic/Other health care facility,12/02/2025
2023-505420-62-00,WINDOCRE,"For patients with active multiple sclerosis, impact of annual versus semi-annual infusions of ocrelizumab after 2 years of initial treatment on the absence of radiological disease activity at 2 years: a multicentre randomised controlled non-inferiority trial","Ongoing, recruiting","France:Ongoing, recruiting","65+ years, 18-64 years",N/A,"Female, Male",244,EEA only,Multiple sclerosis,"[""Diseases [C] - Nervous System Diseases [C10]"",""Diseases [C] - Immune System Diseases [C20]""]",Therapeutic confirmatory  (Phase III),Ocrevus 300 mg concentrate for solution for infusion,Percentage of patients with no new or enlarged T2 lesion >3mm on cerebro-medullary MRI at 24 months compared to inclusion MRI,"Relapse defined as the onset or worsening of symptoms, in the absence of fever, responsible for an increase of at least 0.5 points in the oberall EDSS score, or of 2 points in at least one functional systems of the EDSS, excluding sphincter and mental/cerebral scores, Disability progression defined as an increase of >20% in Multpile Sclerosis Functional Composite (MSFC) score between inclusion and M24. Disability progression defined by an on-study increase in EDSS score of at least 1 point from baseline if EDSS at baseline was <6, or an increase of at least 0.5 points if EDSS at baseline was equal to 6, Percentage of NEDA 3 patients at M24: NEDA 3 (No Evidence of disease activity) corresponds to the absence of radiological activity and clinical activity : absence of relapses and disability progression, Percentage of patients with at least 3 new T2 lesions on cerebro-medullary MRI at 24 months compared to the inclusion MRI, Number of new T2 lesions on cerebral-medullary MRI at 24 months compared to inclusion MRI, Percentage of patients with no new or enlarged T2 lesion >3mm on cerebro-medullary MRI at 12 months compared to inclusion MRI, Hypogammaglobulinemia defined as a value less than 6g/L, Evolution of the gamma globulin level in plasma protein eletrophoresis between inclusion and M24, Evolution of IgG assays between inclusion and M24., Evolution of IgM assays between inclusion and M24., Evolution of IgA assays between inclusion and M24., Evolution of CD19 lymphocyte counts between inclusion and M24, Incidence of infectious events requiring treatment, Incidence of cancer",31/07/2023,09/11/2023,N/A,N/A,No,Hopital Fondation Adolphe De Rothschild,Hospital/Clinic/Other health care facility,06/06/2025
2022-501622-37-00,N/A,"A Double-blind, Randomized, Active-controlled, Parallel-group, Phase 1/3 study to Compare Efficacy, Pharmacokinetics, Pharmacodynamics and Safety of CT-P53 and Ocrevus in Patients with Relapsing-remitting Multiple Sclerosis.","Ongoing, recruitment ended","Romania:Ongoing, recruitment ended, Poland:Ongoing, recruitment ended, Croatia:Ongoing, recruitment ended, Bulgaria:Ongoing, recruitment ended, Czechia:Ongoing, recruitment ended, Spain:Ongoing, recruitment ended",18-64 years,N/A,"Female, Male",432,In both EEA and non-EEA,Multiple Sclerosis,"[""Diseases [C] - Nervous System Diseases [C10]""]",Therapeutic confirmatory  (Phase III),"Zirtek 1 mg/ml oral solution, Ocrevus 300 mg concentrate for solution for infusion, Paracetamol 500 mg HEXAL bei Fieber und Schmerzen, 500 mg Tabletten, OCRELIZUMAB, Solu-Medrone powder and solvent for solution for injection or concentrate for solution for infusion 125 mg/vial., CT-P53","For PK Group: Area under the concentration-time curve from time zero to Week 2 (AUC0-wk2), For PK Group: Area under the concentration-time curve from Week 2 to Week 24 (AUCwk2-wk24), For Main Study Group: Total number of new GdE lesions on T1-weighted brain MRI up to Week 48",N/A,16/10/2023,16/01/2024,N/A,N/A,No,Celltrion Inc.,Pharmaceutical company,28/07/2025
2023-507633-21-01,MN45053,"An Open-Label, Multicenter Extension Study Evaluating the Patient Perspective of the Physical Impact of Multiple Sclerosis and Providing Continued Access to Ocrelizumab in Patients with Multiple Sclerosis Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Study and without Access to A Post Trial Access Program","Ongoing, recruiting","France:Ongoing, recruiting, Germany:Ongoing, recruiting","65+ years, 18-64 years","65-84 years, 85+ years","Female, Male",106,In both EEA and non-EEA,Multiple Sclerosis,"[""Diseases [C] - Nervous System Diseases [C10]""]",Therapeutic confirmatory  (Phase III),"Ocrevus 300 mg concentrate for solution for infusion, Ocrevus 920 mg solution for injection","1. Change from baseline to end of study in Patient-Reported Outcome Measure Information System/Quality of Life in Neurological Disorders Physical Function Measure for Multiple Sclerosis 15a (PROMISnq PFMS-15a), 2. Number of eligible participants who have received access to ocrelizumab in the study (time frame: up to 5 years)","1. The incidence, nature, severity and outcome of serious adverse events, adverse events leading to discontinuation, and adverse events of special interest",22/11/2024,09/12/2024,N/A,N/A,No,F. Hoffmann-La Roche AG,Pharmaceutical company,11/09/2025
2024-519975-24-00,TolDec-COMBINEM,Dendritic cells therapy combined with immunomodulatory treatment in multiple sclerosis,"Authorised, recruitment pending","Spain:Authorised, recruitment pending",18-64 years,N/A,"Female, Male",45,EEA only,Multiple sclerosis,"[""Diseases [C] - Nervous System Diseases [C10]""]",Therapeutic exploratory (Phase II),TolDec,"EFFICACY - Changes from baseline in the number of CUA lesion (mean number of the sum at week 12, 18 and 24). A CUA lesion is defined as a new or persisting gadolinium-enhancing (Gd+) lesion on T1 MRI or a new or enlarging lesion on T2. Lesions identified in both scans were only counted once., SAFETY: - Proportion of patients with any Grade 3 -4 adverse events related to product administration during the study period. - Proportion of patients with any Grade 3 -4 adverse events related to study product.",N/A,13/01/2025,N/A,N/A,N/A,No,Fundacio De Recerca Clinic Barcelona-Institut D’Investigacions Biomediques August Pi I Sunyer,Laboratory/Research/Testing facility,13/01/2025
2023-507556-68-00,CFTY720D2311,"A two-year, double-blind, randomized, multicenter, active controlled
Core Phase study to evaluate the safety and efficacy of fingolimod administered orally once daily versus interferon β-1a i.m. once weekly in pediatric patients with multiple sclerosis with five-year fingolimod Extension Phase","Ongoing, recruitment ended","Germany:Ongoing, recruitment ended, France:Ongoing, recruitment ended, Slovakia:Ongoing, recruitment ended, Spain:Ongoing, recruitment ended, Romania:Ongoing, recruitment ended",0-17 years,"6-11 years, 12-17 years","Female, Male",35,In both EEA and non-EEA,Multiple Sclerosis,"[""Diseases [C] - Nervous System Diseases [C10]""]",Therapeutic confirmatory  (Phase III),"Gilenya 0.5 mg hard capsules, Gilenya 0.25 mg hard capsules","Annualized relapse rate (ARR) and time to relapse, The annualized rate of new/newly enlarged T2 lesion, Patients free of new or newly enlarged T2 lesions","The number of Gd-enhanced T1 lesions, Patients free of Gd-enhanced T1 lesions, Number of CUA lesions, Change from baseline in T2 lesion/ T1 hypointense lesion volume, Percent brain volume change",04/04/2024,26/07/2013,N/A,N/A,No,Novartis Pharma AG,Pharmaceutical company,16/05/2025
2025-522140-40-00,N/A,TARGET-EBV in MS: A prospective randomized controlled parallel group phase 2b double blinded study to investigate if targeting Epstein Barr Virus with Tenofovir Alafenamide Fumarate compared to placebo as add-on treatment to anti-CD20 therapy reduces neuronal damage in multiple sclerosis,"Authorised, recruitment pending","Norway:Authorised, recruitment pending","18-64 years, 65+ years",65-84 years,"Female, Male",60,EEA only,multiple sclerosis,"[""Phenomena and Processes [G] - Immune system processes [G12]"",""Diseases [C] - Nervous System Diseases [C10]"",""Diseases [C] - Virus Diseases [C02]""]",Therapeutic exploratory (Phase II),"Placebo capules, hard, TENOFOVIR ALAFENAMIDE","Change in mean cerebrospinal fluid (CSF) Neurofilament light chain level (NfL) between the treatment groups from baseline (week 0) to End of Study (EOS), (week 52).","Difference in TSPO binding on PET between the treatment groups from baseline (week 0) to EOS (week 52)., Change in patient reported outcomes of fatigue from baseline (week 0) to EOS (week 52)., Difference in number of PRLs in the treatment groups from baseline (week 0) to EOS (week 52)., Total number of AEs, SAEs and SUSARs, Treatment tolerability",11/08/2025,N/A,N/A,N/A,No,Oslo University Hospital HF,Hospital/Clinic/Other health care facility,11/08/2025
2024-516672-16-00,AB20009,"A 96-Week, Prospective, Multicenter, Randomised, Double-Blind, Placebo-Controlled, Phase 3 Study to Compare Efficacy and Safety of Masitinib Dose Titration to 4.5 mg/kg/day versus Placebo in the Treatment of Patients with Primary Progressive or Secondary Progressive Multiple Sclerosis Without Relapse","Authorised, recruiting","Greece:Authorised, recruitment pending, Spain:Authorised, recruitment pending, Poland:Authorised, recruitment pending, France:Authorised, recruiting","65+ years, 18-64 years",N/A,"Female, Male",145,EEA only,Multiple Sclerosis,"[""Diseases [C] - Nervous System Diseases [C10]""]",Therapeutic confirmatory  (Phase III),"masitinib, Placebo to 200mg masitinib, Placebo to 100mg masitinib, masitinib","The primary endpoint is to assess the efficacy of masitinib 3.0 mg/kg/day with a dose escalation to 4.5 mg/kg/day after four weeks on the time to confirmed (12-weeks CDP) EDSS progression. Progression is defined as 1-point worsening when EDSS score ≤5.5, or 0.5-point worsening if baseline score >5.5.","The secondary endpoints of the study include the following: Expanded Disability Status Scale (EDSS): •	Time to confirmed (24-weeks CDP) EDSS progression. Progression is defined as 1-point worsening when EDSS score ≤5.5, or 0.5 if baseline score >5.5) •	Expanded Disability Status Scale (EDSS): Absolute and ordinal change from baseline considering all measurements up to Week 96 •	Time to EDSS score of 7.0, Clinical Global Assessment Tools: •	Timed 25-foot walk (T25-FW) from baseline up to Week 96 and 12 weeks confirmed worsening using 20% threshold •	Nine-hole peg test (9-HPT), right and left hands sides (finger dexterity) from baseline up to Week 96 and 12 weeks confirmed worsening using 20% threshold •	The Symbol Digit Modalities Test (SDMT) from baseline up to Week 96 and 12 weeks confirmed worsening using 4-point threshold, Brain MRI Assessments: •	Brain Volume and Lesions will be measured and assessed at Baseline, Week 48 and Week 96, or early termination (only if patient discontinues after Week 48 and more than 24 weeks have elapsed since last MRI) for the following endpoints: Brain atrophy - Percent brain volume change (PBVC) from baseline at Week 96 or early termination  •	New/newly enlarged T2 lesion count (compared with baseline MRI scan) at Week 96 or early termination, Quality of Life assessment: •	Quality of life assessment: Multiple Sclerosis Quality of Life (MSQOL)-54 instrument from baseline up to Week 96 •	Modified Fatigue Impact Scale (MFIS) from baseline up to Week 96 •	Hamilton Depression Rating Scale (HAM-D) from baseline up to Week 96 •	Disability Impact Profile (DIP) from baseline up to Week 96, Relapses: •	Occurrence of new or worsening neurological symptoms attributable to MS •	Symptoms persisting for >24 hours •	Symptoms not attributable to confounding clinical factors (e.g., fever, infection, injury, adverse reactions to medications) •	Symptoms immediately preceded by a stable or improving neurological state for at least 30 days •	Ssymptoms accompanied by objective neurological worsening consistent with an increase of at least half a step on the EDSS scale, Biomarker(s): •	Comparison of serum Neurofilament Light Chain (NfL) and Glial Fibrillary Acidic Protein (GFAP) levels at Baseline and Week 96 or early termination (only if patient discontinues after Week 48 and more than 24 weeks have elapsed since last test)  These biomarkers are to be tested in a subgroup of 200 patients of pre-selected sites",30/01/2025,02/02/2024,N/A,N/A,No,Ab Science,Pharmaceutical company,31/01/2025
2024-519800-28-00,CN45847,"An Open-Label, Single-Arm Study to Evaluate Pharmacokinetics, Pharmacodynamic Effects, Safety and Tolerability of Fenebrutinib in Children and Adolescents with Relapsing Multiple Sclerosis","Authorised, recruitment pending","Portugal:Authorised, recruitment pending, Spain:Authorised, recruitment pending, France:Not authorised, Poland:Authorised, recruitment pending",0-17 years,"6-11 years, 12-17 years","Female, Male",8,In both EEA and non-EEA,Relapsing Multiple Sclerosis,"[""Diseases [C] - Nervous System Diseases [C10]""]",Therapeutic exploratory (Phase II),"Fenebrutinib, Fenebrutinib","Plasma concentration of fenebrutinib at specified time points, Total number of new T1 gadolinium−enhancing lesions observed on brain MRI scans at Week 12","Occurrence and severity of adverse events, with severity determined according to NCI CTCAE v5.0, Change from baseline in vital signs, Change from baseline in ECG parameters, Change from baseline in clinical laboratory test results, Proportion of participants with suicidal ideation or behavior, as assessed by Columbia-Suicide Severity Rating Scale",24/06/2025,N/A,N/A,N/A,No,F. Hoffmann-La Roche AG,Pharmaceutical company,30/06/2025
2023-504577-21-00,CLADRI_NET,"A phase IV, unicentric, open label clinical trial to evaluate the default mode network in multiple sclerosis patients on Cladribine treatment.","Authorised, recruitment pending","Spain:Authorised, recruitment pending",18-64 years,N/A,"Female, Male",20,EEA only,Multiple Sclerosis,"[""Diseases [C] - Nervous System Diseases [C10]""]",Therapeutic use (Phase IV),MAVENCLAD 10 mg tablets,Changes in resting state functional activity indexes (rs-fMRI) at 18 months compared to baseline,"Changes in resting state functional activity indexes (rs-fMRI) after 18 months of cladribine treatment, Changes in Image Tensor Diffusion of main cerebral tracts after 18 months of cladribine treatment., Changes in volumetric measures from key brain region (corpus callosum, thalamus and hippocampus) after 18 months of cladribine treatment, The contribution of cortico-cerebellar connectivity to MS cognitive performance after 18 months of cladribine treatment, Changes in cortical Atrophy Index after 18 months of cladribine treatment after 18 months of cladribine treatment., Changes in Brain Activity during processing speed task after 18 months of cladribine treatment., Changes in cognitive functioning indexes measured with neuropsychological tests after 18 months of cladribine treatment., Changes in emotional/behavioural indexes measured with neuropsychological tests after 18 months of cladribine treatment., Changes in clinical neurological status measured with EDSS and ARR after 18 months of cladribine treatment.",26/06/2023,N/A,N/A,N/A,No,María Luisa Martínez Ginés,Health care,26/06/2023
2023-507874-42-00,N/A,A phase 2 trial assessing Ifenprodil as a ReMyelinating repurpOsed Drug in Multiple Sclerosis – MODIF-MS,"Ongoing, recruiting","France:Ongoing, recruiting",18-64 years,N/A,"Female, Male",80,EEA only,Multiple sclerosis,"[""Diseases [C] - Musculoskeletal Diseases [C05]""]",Phase I and Phase II (Integrated)- Other,N/A,N/A,N/A,18/03/2024,27/08/2024,N/A,N/A,No,Assistance Publique Hopitaux De Paris,Hospital/Clinic/Other health care facility,18/03/2024
2024-513292-40-00,RECHMPL23_0397,DESIRE MS: A prospective randomized non-inferiority trial comparing anti-CD20 maintenance versus De-Escalation Strategy In Relapsing-Remitting Multiple Sclerosis,"Authorised, recruitment pending","France:Authorised, recruitment pending","65+ years, 18-64 years",N/A,"Female, Male",250,EEA only,Multiple sclerosis,"[""Diseases [C] - Nervous System Diseases [C10]""]",Therapeutic confirmatory  (Phase III),"OFATUMUMAB, DIMETHYL FUMARATE, OCRELIZUMAB, PEGINTERFERON BETA-1A, DIMETHYL FUMARATE, GLATIRAMER ACETATE, TERIFLUNOMIDE, GLATIRAMER ACETATE, DIROXIMEL FUMARATE, INTERFERON BETA-1A, RITUXIMAB, INTERFERON BETA-1A",The % of patients without disease activity between D0 and M36. Disease activity is defined as 1) the presence of at least one clinical relapse between inclusion and M36 AND/OR 2) Brain MRI activity defined as at least 1 new/enlarged T2/FLAIR lesion on MRI scans between baseline MRI and M36.,"Relapses, Disability, New/enlarged T2/FLAIR lesions, Adverse event and severe adverse events, Infections and serious infections, B-cells counts, Serum immunoglobulin levels (IgG, A, M), Brain volume, Neurofilaments light chain values, EQ5D-5L score, MUSICARE score, Incremental cost-utility ratio at year 3, Annual budget impact from the SNDS (Système National des Données de Santé hosted by French Health Insurance)",28/04/2025,N/A,N/A,N/A,No,Centre Hospitalier Universitaire De Montpellier,Hospital/Clinic/Other health care facility,28/04/2025
2024-519284-18-00,TG1101-RMS401,"Evaluating safety, efficacy and pharmacokinetics of a modified regimen of ublituximab (ENHANCE)","Ongoing, recruitment ended","Poland:Ongoing, recruitment ended","18-64 years, 65+ years",N/A,"Female, Male",150,In both EEA and non-EEA,Relapsing multiple sclerosis,"[""Diseases [C] - Nervous System Diseases [C10]""]",Therapeutic confirmatory  (Phase III),"PARACETAMOL, CETIRIZINE, DEXAMETHASONE, GADOBUTROL, ublituximab, METHYLPREDNISOLONE, DIPHENHYDRAMINE, ublituximab placebo","The proportion of participants with no change or reduction in number of T1 Gd-enhancing lesions from baseline to Week 48, Part B: PK (AUC) over the first 16 weeks (AUC0-W16)","Part A: The proportion of participants free of T1 Gd-enhancing lesions at Week 48, Part A: The proportion of participants experiencing IRRs as reported by the Investigator, Part A: Treatment Satisfaction Questionnaire for Medication (TSQM-9) scores at Week 24 and Week 48, Part A: Pharmacokinetics of ublituximab, Part B: The proportion of participants who experience any grade treatment-emergent adverse events (TEAEs), Part B: The proportion of participants experiencing infusion related reaction (IRR) as reported by the Investigator, Part B: The number of T1 Gd-enhancing lesions per MRI scan at Week 24 and Week 48, Part B: PK (Cmax) at Day 1 and Day 15, Part B: The proportion of participants with CD19+ B-cell counts below a specific level at all timepoints",20/03/2025,18/06/2025,N/A,N/A,No,Tg Therapeutics Inc.,Pharmaceutical company,19/09/2025
2024-516732-97-00,FETEM,"AMANTADINE AND TRANSCRANIAL MAGNETIC TRANSCRANIAL MAGNETIC STIMULATION FOR FATIGUE IN MULTIPLE SCLEROSIS: A PHASE III, CONTROLLED, RANDOMISED, DOUBLE-BLIND, CROSSOVER TRIAL","Ongoing, recruitment ended","Spain:Ongoing, recruitment ended","65+ years, 18-64 years",N/A,"Female, Male",144,EEA only,multiple sclerosis (MS),"[""Diseases [C] - Nervous System Diseases [C10]""]",Therapeutic confirmatory  (Phase III),Amantadine Level 100 mg cápsulas duras,The change in the values of the MFIS questionnaire is considered as the main study variable for the evaluation of effectiveness.,"- Patient-perceived quality of life. The change in the mean score of the patient-perceived quality of life scale (SF-12) between the time of inclusion in the study and at the beginning and end of each phase will be assessed. - Beck Depression Inventory-II to assess depressive symptomatology. The assessment will be made at inclusion, and at the beginning and end of each phase. - Total costs per patient. Total costs of hospitalisation and treatment as well as other health care will be measured. -",11/09/2024,28/11/2022,N/A,N/A,No,Fundacion Para La Investigacion Biomedica Del Hospital Clinico San Carlos,Laboratory/Research/Testing facility,11/09/2024
2022-502619-13-00,GN43271,"A Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy of Fenebrutinib in Relapsing Multiple Sclerosis","Ongoing, recruitment ended","Czechia:Ongoing, recruitment ended, Croatia:Ongoing, recruitment ended, Slovakia:Ongoing, recruitment ended",18-64 years,N/A,"Female, Male",67,In both EEA and non-EEA,Relapsing Multiple Sclerosis,"[""Diseases [C] - Nervous System Diseases [C10]""]",Therapeutic exploratory (Phase II),N/A,"1. Total number of new gadolinium-enhancing T1 lesions observed on MRI scans of the brain at Weeks 4, 8, and 12","1. Total number of new or enlarging T2- weighted lesions observed on brain MRI at Weeks 4, 8, and 12, 2. Proportion of participants free from any new gadolinium-enhancing T1 lesions and new or enlarging T2-weighted lesions observed on brain MRI at Weeks 4, 8, and 12, 3. Incidence and severity of adverse events, 4. Change from baseline in vital signs, 5. Change from baseline in targeted clinical laboratory test results, 6. Proportion of participants with suicidal ideation or behavior, as assessed by Columbia-Suicide Severity Rating Scale, 7. Plasma concentration of fenebrutinib at specified timepoints",01/08/2024,25/01/2022,N/A,N/A,No,F. Hoffmann-La Roche AG,Pharmaceutical company,13/02/2025
2024-512707-40-00,ZB012-02-002,"A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Obexelimab in Patients with Relapsing Multiple Sclerosis","Authorised, recruiting","Greece:Ongoing, recruitment ended, Finland:Ended, Italy:Ongoing, recruitment ended, Czechia:Ongoing, recruitment ended, Denmark:Ongoing, recruitment ended, Austria:Ongoing, recruitment ended, Croatia:Ongoing, recruitment ended, Spain:Ongoing, recruitment ended, Belgium:Ongoing, recruitment ended, Poland:Ongoing, recruitment ended",18-64 years,N/A,"Female, Male",60,In both EEA and non-EEA,RELAPSING MULTIPLE SCLEROSIS,"[""Diseases [C] - Nervous System Diseases [C10]""]",Therapeutic exploratory (Phase II),"Placebo sterile solution for SC injection, Obexelimab","Cumulative number of new GdE T1 hyperintense lesions over Week 8 and Week 12, as measured by brain MRI","Cumulative number of new and/or enlarging T2 weighted hyperintense lesions detected over Week 8 and Week 12, Number of new GdE T1 hyperintense lesions at Week 4, Week 8, and Week 12, Change from baseline in volume of T2 lesions at Week 12, Change from baseline in serum NfL at Week 12, Incidence of adverse events (AEs), serious adverse events (SAEs), and AEs of special interest, (AESI), as defined by the Common Terminology of Criteria for Adverse Events (CTCAE) Version 5.0",27/09/2024,07/11/2024,N/A,N/A,No,Zenas Biopharma (USA) LLC,Pharmaceutical company,19/08/2025
2024-511028-15-00,STEMS2,"A phase 2, randomized, patient and assessor blind, multicentre study comparing foetal neural stem cells transplantation to sham procedure in progressive multiple sclerosis (STEMS2)",Temporarily halted,Italy:Temporarily halted,"65+ years, 18-64 years",65-84 years,"Female, Male",86,EEA only,Progressive Multiple Sclerosis,"[""Diseases [C] - Nervous System Diseases [C10]""]",Therapeutic exploratory (Phase II),"TACROLIMUS, human fetal neural precursor cells",Change in whole brain volume evaluated through magnetic resonance imaging (MRI) in 96 weeks (W) of follow-up,"Rate and nature of the adverse events, classified according to the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 and attributed to the investigational medicinal product accordingly to national cancer institute (NCI) guidelines of adverse event (AE) reporting requirements., Percentage change in brain grey matter volume evaluated through MRI in 96 weeks of follow-up., Percentage change in brain white matter volume evaluated through MRI in 96 weeks of follow-up., Proportion of patients with no evidence of 24-weeks confirmed disability progression (defined as progression by 1 step on the Expanded Disability Status Scale (EDSS) in patients with EDSS ≤ 5.5 or of 0.5 EDSS steps in patients with EDSS ≥ 6, confirmed after 24 weeks interval) in 96 weeks of follow-up, Proportion of patients with no evidence of progression (defined as no progression sustained for at least 24 weeks on all of the following three components: confirmed disability progression; ≥20% increase in timed 25-foot walk test [T25FWT]; ≥20% increase in nine-hole peg test [9HPT]. The T25FWT will not be considered for patients who are unable to complete the test at baseline [EDSS score ≥ 7.0] in 96 weeks of follow-up., Proportion of patients with no active disease, defined as no clinical relapses, no enlarging or new T2 hyperintense lesions, and no gadolinium (Gd+)-enhancing lesions in 96 weeks of follow-up., Change in cognitive function as measured by the symbol digit modalities test (SDMT) in 96 weeks of follow-up.",12/08/2024,04/08/2025,N/A,N/A,No,Ospedale San Raffaele S.r.l.,Hospital/Clinic/Other health care facility,18/03/2025
2023-508439-30-00,NXPTEGO/23/P1-4,Safety Study to Compare the Gastrointestinal Tolerability of Oral Tegomil Fumarate and Dimethyl Fumarate (Tecfidera®) in Healthy Volunteers.,"Ongoing, recruiting","Portugal:Ongoing, recruiting",18-64 years,N/A,"Female, Male",210,EEA only,Multiple Sclerosis,"[""Diseases [C] - Nervous System Diseases [C10]""]",Human Pharmacology (Phase I)-  Other,N/A,N/A,N/A,15/03/2024,21/08/2024,N/A,N/A,No,Neuraxpharm Pharmaceuticals S.L.,Pharmaceutical company,07/03/2025
2023-503814-62-00,N/A,Tenofovir Alafenamide Fumarate and Epstein-Barr virus activity in people with MS – The TAF-MS study,"Ongoing, recruitment ended","Norway:Ongoing, recruitment ended",18-64 years,N/A,"Female, Male",50,EEA only,Multiple sclerosis,"[""Diseases [C] - Nervous System Diseases [C10]""]",Therapeutic exploratory (Phase II),"Capsule coated tablets, Tysabri 300 mg concentrate for solution for infusion, Vemlidy 25 mg film-coated tablets.",Total number of SAEs from baseline to 24 weeks after start of study treatment,"Change in IgG antibodies to EBNA1 and other EBV antigens from baseline to 2, 8 and  24 weeks after start of study treatment., Change in EBV viral load in saliva from baseline to 2, 8 and 24 weeks after start of  study treatment., Key secondary endpoints Change in EBV shedding in saliva",20/11/2023,06/02/2024,N/A,N/A,No,Helse Bergen HF,Hospital/Clinic/Other health care facility,08/11/2024
2024-514549-12-00,FNO-RS2-OCREPRIPRO,The use of therapeutic monitoring of ocrelizumab serum concentrations for personalized pharmacotherapy of relapsing-remitting and primary progressive multiple sclerosis,"Ongoing, recruiting","Czechia:Ongoing, recruiting","65+ years, 18-64 years",N/A,"Female, Male",100,EEA only,Multiple Sclerosis,"[""Diseases [C] - Nervous System Diseases [C10]""]",Therapeutic use (Phase IV),"Ocrevus 920 mg solution for injection, Ocrevus 300 mg concentrate for solution for infusion","To determine serum concentrations of neurofilament light chains (ng/L), To determine serum concentrations of glial fibrillary acidic protein (ng/L), To determine the presence of antibodies against OCR (mg/L), To determine the number of CD19+ cells (or other cells of the immune system that are associated with MS), To determine the quality of life measured with the MSQOL-54 questionnaire (point value score), To assess clinical status using the 25FWT, 9HPT and SDMT tests (point value score), To assess the results of brain magnetic resonance examination (number of new or recently enlarged T2 lesions or T1 Gd+ lesions, average percentage change in brain volume), To determine disability progression (assessed as change on the EDSS scale), To determine the course of MS (assessed as NEDA-3 concept), To determine  occurrence of relapses since the previous check-up (for patients with relapsing remitting MS)","To determine serum concentrations of OCR in patients with RR and/or PP RS – observational goal, To determine whether the dose of OCR or the serum concentration of OCR better correlates with the development of paraclinical and clinical parameters  and with the prognosis of patients with RR and/or PP MS - observational goal, To analyze the correlation of possible adverse effects of OCR with its measured serum concentration; evaluated variables: OCR adverse effects (infectious and other), blood count, serum creatinine concentration (µmol/L), eGFR (ml/s), serum concentration of IgG (g/L) and IgM (g/L) – safety target, On the basis of the obtained data, possibly introduce TDM OCR into routine clinical practice in patients with RR and/or PP MS and thus expand the multidisciplinary approach to patients with this diagnosis – implementation goal",10/09/2024,16/06/2025,N/A,N/A,No,Fakultni Nemocnice Ostrava,Hospital/Clinic/Other health care facility,05/09/2025
2024-510716-71-00,N/A,Ocrelizumab VErsus Rituximab off-Label at the Onset of Relapsing MS Disease (OVERLORD-MS),"Ongoing, recruitment ended","Norway:Ongoing, recruitment ended, Sweden:Ongoing, recruitment ended",18-64 years,N/A,"Female, Male",214,EEA only,Multiple Sclerosis,"[""Diseases [C] - Nervous System Diseases [C10]""]",Therapeutic confirmatory  (Phase III),"MabThera 500 mg concentrate for solution for infusion, Ocrevus 300 mg concentrate for solution for infusion","Proportion of patients with no new or enlarging T2-weighted brain MRI lesions from month 6 (re-baseline) to month 24, SWITCH: Proportion of patients with no new or enlarging T2-weighted brain MRI lesions from  month 24 to month 36, REDUCE: Proportion of patients with no new or enlarging T2-weighted brain MRI lesions from  month 36 to month 60 compared to the period before (month 0-36","The annual relapse rate from baseline to month 24, Proportion of patients without relapses from baseline to month 24, Proportion of patients with progression in SDMT from baseline to month 24. Progression in SDMT is defined as patients experiencing a reduction of 15% or more from baseline (Strober, DeLuca et al. 2019, Marstrand, Osterberg et al. 2020), Frequency of SAE/SAR and AESI during 24 months of treatment, The frequency of immediate and delayed infusion reactions during 24 months of treatment, The frequency of infections during 24 months of treatment, The frequency any malignancies during 24 months of treatment, Proportion of patients with no new or enlarging T2-weighted brain MRI lesions from  baseline to month 6, and from baseline to month 24, Proportion of patients without new gadolinium enhancing T1-weighted brain MRI lesions  at month 6, month 12 and month 24, Change in brain volumes from baseline to month 24 and from month 6 to month 24, SWITCH: The annual relapse rate from month 30 to month 36, SWITCH: Proportion of patients without relapses from month 30 to month 36, SWITCH: Proportion of patients without new gadolinium enhancing T1-weighted brain MRI lesions  from month 24 to month 36, SWITCH: Change in brain volumes from month 24 to month 36, SWITCH: Proportion of patients with 6-months confirmed disability progression (6M-CDP) as  measured by the Expanded disability status scale (EDSS) from month 30 to month 36, SWITCH: Proportion of patients with 6-months confirmed disability improvement (6M-CDI) as  measured by the Expanded disability status scale (EDSS) from month 30 to month 36, SWITCH: Proportion of patients with 6M-CDP in SDMT from month 30 to month 36, SWITCH: Frequency of SAE/SAR and AESI from month 30 to month 36, SWITCH: The frequency of immediate and delayed infusion reactions from month 30 to month 36, SWITCH: The frequency of infections from month 30 to month 36, SWITCH: The frequency any malignancies from month 30 to month 36, REDUCE: The annual relapse rate from month 36 to month 60, REDUCE: Proportion of patients without relapses from month 36 to month 60, REDUCE: Proportion of patients with no new or enlarging T2-weighted brain MRI lesions from  month 36 to month 60, REDUCE: Change in brain volumes from month 36 to month 60, REDUCE: Proportion of patients with 6-months confirmed disability progression (6M-CDP) as  measured by the Expanded disability status scale (EDSS) (Kurtzke 1983) from month 36  to month 60, REDUCE: Proportion of patients with 6-months confirmed disability improvement (6M-CDI) as  measured by the Expanded disability status scale (EDSS) (Kurtzke 1983) from month 36  to month 60, REDUCE: Proportion of patients with 6M-CDP in SDMT from month 36 to month 60, REDUCE: Frequency of SAE/SAR and AESI from month 36 to month 60, REDUCE: The frequency of grade 2 or above immediate and delayed infusion reactions from month  36 to month 60, REDUCE: The frequency of grade 2 or above infections from month 36 to month 60, REDUCE: The frequency any malignancies from month 36 to month 60, Proportion of patients with 6-months confirmed disability progression (6M-CDP) as measured by the Expanded disability status scale (EDSS) (Kurtzke 1983) from baseline to month 24.EDSS at month 24 is confirmed at month 30 (6M-CDP is defined in section 8.2.3)., Proportion of patients with 6-months confirmed disability improvement (6M-CDI) as measured by the Expanded disability status scale (EDSS) (Kurtzke 1983) from baseline to month 24. EDSS at month 24 is confirmed at month 30 (6M-CDI is defined in section 8.2.3), SWITCH: Proportion of patients with no new or enlarging T2-weighted brain MRI lesions from  month 24 to month 36",09/10/2024,21/10/2020,N/A,N/A,No,Helse Bergen HF,Hospital/Clinic/Other health care facility,16/09/2025
2024-517336-21-00,N/A,"Prospective, randomized, double-blind, placebo-controlled, single-center comparative trial evaluating oral Istradefylline 40 mg once daily for reducing microglial activation in the brain of patients with progressive multiple sclerosis (MS)","Authorised, recruitment pending","Finland:Authorised, recruitment pending",18-64 years,N/A,"Female, Male",34,EEA only,Progressive multiple sclerosis,"[""Diseases [C] - Nervous System Diseases [C10]"",""Diseases [C] - Immune System Diseases [C20]""]",Therapeutic exploratory (Phase II),"Placebo tablets will be white, round, flat, scored tablet, 9 mm in diameter sourced from Yliopiston Apteekki, ISTRADEFYLLINE",The change in proportion of active voxels in supratentorial cerebral white matter in the end-of-treatment TSPO-PET images vs. baseline TSPO-PET images in participants with progressive MS treated with istradefylline vs. placebo,"Change in number of TSPO-PET–measurable chronic active lesions, Change in proportion of TSPO-PET–detectable active voxels at the rim of chronic lesions (change in proportion of active voxels), Change in proportion of TSPO-PET–detectable active voxels in the NAWM (change in proportion of active voxels), Change in TSPO-PET signal (DVR, distribution volume ratio) at the rim of chronic lesions, Change in DVR in the NAWM, Change in QSM-positive iron rim lesions, Change in MRI volumetric measures in the brain regions of interest, Change in T1 and T2 lesion burden using MRI, Change in neuroaxonal damage measured by DTI-MRI parameters, Change in disease worsening measured using the Timed 25 Foot Walk, Change in hand dexterity measured using the 9-Hole Peg Test, Change in functional Systems and Expanded Disability Status Scale, Change in cognition measured using neuropsychological evaluation, Change in health-related quality of life measured using the RAND 36-Item Health Survey and Multiple Sclerosis Impact Scale questionnaires, Change in fatigue measured using the Modified Fatigue Impact Scale and Fatigue Severity Scale questionnaires, Change in blood serum neurofilament light chain and glial fibrillary acdic protein levels",15/11/2024,N/A,N/A,N/A,No,University Of Turku,Educational Institution,12/02/2025
2024-513639-26-00,WN45319,"A Study to Investigate Single Ascending Doses of Ocrelizumab for Safety and Side Effects, How The Body Handles It Over A Period of Time, How The Body Notices and Reacts To It, And Its Effect On The Body When Given As A Subcutaneous Injection In Patients With Multiple Sclerosis",Ended,"Belgium:Ended, France:Ended, Czechia:Ended, Spain:Ended, Poland:Ended",18-64 years,N/A,"Female, Male",44,In both EEA and non-EEA,Multiple Sclerosis (MS),"[""Diseases [C] - Immune System Diseases [C20]"",""Diseases [C] - Nervous System Diseases [C10]""]",Human Pharmacology (Phase I)-  Other,N/A,N/A,N/A,14/10/2024,N/A,18/03/2025,N/A,No,F. Hoffmann-La Roche AG,Pharmaceutical company,21/10/2024
2024-516433-13-00,21-PP-23,LONG-TERM EFFECTIVENESS AND SAFETY EVALUATION OF OCRELIZUMAB IN FRENCH PATIENTS WITH PROGRESSIVE MS: CONSONANCE EXTENSION STUDY,"Authorised, recruitment pending","France:Authorised, recruitment pending",18-64 years,N/A,"Female, Male",89,EEA only,Progressive multiple sclerosis,"[""Diseases [C] - Nervous System Diseases [C10]""]",Therapeutic confirmatory  (Phase III),N/A,N/A,N/A,19/09/2024,N/A,N/A,N/A,No,Centre Hospitalier Universitaire De Nice,Hospital/Clinic/Other health care facility,19/09/2024
2024-514619-88-00,P3-IMU-838-RMS-02,"P3-IMU-838-RMS-02 - A Multi-Center, Randomized, Double-Blinded Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of IMU-838 versus Placebo in Adults with Relapsing Multiple Sclerosis (ENSURE-2)","Ongoing, recruitment ended","Romania:Ongoing, recruitment ended, Germany:Ongoing, recruitment ended, Estonia:Ongoing, recruitment ended, Poland:Ongoing, recruitment ended",18-64 years,N/A,"Female, Male",321,In both EEA and non-EEA,Relapsing Multiple Sclerosis,"[""Diseases [C] - Nervous System Diseases [C10]""]",Therapeutic confirmatory  (Phase III),"IMU-838 30 mg tablet, IMU-838 15 mg tablets, Placebo for IMU-838 Tablets","Time to first confirmed relapse, as determined by the Independent Neurology Evaluation Committee (INEC), relapse occurred after the start of treatment administration and before the end of the main period (EOMP), censored at a maximum of 72 weeks, Visit 8 (V8)/EOMP","Key secondary efficacy: 1) Changes in total volume of new T2-lesions from baseline (BL, SV2) magnetic resonance imaging (MRI) until Week 24 MRI;, 2) Time to 12-week confirmed disability worsening (12wCDW) as assessed on Expanded Disability Status Scale (EDSS); as defined in this protocol during the MP (censored until at Week 72/EOMP visit but with confirmation potentially done within EP, if applicable);, 3) Time to confirmed clinically relevant changes in Symbol Digit Modalities Test (SDMT) in the MP (censored Week 72/EOMP);, 4) Annualized rate of percentage changes in whole brain volume from BL MRI to until V8/EOMP MRI; Please refer to protocol for secondary efficacy, safety, and exploratory endpoints.",04/10/2024,18/03/2022,N/A,N/A,No,Immunic AG,Pharmaceutical company,03/04/2025
2023-507493-41-00,COMB157G23101,"A single-arm, prospective, multicentre, open-label study to evaluate ofatumumab treatment effectiveness and patient-reported outcomes (PRO) in patients with relapsing multiple sclerosis (RMS) transitioning from fumarate-based RMS approved therapies or fingolimod.",Ended,"Poland:Ended, Bulgaria:Ended, Portugal:Ended, Slovakia:Ended, Germany:Ended, Slovenia:Ended, Spain:Ended, Latvia:Ended",18-64 years,N/A,"Female, Male",293,In both EEA and non-EEA,relapsing multiple sclerosis (RMS),"[""Diseases [C] - Nervous System Diseases [C10]""]",Therapeutic confirmatory  (Phase III),"Kesimpta 20 mg solution for injection in pre-filled pen, Kesimpta 20 mg solution for injection in pre-filled pen","Annual relapse rate (ARR, based on confirmed relapses) measured over the 96 weeks","Proportion of subjects with adverse events, including injection related reactions, Proportion of patients with laboratory or vital signs results meeting abnormal criteria, The proportion of subjects discontinuing treatment due to insufficient effectiveness (lack of efficacy) or tolerability/safety reasons",08/07/2024,04/08/2020,27/09/2024,11/03/2025,No,Novartis Pharma AG,Pharmaceutical company,24/07/2024
2024-514618-11-00,P3-IMU-838-RMS-01,"P3-IMU-838-RMS-01 - A Multi-Center, Randomized, Double-Blinded Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of IMU-838 versus Placebo in Adults with Relapsing Multiple Sclerosis (ENSURE-1)","Ongoing, recruitment ended","Germany:Ongoing, recruitment ended, Lithuania:Ongoing, recruitment ended, Bulgaria:Ongoing, recruitment ended, Poland:Ongoing, recruitment ended",18-64 years,N/A,"Female, Male",423,In both EEA and non-EEA,Relapsing Multiple Sclerosis,"[""Diseases [C] - Nervous System Diseases [C10]""]",Therapeutic confirmatory  (Phase III),"IMU-838 15 mg tablets, Placebo for IMU-838 Tablets, IMU-838 30 mg tablet","Time to first confirmed relapse, as determined by the Independent Neurology Evaluation Committee (INEC), relapse occurred after the start of treatment administration and before the end of the main period (EOMP), censored at a maximum of 72 weeks, Visit 8 (V8)/EOMP","Key secondary efficacy: 1) Changes in total volume of new T2-lesions from baseline (BL, SV2) magnetic resonance imaging (MRI) until Week 24 MRI;, 2) Time to 12-week confirmed disability worsening (12wCDW) as assessed on Expanded Disability Status Scale (EDSS); as defined in this protocol during the MP (censored until at Week 72/EOMP visit but with confirmation potentially done within EP, if applicable);, 3) Time to confirmed clinically relevant changes in Symbol Digit Modalities Test (SDMT) in the MP (censored Week 72/EOMP), 4) Annualized rate of percentage changes in whole brain volume from BL MRI to until V8/EOMP MRI; Please refer to protocol for secondary efficacy, safety, and exploratory endpoints.",15/10/2024,01/03/2022,N/A,N/A,No,Immunic AG,Pharmaceutical company,03/04/2025
2023-506863-32-00,BN44083,"A Study to Investigate the Safety, Tolerability, Immunogenicity, Pharmacokinetics, and Pharmacodynamics of Ascending Intravenous Doses of Glofitamab, Administered after Ocrelizumab Pretreatment, in Patients with Multiple Sclerosis","Ongoing, recruitment ended","Croatia:Ongoing, recruitment ended, Czechia:Ongoing, recruitment ended",18-64 years,N/A,"Female, Male",5,EEA only,Multiple Sclerosis (MS),"[""Diseases [C] - Nervous System Diseases [C10]""]",Human Pharmacology (Phase I)-  Other,N/A,N/A,N/A,11/07/2024,25/07/2023,N/A,N/A,No,F. Hoffmann-La Roche AG,Pharmaceutical company,03/09/2025
2023-508457-10-00,MELATOMS-1,"Randomized, Single-blind, Placebo-controlled Clinical Trial to Evaluate the
Safety and Efficacy of Melatonin Administration in Patients With Multiple
Progressive Primary Sclerosis (MELATOMS)","Authorised, recruitment pending","Spain:Authorised, recruitment pending","65+ years, 18-64 years",N/A,"Female, Male",50,EEA only,Primary Progressive Multiple Sclerosis,"[""Diseases [C] - Nervous System Diseases [C10]""]",Phase I and Phase II (Integrated)- First administration to humans,"MELATONIN, Excipient No. 1 for Fagron capsules (200 milligrams), Composition: 98.05% microcrystalline cellulose AND 1.95% colloidal silica.",Disease progression: rates of neurological impairment (Kurtzke Expanded Disability Status Scale) and rates of disability (Multiple Sclerosis Functional Composite - MSFC scale).,"Number of participants with treatment-related adverse events, Cerebral atrophy, Fatigue, Quality of life, Sleep disorders, Spasticity, Efficacy of neuroinflammation, Axonal damage, Oxidative stress, Impact on microbiota",15/11/2024,N/A,N/A,N/A,No,Fundacion Publica Andaluza Para La Gestion De La Investigacion En Salud De Sevilla,Laboratory/Research/Testing facility,15/11/2024
2023-509538-20-01,35RC21_9806,"MAESTRO-4MS : ""Allogenic Adipose tissue-derived Mesenchymal Stromal Cells for the treatment of Primary Progressive Multiple Sclerosis: an open-label phase I clinical trial.""","Ongoing, recruiting","France:Ongoing, recruiting",18-64 years,N/A,"Female, Male",15,EEA only,Primary Progressive Multiple Sclerosis,"[""Diseases [C] - Nervous System Diseases [C10]""]",Human Pharmacology (Phase I)- First administration to humans,N/A,N/A,N/A,04/07/2024,06/03/2025,N/A,N/A,No,Centre Hospitalier Universitaire De Rennes,Hospital/Clinic/Other health care facility,07/08/2025
2023-507431-37-00,COMB157G3301,"An Open-Label, Rater-Blind, Randomized, Multi-Center, Parallel-Arm, Active-Comparator Study to Assess the Efficacy and Tolerability of Ofatumumab 20mg SC monthly vs. First Line DMT - physician’s choice in the treatment of newly diagnosed RMS (STHENOS)","Ongoing, recruitment ended","France:Ongoing, recruitment ended, Germany:Ongoing, recruitment ended, Italy:Ongoing, recruitment ended, Spain:Ended",18-64 years,N/A,"Female, Male",186,EEA only,relapsing multiple sclerosis (RMS),"[""Diseases [C] - Nervous System Diseases [C10]""]",Therapeutic confirmatory  (Phase III),"TERIFLUNOMIDE, INTERFERON BETA-1A, DIROXIMEL FUMARATE, INTERFERON BETA-1A, INTERFERON BETA-1A, GLATIRAMER ACETATE, Betaferon 250 microgram/ml, powder and solvent for solution for injection, OFATUMUMAB, GLATIRAMER ACETATE, DIMETHYL FUMARATE, PEGINTERFERON BETA-1A, DIMETHYL FUMARATE",NEDA-3 status (yes or no)  NEDA-3 is defined as:  1.	Absence of confirmed clinical relapse  2.	Absence of new MRI activity (Gd+ T1 lesion or new/enlarged T2 lesion) with MRI re-baselined at Month 3  3.	Absence of 3-month confirmed disability worsening,"Number of relapses up to Month 15/ EOS, Annual Relapse Rate (ARR), Mean time to first relapse, Proportion of relapse-free patients at Month 3, 9 and 15, Proportion of relapse-free patients with MRI activity-free (no new Gd+ T1 lesion or new/enlarged T2 lesion) at Month 3, 9 and 15, Time to 3-month Confirmed Disability Worsening (3mCDW), Time to 6-month Confirmed Disability Worsening (6mCDW), Change in expanded disability status scale (EDSS) from Baseline to end of study, Proportion of disability progression free patient at EOS, Number of Gadolinium enhancing (Gd+) T1 lesions of brain, Volume of Gd+ T1 lesions of brain, Number of new/enlarging T2 lesions of brain, Volume of new/enlarging T2 lesions of brain, Proportion of SAEs, and SAEs with hospitalizations between ofatumumab 20 mg s.c. and first line self-administered DMTs, Proportion of patients with adverse events, including injection related reactions, Proportion of patients who withdrew due to abnormal lab values, Proportion of treatment discontinuation or interruptions for safety/ tolerability reason, Compliance to treatment using patient diary",27/06/2024,23/07/2021,N/A,N/A,No,Novartis Pharma AG,Pharmaceutical company,02/06/2025
2024-512714-18-00,CYTB323N12101,"An open-label, multi-center, phase 1/2 study to assess safety, efficacy, and cellular kinetics of YTB323 in participants with Relapsing Multiple Sclerosis with breakthrough disease activity during previous treatment with a highly efficacious therapy","Authorised, recruitment pending","France:Authorised, recruitment pending, Germany:Authorised, recruitment pending, Italy:Authorised, recruitment pending, Spain:Authorised, recruitment pending",18-64 years,N/A,"Female, Male",15,In both EEA and non-EEA,Relapsing Multiple Sclerosis,"[""Diseases [C] - Nervous System Diseases [C10]""]",Phase I and Phase II (Integrated)- Other,"TOCILIZUMAB, YTB323, FLUDARABINE PHOSPHATE, CYCLOPHOSPHAMIDE","Change in safety parameters including, but not limited to severity and frequency dose limiting toxicities (DLTs) of Adverse Events (AEs) and findings in vital signs, laboratory, ECG, neurological status, and safety MRI of the brain","Clinical measures for relapses and disability (includes EDSS, XX, T25FW, 9HPT, SDMT, XX) and MRI changes in disease activity (including new and enlarging T2 lesions and Gd-enhancing T1 lesions), YTB323 transgene expression levels by qPCR over time in blood; cellular kinetics parameters (Cmax, AUC, Tmax, Clast, Tlast), Safety data from each dose level, Pre-existing and treatment-induced immunogenicity (humoral, anti-YTB323 antibody; and cellular, presence of CAR19 specific CD4 and CD8 T cells measuring interferon gamma production)",21/03/2025,N/A,N/A,N/A,No,Novartis Pharma AG,Pharmaceutical company,17/04/2025
2024-516680-91-00,TG1101-RMS303,An Open Label Extension Study of Ublituximab in Subjects with Relapsing Multiple Sclerosis,"Ongoing, recruitment ended","Poland:Ongoing, recruitment ended, Croatia:Ongoing, recruitment ended",18-64 years,N/A,"Female, Male",137,In both EEA and non-EEA,relapsing multiple sclerosis,"[""Diseases [C] - Nervous System Diseases [C10]""]",Therapeutic confirmatory  (Phase III),ublituximab,"Relapses: • Annualized Relapse Rate (ARR) is defined as the number of relapses per- subject year. The estimate of ARR will be the total number of relapses divided by the sum of duration on study treatment (years)., MRI parameters: • T1 gadolinium enhancing (Gd-enhancing) • T1 hypointense lesions • T2 lesions • Brain atrophy, Disability: • 24-Week Confirmed Disability Progression (CDP) • 24-Week Confirmed Disability Improvement (CDI) • Mean change from baseline in EDSS score, No Evidence of Disease Activity (NEDA): • NEDA is defined as subjects without relapses, MRI activities (no T1 Gd-enhancing lesions and no new/enlarging T2 lesions), and no 24-week confirmed disability progression. • The percent of subjects with no evidence of disease activity, Cognition and Function: • Cognition will be measured by Symbol Digit Modalities Test (SDMT) • Function will be measured by Multiple Sclerosis Functional Composite (MSFC), Safety Endpoints: All AEs will be reported and evaluated during the treatment period using NCI CTCAE v.5.0 grading system; the number and severity of infusion-associated events; the number and severity of infectious AEs; any clinically significant changes in laboratory or vital sign measurements; the incidence of anti-drug antibodies",N/A,11/11/2024,21/05/2020,N/A,N/A,No,Tg Therapeutics Inc.,Pharmaceutical company,28/11/2024
2023-505975-54-00,CN42097,"A Phase III, Non-Inferiority, Randomized, Open-Label, Parallel Group, Multicenter Study to Investigate the Pharmacokinetics, Pharmacodynamics, Safety and Radiological and Clinical Effects of Subcutaneous Ocrelizumab Versus Intravenous Ocrelizumab in Patients with Multiple Sclerosis",Ended,"Spain:Ended, Czechia:Ended, Poland:Ended, Italy:Ended",18-64 years,N/A,"Female, Male",153,In both EEA and non-EEA,Multiple Sclerosis (MS),"[""Diseases [C] - Immune System Diseases [C20]"",""Diseases [C] - Nervous System Diseases [C10]""]",Therapeutic confirmatory  (Phase III),"Ocrevus, Ocrevus 300 mg concentrate for solution for infusion",1. Serum ocrelizumab area under the concentration-time curve (AUC[w1-12]) after SC administration compared to IV infusion from Day 1 to Week 12,"1. Maximum serum concentration (Cmax) of ocrelizumab SC in patients with MS, 2. Total number of T1Gd+ lesions as detected by brain magnetic resonance imaging (MRI) at Weeks 8 and 24, 3. Total number of new or enlarging T2 lesions as detected by brain MRI at Weeks 12 and 24 relative to the previous scan, 4. Incidence and severity of adverse events, with severity determined according to the national cancer institute common terminology criteria for adverse events (NCI-CTCAE) version 5.0, 5. Change from baseline in targeted vital signs, 6. Change from baseline in targeted clinical laboratory test results, 7. Incidence of treatment-emergent antidrug antibodies (ADAs) to ocrelizumab after SC or IV administration relative to the presence of ADAs at baseline, 8. Relationship between ADA status to ocrelizumab and pharmacokinetics, pharmacodynamics, and safety, 9. Incidence of treatment-emergent antibodies to rHuPH20 after SC administration relative to the presence at baseline, 10. Relationships between antibodies to rHuPH20 and safety, 11. Percentage of patients achieving CD19+ B cell level <5 cells/microliter at Weeks 12, 24, 48, and/or 96, 12. Levels of biomarkers including but not limited to neurofilament light (NfL) in serum compared between dosing arms at Weeks 12, 24, 48 and/or 96 compared to baseline",10/06/2024,28/03/2022,06/06/2025,07/06/2025,No,F. Hoffmann-La Roche AG,Pharmaceutical company,01/04/2025
2024-517745-14-00,IM045-1018,"A Phase 2, Randomized, Double-Blind, Four-Arm, Placebo-Controlled, Multicenter Study Assessing the Efficacy, Safety and Tolerability of three doses of orally administered BMS-986368, a FAAH/MAGL Inhibitor, for the treatment of Spasticity in Participants with Multiple Sclerosis (BALANCE-MSS-1)","Authorised, recruitment pending","Germany:Authorised, recruitment pending, Czechia:Authorised, recruitment pending, Poland:Authorised, recruitment pending","65+ years, 18-64 years",N/A,"Female, Male",100,In both EEA and non-EEA,Multiple Sclerosis Spasticity,"[""Diseases [C] - Nervous System Diseases [C10]"",""Diseases [C] - Immune System Diseases [C20]""]",Therapeutic exploratory (Phase II),"CC-97489 1mg , CC-97489 3mg, CC-97489, CC-97489",The way we are measuring the main study goals (the main trial endpoint) is by looking at how much the stiffness in the person's most affected leg changes from the start of the study to the end of Week 6. We will use a tool called the Total Numeric-transformed Modified Ashworth Scale-Most Affected Lower Limb (TNmAS-MALL) to measure this,"The secondary trial endpoints include the Numeric Rating Scale-Spasticity (NRS-S), which is a question answered every day using an eDiary provided to the participant., Other secondary endpoints include the MS Spasticity Scale (MSSS-88), a set of questions asking about spasticity in the participant’s daily life, the Timed 25-Foot Walk (T25FW) test, a test to see how long it takes the participant to walk 25 feet, and the Clinical Global Impression of Severity, a question for the investigator to determine how severe the participant’s condition is.",08/09/2025,N/A,N/A,N/A,No,Celgene Corp.,Pharmaceutical company,12/09/2025
2023-507313-94-00,WA39085,"An Open-Label, Parallel-Group Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Effects of Ocrelizumab in Children and Adolescents with Relapsing-Remitting Multiple Sclerosis","Ongoing, recruitment ended","Italy:Ongoing, recruitment ended, Poland:Ongoing, recruitment ended",0-17 years,"6-11 years, 12-17 years","Female, Male",12,In both EEA and non-EEA,Relapsing-Remitting Multiple Sclerosis (RRMS),"[""Diseases [C] - Nervous System Diseases [C10]""]",Therapeutic exploratory (Phase II),"Methylprednisolone 500 mg powder and solvent for solution for injection/infusion, Diphenhydramine Hydrochloride Tablets 50 mg, Ocrevus 300 mg concentrate for solution for infusion, Paracetamol 500mg Tablets, Ocrevus 300 mg concentrate for solution for infusion","1.Serum concentration of ocrelizumab at specified timepoints, 2.Levels of CD19+ B-cell count in blood","1.Occurrence and severity of adverse events, with severity determined according to National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0 (NCI CTCAE v5.0), 2.Change from baseline in vital signs, 3.Change from baseline in clinical laboratory test results, 4.Level of circulating B cells, T cells, natural killer cells, and other leukocytes, 5.Developmental milestones (e.g., growth, bone age, age at menarche, Tanner staging), 6.Non-MS central nervous system (CNS) pathology as measured by brain MRI scans, 7.Levels of blood immunoglobulins, 8.Antibody titers against standard vaccines, 9.Presence of ADAs during the study relative to the presence of ADAs at baseline",05/12/2023,18/10/2019,N/A,N/A,No,F. Hoffmann-La Roche AG,Pharmaceutical company,12/09/2025
2023-509555-13-00,TG1101-RMS-SC101,Pharmacokinetic/pharmacodynamic evaluation of ublituximab in patients with autoimmune diseases,"Ongoing, recruiting","Poland:Ongoing, recruiting","65+ years, 18-64 years",N/A,"Female, Male",164,EEA only,"Myasthenia Gravis, Relapsing multiple sclerosis","[""Diseases [C] - Nervous System Diseases [C10]""]",Human Pharmacology (Phase I)- First administration to humans,"ublituximab, ublituximab, PARACETAMOL, CETIRIZINE, Ublituximab, METHYLPREDNISOLONE, DEXAMETHASONE, DIPHENHYDRAMINE","Pharmacokinetic assessment of intravenous and subcutaneous administration of ublituximab, B-cell count following intravenous and subcutaneous administration of ublituximab",N/A,06/05/2024,15/05/2024,N/A,N/A,No,Tg Therapeutics Inc.,Pharmaceutical company,18/09/2025
2024-516739-29-00,P2-IMU-838-MS,"P2-IMU-838-MS - Randomized, double-blind, placebo-controlled, multicenter Phase 2 trial assessing the effect of IMU-838 on disease activity, as measured by magnetic resonance imaging (MRI), as well as safety and tolerability in patients with relapsingremitting multiple sclerosis (RRMS) (EMPhASIS)","Authorised, recruiting","Germany:Authorised, recruiting, Bulgaria:Authorised, recruiting, Romania:Authorised, recruiting, Poland:Authorised, recruiting",18-64 years,N/A,"Female, Male",142,In both EEA and non-EEA,Relapsing-remitting multiple sclerosis,"[""Diseases [C] - Nervous System Diseases [C10]""]",Therapeutic exploratory (Phase II),"IMU-838 30 mg tablet, Placebo for IMU-838 Tablets, IMU-838 22.5 mg tablet, IMU-838 15 mg tablets",Efficacy Cohort 1 (C1): Difference between 45 mg/day IMU-838 and placebo in the cumulative number of combined unique active (CUA) MRI lesions up to Week 24 Cohort 2 (C2): Between-treatment differences in the cumulative number of CUA MRI and Gd+ lesions up to Week 24,"Key secondary (hierarchical testing to primary efficacy) Efficacy C1: Difference between 30 mg/day IMU-838 and placebo in the cumulative number of CUA MRI lesions up to Week 24, Efficacy: C1: Difference between 45 mg/day IMU-838 and 30 mg/day IMU-838 in the cumulative number of CUA MRI lesions at Week 24, Efficacy: C1: Difference between 30 mg/day IMU-838 and placebo, 45 mg/day IMU-838 and placebo, and 30 mg/day and 45 mg/day IMU-838, C1: Differences between individual treatments and between the pooled 30 mg/day and 45 mg/day groups and placebo in the following relapserelated clinical endpoints: Mean annualized relapse rate (during main and extended treatment period); Proportion of relapse-free patients up to Week 24 and at extended periods thereafter; Time to relapse at time of final analysis of main part, C2: Number of relapses in each treatment arm, C1: Differences between treatments in changes of disease activity as measured by the following clinical parameters: Mean change in the EDSS as compared to Baseline during the main and extended period (every 12 weeks starting at Week 12); Proportion of patients with EDSS progression during the main and extended period (every 12 weeks starting at Week 12, and cumulatively), C2: Change of EDSS from Baseline to Weeks 12 and 24 C1: Correlation of MRI-based assessments with quartiles of IMU-838 trough levels at Week 6 and Week 24 C2: Correlation of MRI-based assessments with quartiles of IMU-838 trough levels at Week 24, Safety C1+C2: AEs, serious AEs and clinically significant laboratory abnormalities (as assessed by the investigator), C1+C2: AEs of special interest: Red blood cell urine positive, at least of moderate intensity; Hematuria; Retroperitoneal colicky pain with suspected or confirmed nephrolithiasis, C1: Proportion of patients treated with 30 mg/day or 45 mg/day IMU 838 as compared to placebo who experienced at least one of the following AEs, C2: Proportion of patients treated with 10 mg/day as compared to placebo who experienced at least one of the following AEs:Neutropenia; Lymphopenia; Diarrhea; Alopecia; Hemorrhage; Abnormalities in alanine aminotransferase, aspartate aminotransferase, gamma glutamyl transferase, and total bilirubin with both elevations ˃1.5 x ULN and ≥35% elevated compared to Baseline, ECG, physical examination, and vital signs, C1: Micro ribonucleic acid-122 expression (Change from Baseline to 4 hours after first dose), C1: Presence of John Cunningham virus (JCV) deoxyribonucleic acid (DNA) in urine in patients with detectable JCV-DNA in urine at Screening Visit 1, at Week 24, and at EoS, C1+C2: Time to treatment discontinuation for any reason, C1+C2: Rate of treatment discontinuations up to Week 24, Pharmacokinetics C1+C2: Population PK at Week 6 (3-10 hours post-dose) C1+C2: Plasma trough levels of IMU-838 at Days 7 and Weeks 6, 12, 18, and 24, Pharmacodynamics C1: Changes from Baseline in lymphocyte subset parameters as measured by flow cytometry at Weeks 6 and 24 (in selected Biomarker Centers only), C1: Changes from Baseline in biased T-cell clonal repertoire based on T-cell receptor deep sequencing at Weeks 6 and 24 (in selected Biomarker Centers only), C1+C2: Changes from Baseline in serum neurofilament at Week 24 C2: Changes in serum C4 (7α-hydroxy-4-cholesten-3-one) C2: Changes in serum fibroblast growth factor 19 (FGF-19), Health outcome (C1) Treatment Satisfaction Questionnaire for Medication at Week 6, Week 24 and EoS",11/09/2024,23/01/2019,N/A,N/A,No,Immunic AG,Pharmaceutical company,03/04/2025
2024-512761-13-00,APHP200056,Remyelination in Multiple Sclerosis: a PET-MR longitudinal study investigating individual profiles of myelin repair and the contribution of neuroinflammation (SMART in MS),"Authorised, recruiting","France:Authorised, recruiting",18-64 years,N/A,"Female, Male",60,EEA only,Remyelination in Multiple Sclerosis,"[""Diseases [C] - Nervous System Diseases [C10]""]",Therapeutic confirmatory  (Phase III),N/A,N/A,N/A,03/12/2024,24/01/2022,N/A,N/A,No,Assistance Publique Hopitaux De Paris,Hospital/Clinic/Other health care facility,24/04/2025
2022-501332-42-00,IM047-050,"A Phase 3, Multicenter, Double Blind, Active-Controlled Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Oral Ozanimod Compared to Oral Fingolimod in Children and Adolescents with Relapsing Remitting Multiple Sclerosis","Ongoing, recruiting","Spain:Authorised, recruiting, Poland:Authorised, recruiting, Portugal:Ongoing, recruiting, Italy:Authorised, recruiting, Romania:Authorised, recruiting",0-17 years,N/A,"Female, Male",38,In both EEA and non-EEA,Relapsing Remitting Multiple Sclerosis,"[""Diseases [C] - Nervous System Diseases [C10]""]",Therapeutic confirmatory  (Phase III),"Ozanimod HCl, Ozanimod HCl, Fingolimod 0.25 mg capsule, Fingolimod 0.5 mg capsule, Ozanimod HCl, FINGOLIMOD, Ozanimod HCl 0.23 mg , Ozanimod HCl 1 mg , Ozanimod HCl 0.0575 mg , Ozanimod HCl 0.25 mg, FINGOLIMOD, Ozanimod HCl",Core phase: To assess rate of Multiple Sclerosis (MS) relapse over 2 years,"Core and Extension Phase: proportion of the participants who have worsening or improving RRMS, Core and Extension Phase: occurrence of adverse events (type, severity and relationship to the study drug), Core and Extension Phase: early study discontinuation, Core and Extension Phase: measurements of the amount of ozanimod in a participant’s body",11/09/2024,26/02/2025,N/A,N/A,No,Celgene International II S.a.r.l.,Pharmaceutical company,16/04/2025
2024-517845-14-00,7109,TestOsterone TreatmEnt on Neuroprotection and Myelin Repair in Relapsing Remitting Multiple Sclerosis (TOTEM-RRMS),"Authorised, recruitment pending","France:Authorised, recruitment pending",18-64 years,N/A,Male,80,EEA only,Relapsing Remitting Multiple sclerosis,"[""Diseases [C] - Nervous System Diseases [C10]""]",Therapeutic exploratory (Phase II),"Placebo to Nebido, NEBIDO 1000 mg/4 ml, solution injectable","Binary criterion comparing the success rate in each treatment group, defined by thalamic atrophy less than 0.5% per year and / or a decrease in transverse diffusivity in lesions less than 0.5% per year.","Efficiency of treatment by imaging: XML File Identifier: 0bHUQtIJ9JZx4QdRJTxm0++LBOc= Page 13/24 • evolution of conventional MRI parameters: volume and number of T1 hypointense lesions, volume and number of new or enlarged T2 lesions, total volume of hyper-intensity FLAIR. • evolution of unconventional MRI parameters: diffusion tensor imaging (NODDI), quantitative magnetization transfer imaging (MPF)., Clinical efficiency of treatment: • Brief International Cognitive Assessment for Multiple Sclerosis, test consisting of the symbol digit modalities test, the California Verbal Learning Test Second Edition, and the Brief Visuospatial Memory Test Revised test • Changes in quality of life and health-related quality of life as measured by the SF-36 and EQ-5D questionnaires respectively., Clinical efficiency of treatment:Impact of MS on workplace productivity and day-to-day activities, as assessed by the WPAI (Work productivity and activity impairment) questionnaire. • Impact on fatigue, as measured by the Multi-Dimensional Fatigue Impact Scale (MFIS),, Clinical efficiency of treatment:Hospital assessment scale for anxiety and depression, as measured by the hospital anxiety and depression scale (HADS) questionnaire. • Evolution of handicap by the EDSS Score, Safe use of the treatment: number and nature of adverse events, evaluation of vital signs at each visit, clinical and neurological examinations, biological results, locally interpreted MRI for tolerance (non-MS pathology of the CNS) and monitoring of concomitant medications ( outside Tysabri®).",03/10/2024,N/A,N/A,N/A,No,Les Hopitaux Universitaires De Strasbourg,Hospital/Clinic/Other health care facility,16/06/2025
2023-505632-35-00,109MS306,"Open-Label, Randomized, Multicenter, Multi-Dose, Active Controlled, Parallel-Group, Efficacy and Safety Study of BG00012 in Children from 10 to Less Than 18 Years of Age with Relapsing-Remitting Multiple Sclerosis with Optional Open-Label Extension (CONNECT)",Ended,France:Ended,0-17 years,"6-11 years, 12-17 years","Female, Male",37,In both EEA and non-EEA,Relapsing-Remitting Multiple Sclerosis,"[""Diseases [C] - Nervous System Diseases [C10]""]",Therapeutic confirmatory  (Phase III),TECFIDERA,"The primary endpoint of Part 1 of the study is the proportion of participants free of new/newly enlarging T2 hyperintense lesions on brain MRI scans at Week 96., The primary endpoint of the Part 2 is the incidence of adverse events, serious adverse events and discontinuations of BG00012 due to an adverse event","Part 1:   Number of new/newly enlarging T2 hyperintense lesions on brain MRI scans at Weeks 24 and 96, Proportion of participants free of new/newly enlarging T2 hyperintense lesions on brain MRI scans at Weeks 24 and 48, Proportion of participants free of new MRI activity (new MRI activity includes: Gd enhancing MRI lesion on brain MRI scans; new T2 MRI lesions on brain MRI scans and newly enlarging LRI lesions on brain MRI scans) at Weeks 24, 48, and 96, Time to first relapse up to week 96, Proportion of participants who do not experience relapse up to Week 96, Annualized relapse rate at Weeks 48 and 96, Number of participants that experience Adverse Events (AEs) and serious adverse events (SAEs) Including prospective and followup of flushing, nausea, abdominal pain and diarrhea up to Week 96, Fatigue as measured by the Pediatric Quality of Life Inventory (PedsQL) Multidimensional Fatigue Scale scores up to Week 96, Change from baseline to Week 96 in the Expanded Disability Status Scale (EDSS) score up to Week 96., Vital signs, electrocardiograms (ECGs) and changes in clinical laboratory data, including monitoring of liver function, renal function, hematologic, and coagulation parameters up to Week 96., Part 2:  include annualized relapse rate; EDSS; cognition as measured by BVMT-R, SDMT, and school progression query; vital signs; ECGs; clinical laboratory data;  changes from baseline in height, weight, and bone age; and Tanner stage.",17/10/2024,24/07/2014,08/07/2025,08/07/2025,No,Biogen Idec Research Limited,Pharmaceutical company,17/10/2024
2024-512914-16-00,20230309,"A Randomized, Double-blind, Parallel-group Study to Compare Pharmacokinetics, Pharmacodynamics, Clinical Effects, and Safety between ABP 692 and Ocrevus® (Ocrelizumab) in Subjects with Relapsing-remitting Multiple Sclerosis","Authorised, recruitment pending","Germany:Authorised, recruitment pending, Spain:Authorised, recruitment pending, Czechia:Authorised, recruitment pending, Sweden:Authorised, recruitment pending, Lithuania:Authorised, recruitment pending, Belgium:Authorised, recruitment pending, Denmark:Authorised, recruitment pending, Italy:Authorised, recruitment pending, Bulgaria:Authorised, recruitment pending, Slovakia:Authorised, recruitment pending, Croatia:Authorised, recruitment pending, France:Authorised, recruitment pending, Poland:Authorised, recruitment pending",18-64 years,N/A,"Female, Male",364,In both EEA and non-EEA,Relapsing-remitting Multiple Sclerosis,"[""Diseases [C] - Nervous System Diseases [C10]""]",Therapeutic confirmatory  (Phase III),"Ocrevus 300 mg concentrate for solution for infusion, ABP 692, Ocrevus","Area under the serum  concentration-time curve (AUC) from time 0 to day 15 (AUC0-d15) following infusion 1 of the initial dose, AUC from time 0 extrapolated to  infinity (AUC0-inf) of the entire initial dose, Total number of new GdE T1-weighted lesions (assessed by brain MRI) over weeks 4, 8, 12, 16, 20, and 24",N/A,18/03/2025,N/A,N/A,N/A,No,Amgen Inc.,Pharmaceutical company,09/09/2025
2023-507820-22-00,CA061-1006,"A Phase 1 Study of CD19-targeted NEX-T CAR T Cells in Participants with RMS, PMS, or 
MG(Breakfree-2)","Ongoing, recruiting","Germany:Ongoing, recruiting, Belgium:Ongoing, recruiting, France:Ongoing, recruiting, Spain:Ongoing, recruiting",18-64 years,N/A,"Female, Male",56,In both EEA and non-EEA,"Relapsing Multiple Sclerosis (RMS), Progressive Multiple Sclerosis (PMS), Myasthenia gravis (MG)","[""Diseases [C] - Immune System Diseases [C20]""]",Human Pharmacology (Phase I)-  Other,N/A,N/A,N/A,02/05/2024,22/05/2024,N/A,N/A,No,Celgene Corp.,Pharmaceutical company,30/04/2025
2024-515470-26-00,NET-MS,NO EVIDENCE OF DISEASE ACTIVITY AFTER AUTOLOGOUS HAEMATOPOIETIC STEM CELL TRANSPLANTATION IN AGGRESSIVE MULTIPLE SCLEROSIS: THE NET-MS STUDY,"Ongoing, recruiting","Italy:Ongoing, recruiting",18-64 years,N/A,"Female, Male",90,EEA only,Relapsing Remitting Multiple Sclerosis,"[""Diseases [C] - Nervous System Diseases [C10]""]",Therapeutic exploratory (Phase II),"FILGRASTIM, RABBIT ANTI-HUMAN THYMOCYTE IMMUNOGLOBULIN, CYTARABINE, Kesimpta 20 mg solution for injection in pre-filled pen, Ocrevus 300 mg concentrate for solution for infusion, Tysabri 300 mg concentrate for solution for infusion, CYTARABINE, MELPHALAN FLUFENAMIDE, ETOPOSIDE, CYTARABINE, CARMUSTINE, ANTI-HUMAN T-LYMPHOCYTE IMMUNOGLOBULIN FROM RABBITS, CYCLOPHOSPHAMIDE, CARMUSTINE, UBLITUXIMAB, CYCLOPHOSPHAMIDE, FILGRASTIM, CYCLOPHOSPHAMIDE, CYTARABINE, CARMUSTINE, LEMTRADA 12 mg concentrate for solution for infusion","The primary outcome is the occurrence of any evidence of multiple sclerosis disease activity (NEDA-3) over 36 months, analyzed as time-to-event [Time frame: from randomization up to 36 months post randomization]","The proportion of participants who experience a serious adverse event [Time frame: from randomization up to 36 months post randomization], The proportion of participants who experience a serious late adverse event [Time frame: from day 100 post AHSCT up to 36 months post randomization]., The annual relapse rate at 12, 24 and 36 months, The incidence of 6 months confirmed disability improvement as measured by the EDSS over 36 months, The prevalence of disability improvement over 36 months, The proportion of patients who have confirmed disability improvement, confirmed stable EDSS or confirmed disability progression at 12, 24 and 36 months, The incidence of 6 months confirmed progression on hand/arm function as measured by the 9HPT over 36 months, The incidence of 6 months confirmed progression on ambulation as measured by the T25FW test over 36 months, Number of new brain lesions at 12, 24 and 36 months, Number of gadolinium-enhancing brain lesions at 12, 24 and 36 months, Changes in whole brain volume at 12, 24 and 36 months, The proportion of patients with no evidence of disease activity including atrophy (NEDA-4) at 12, 24 and 36 months, Changes in MRI T2-weighted hyperintense lesion volume over 36 months, Changes in MRI T1-weighted hypointense lesion volume over 36 months, Changes in BICAMS z-scores at 12, 24 and 36 months, Changes in MSFC z-scores at 12, 24 and 36 months, Changes in serum neurofilament light chain concentration at 12, 24 and 36 months, Changes in the IgG/IgM index in the cerebrospinal fluid at 36 months, Presence of oligoclonal bands in the cerebrospinal fluid at 36 months, Changes in the 2.5 low contrast visual acuity at 12, 24 and 36 months, Changes in the peripheral retinal nerve fiber layer thickness assessed by optical coherence tomography at 12, 24 and 36 months, Changes in the retinal inner nuclear layer thickness assessed by optical coherence tomography at 12, 24 and 36 months, Changes in the Multiple Sclerosis Impact Scale at 12, 24 and 36 months, Changes in Multiple Sclerosis Walking Scale over at 12, 24 and 36 months, Changes in the Modified Fatigue Impact Scale at 12, 24 and 36 months, Changes in the WHO-QOL-Bref and the EuroQoL EQ-5D at 12, 24 and 36 months, All-cause mortality over 36 months, Proportion of participants who develop secondary autoimmune diseases over 36 months, Time to neutrophil engraftment among AHSCT recipients, Proportion of AHSCT recipients who experience primary or secondary graft failure, Percentage of female patients who experiences amenorrhoea during the study period, Percentage of female patients of child-bearing potential who maintains or resumes regular menstruation, Time to resumption of spontaneous menses after AHSCT and/or interruption of hormonal contraception, Variation in ovarian reserve parameters (anti-mullerian hormone levels and antral follicular count) over 36 months, Variation in sperm count, motility and morphology over 36 months, Percentage of pregnancy within 12 months of attempts among patients that will try to conceive after AHSCT [Time frame: from day 365 post AHSCT up to 36 months post randomization]., Number of new cervical spinal cord T2 lesions and of T1 gadolinium-enhancing lesions at 36 months.",09/12/2024,31/10/2024,N/A,N/A,No,Fondazione Italiana Sclerosi Multipla Ente Del Terzo Settore/et S,Patient organisation/association,27/08/2025
2024-519552-93-00,AUTO1-MS1,"A SINGLE-ARM, OPEN-LABEL, PHASE I STUDY TO DETERMINE THE SAFETY, TOLERABILITY, AND PRELIMINARY EFFICACY OF OBE-CEL IN PARTICIPANTS WITH REFRACTORY PROGRESSIVE FORMS OF MULTIPLE SCLEROSIS","Authorised, recruitment pending","Spain:Authorised, recruitment pending",18-64 years,N/A,"Female, Male",3,In both EEA and non-EEA,Refractory Progressive Multiple Sclerosis,"[""Diseases [C] - Immune System Diseases [C20]""]",Human Pharmacology (Phase I)-  Other,N/A,N/A,N/A,26/06/2025,N/A,N/A,N/A,No,Autolus Limited,Pharmaceutical company,22/09/2025
2023-510127-30-00,MSB-IG-H-2101,"Multicenter, Phase Ib/IIa Study on the Safety and Efficacy of Autologous Peptide-coupled Red Blood Cells in Patients with Relapsing Remitting Multiple Sclerosis","Ongoing, recruitment ended","Italy:Ongoing, recruitment ended, Germany:Ongoing, recruitment ended, Czechia:Ongoing, recruitment ended",18-64 years,N/A,"Female, Male",126,In both EEA and non-EEA,Relapsing Remitting Multiple Sclerosis (RRMS),"[""Diseases [C] - Nervous System Diseases [C10]""]",Phase I and Phase II (Integrated)- First administration to humans,Autologous uncoupled red blood cells (RBCs),"Safety (Part A and B): Safety and tolerability of CLS12311 measured by the number and severity of treatment-emergent adverse events (TEAEs) and treatment-emergent serious adverse events (TESAEs) and/or worsening of disease by clinical (relapses) and imaging (number and size of MRI brain lesions)., Efficacy (Part B only): The cumulative number of new brain lesions on the MRI scans developed in the treatment phase between weeks 16 and 24 compared to the pre-treatment number of new brain MRI lesions developed between weeks -8 and 0 for any dose., New lesions on brain MRI are defined as being: Contrast enhancing lesions on the reference scan at weeks -8 and 16 or new/enlarging T2 lesions on scan at: week 0 compared to scan at week -8; week 24 compared to scan at week 16, MRIs will be assessed centrally by independent readers","[Safety endpoints (Part A and B)]: Number and severity of TEAEs and TESAEs in each dose group, [Safety endpoints (Part A and B)]: Number of confirmed relapses in the treatment phase in each dose group, [Safety endpoints (Part A and B)]: Changes in clinical measures of disease severity (EDSS, 9-HPT, T25- FW, SDMT) following CLS12311 administration in each dose group (Part A only EDSS), [Efficacy endpoints (Part B)]: Number of new lesions on brain MRI (as defined above) in weeks 16- 24 in the three dose groups • Efficacy of CLS12311 in reducing the number of new brain MRI lesions (as defined above) in defined subgroups, e.g. stratified for HLA or immunological parameters, [Efficacy endpoints (Part B)]: Efficacy of CLS12311 in reducing the number of new brain MRI lesions (as defined above) in defined subgroups, e.g. stratified for HLA or immunological parameters, [Exploratory immunological and biomarker measures (Part A and B)]: Percentage of patients in each dose group showing a reduction of antigen-specific T cells against the protein(s) they responded to at the study entry, [Exploratory immunological and biomarker measures (Part A and B)]: Changes in predefined serum biomarkers of disease activity and in other markers related to tolerance induction, [Exploratory immunological and biomarker measures (Part A and B)]: Mechanistic profiling of serum and blood cells will be performed by measuring specific biomarkers of tolerance, tissue damage and inflammation as well as broad-based methods including but not limited to multi-analyte measurements, transcriptomics and proteomics.",19/09/2024,17/04/2024,N/A,N/A,No,Cellerys AG,Pharmaceutical company,25/03/2025
2024-516992-33-02,504-15-021-21003,"CLASP MS: The study evaluating the efficacy and safety of Polish cladribine in the treatment of patients with secondary progressive multiple sclerosis - a phase 2, randomized, double-blind, placebo-controlled trial.","Authorised, recruitment pending","Poland:Authorised, recruitment pending",18-64 years,N/A,"Female, Male",188,EEA only,Multiple sclerosis secondary progressive form,"[""Diseases [C] - Nervous System Diseases [C10]""]",Therapeutic exploratory (Phase II),"BIODRIBIN, 1 mg/ml, roztwór do infuzji, 0.9% physiological saline (sodium chloride)",Percent brain volume change from last cladribine dose (week 26) to end of study (week 122).,"1.Time to 24-week confirmed composite progression of disability defined as the occurrence of any of the following events: an increase in EDSS score, in time of Timed 25-Foot Walk and 9-Hole Peg Test. 2.Change from baseline in cognitive function (CANTAB, CVLT, SDMT) and quality of life (MSQeL-54) 3.Neuroimaging: number of Gd+ lesions, new T2 lesions, QSM rim+ lesions, volume of T1 lesions (black holes), volume of cervical spinal cord in T1; 4. Serum level of NfL, GFAP, oligoclonal bands presence",30/01/2025,N/A,N/A,N/A,No,Instytut Psychiatrii I Neurologii,Educational Institution,30/01/2025
2022-502552-31-00,257MS201,"A 2-Part, Multicenter, Randomized, Blinded, Active-Controlled Phase 2 Study to Sequentially Evaluate the Safety and Efficacy of BIIB091 Monotherapy and BIIB091 Combination Therapy With Diroximel Fumarate in Participants With Relapsing Forms of Multiple Sclerosis","Ongoing, recruiting","Germany:Ongoing, recruiting, Czechia:Ongoing, recruiting, Spain:Ongoing, recruiting, Italy:Ongoing, recruiting, Poland:Ongoing, recruiting, Bulgaria:Ongoing, recruiting, Romania:Ongoing, recruiting",18-64 years,N/A,"Female, Male",225,In both EEA and non-EEA,Relapsing Forms of Multiple Sclerosis,"[""Diseases [C] - Nervous System Diseases [C10]""]",Therapeutic exploratory (Phase II),"Use of placebo is for masking purposes only in this study. all participants will be randomized to one of the active treatment arms. this study does not have a placebo control group, i.e., no participant will receive placebo treatment only., Solu-Moderín 125 mg polvo y disolvente para solución inyectable, Clariscan 0,5 mmol/ml Injektionslösung, BIIB091, Vumerity 231 mg gastro-resistant hard capsules, BIIB091, Use of placebo is for masking purposes only in this study. All participants will be randomized to one of the active treatment arms. This study does not have a placebo control group, i.e., no participant will receive placebo
treatment only.","Part 1: Number of Participants With Adverse Events (AEs), Part 1: Number of Participants With Serious Adverse Events (SAEs), Part 2: Cumulative Number of New T1 Gadolinium-Enhancing (GdE) Lesions","Part 1: Cumulative Number of New T1 Gadolinium-Enhancing (GdE) Lesions, Part 1: Cumulative Number of New or Enlarging T2 Hyperintense Lesions, Part 1: Cumulative Volume of New or Enlarging T2 Hyperintense Lesions, Part 1: Mean Change From Baseline in QT Interval Corrected for Heart Rate Using Fridericia's Formula (QTcF), RR, PR, QRS, and QT Intervals, Part 1: Number of Participants With Change From Baseline in Heart Rate, Part 1: Number of Participants With Clinically Significant Electrocardiogram (ECG) Abnormalities, Part 2: Cumulative Number of New or Enlarging T2 Hyperintense Lesions, Part 2: Cumulative Volume of New or Enlarging T2 Hyperintense Lesions, Part 2: Number of Participants With AEs, Part 2: Number of Participants With SAEs, Part 2: Number of Participants With Change From Baseline in QTcF, RR, PR, QRS, and QT intervals, Part 2: Number of Participants With Change From Baseline in Heart Rate, Part 2: Number of Participants With ECG Abnormalities as Assessed by 12-Lead ECG Measurements",14/08/2023,03/10/2023,N/A,N/A,No,Biogen Idec Research Limited,Pharmaceutical company,21/07/2025
2023-505980-36-00,WA40404,"A Phase IIIb Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis","Ongoing, recruitment ended","France:Ongoing, recruitment ended, Italy:Ongoing, recruitment ended, Romania:Ongoing, recruitment ended, Bulgaria:Ongoing, recruitment ended, Portugal:Ongoing, recruitment ended, Poland:Ongoing, recruitment ended, Croatia:Ongoing, recruitment ended, Belgium:Ongoing, recruitment ended, Spain:Ongoing, recruitment ended",18-64 years,N/A,"Female, Male",363,In both EEA and non-EEA,Primary progressive multiple sclerosis (PPMS),"[""Diseases [C] - Nervous System Diseases [C10]"",""Diseases [C] - Immune System Diseases [C20]""]",Therapeutic confirmatory  (Phase III),"Ocrevus 300 mg concentrate for solution for infusion, Placebo Ocrevus, Dormutil N, Ocrevus 300 mg concentrate for solution for infusion, METHYLPREDNISOLONE","1. Time to onset of composite 12-week CDP defined as the time from randomization to the first occurrence of either 12-week CDP in 9-HPT, or 12-week CDP in EDSS","1. Time to 12-week CDP in EDSS, as a pre-defined increase in EDSS score confirmed for at least 12 weeks, 2. Time to 24-week CDP in 9-HPT, 3. Time to 24-week CDP in EDSS, as a pre-defined increase in EDSS score confirmed for at least 24 weeks, 4. Annual rate of percent change from baseline in total volume of T2 lesions, 5. Annual rate of percent change from Week 24 in total brain volume, 6. Incidence and nature of adverse events, serious adverse events, adverse events leading to study treatment withdrawal, 7. Change from baseline in laboratory test results for hematology and chemistry association of decrease in certain laboratory parameters, and serious infections, 8. Presence of ADA during the study relative to baseline, 9. Total plasma clearances (CL) of ocrelizumab, 10. Volumes of distribution(Vd) of ocrelizumab, 11. Area under the concentration-time curve (AUC) of ocrelizumab",31/01/2024,19/09/2019,N/A,N/A,No,F. Hoffmann-La Roche AG,Pharmaceutical company,12/08/2025
2023-505283-11-00,COMB157G2410,"A phase IV, prospective, multicenter, open-label, mother-milk study to evaluate ofatumumab concentration in the breast milk of lactating women with relapsing forms of multiple sclerosis receiving ofatumumab (Kesimpta®)","Authorised, recruiting","Germany:Ongoing, recruiting, France:Not authorised, Italy:Ongoing, recruiting, Poland:Ongoing, recruiting",18-64 years,N/A,Female,15,In both EEA and non-EEA,Relapsing forms of Multiple Sclerosis (RMS),"[""Diseases [C] - Nervous System Diseases [C10]""]",Therapeutic use (Phase IV),Kesimpta 20 mg solution for injection in pre-filled syringe,"The concentration of ofatumumab in breast milk at the following timepoints: (pre-dose) on the day of the second (or any subsequent) maintenance dose, then 7, 14, 21 and (pre-dose) 28 days after the second (or any subsequent) maintenance dose.","Proportion of participants with at least 1 sample with quantifiable ofatumumab concentrations in breast milk, Maximum concentration (Cmax) of ofatumumab in breast milk over 28 days after the second (or any subsequent) maintenance dose., The exposure (area under the curve (AUC) of ofatumumab in milk over 28 days (from the second or any subsequent maintenance dose to the next maintenance dose after initiation or re-initiation of ofatumumab post-partum), Milk/Plasma (M/P) ratio of ofatumumab at 28 days after the second or any subsequent maintenance dose., Estimated relative infant dose (RID, %) over 28 days after the lactating mother receives second or subsequent maintenance dose, Rate and nature of adverse events in the mothers treated with ofatumumab up to 12 months after ofatumumab treatment initiation/re-initiation, Rate and nature of serious adverse events and any infections in the breast-fed infants of mothers up to 12 months after ofatumumab treatment initiation/re-initiation",06/06/2024,10/12/2024,N/A,N/A,No,Novartis Pharma AG,Pharmaceutical company,07/07/2025
2024-514006-31-00,CYTB323R12101,"An open-label, multi-center, phase I/II study to assess safety, disease progression, and cellular kinetics following YTB323 administration in participants with non-active Progressive Multiple Sclerosis (PMS)","Authorised, recruitment pending","Spain:Authorised, recruitment pending, France:Authorised, recruitment pending, Italy:Authorised, recruitment pending, Germany:Authorised, recruitment pending",18-64 years,N/A,"Female, Male",18,In both EEA and non-EEA,Non-active Progressive Multiple Sclerosis (PMS),"[""Diseases [C] - Nervous System Diseases [C10]""]",Phase I and Phase II (Integrated)- Other,"CYCLOPHOSPHAMIDE, TOCILIZUMAB, YTB323, FLUDARABINE PHOSPHATE","Occurrence, severity and frequency of dose limiting toxicities (DLTs), Adverse Events (AEs) and change from baseline over 2 years in safety parameters including, but not limited to vital signs, laboratory, ECG, neurological status, and safety measures from brain MRI.","Change from baseline for clinical measures of disability (includes EDSS, T25FW, 9HPT, SDMT)., YTB323 transgene expression levels by qPCR over time in blood; cellular kinetics parameters (Cmax, AUC, Tmax, Clast, Tlast)., Safety data from each dose level., Pre-existing and treatment-induced immunogenicity (humoral, anti-YTB323 antibody; and cellular, presence of CAR19 specific CD4 and CD8 T cells measuring interferon gamma production).",22/04/2025,N/A,N/A,N/A,No,Novartis Pharma AG,Pharmaceutical company,24/04/2025
2024-518859-27-00,N/A,"Effect of ozanimod on meningeal inflammation and glial activation in Multiple Sclerosis: one year phase 4 experimental study
PROTOCOL CODE: OZA22 / IM047 - 048","Ongoing, recruiting","Italy:Ongoing, recruiting","65+ years, 18-64 years",N/A,"Female, Male",50,EEA only,"Relapsing Multiple Sclerosis (relapsing-remitting, relapsing-progressive)","[""Diseases [C] - Nervous System Diseases [C10]""]",Therapeutic use (Phase IV),Zeposia 0.92 mg hard capsules,CSF (and serum) concentration of CXCL13 protein (ng/ml/mgPro) measured before starting ozanimod treatment (Prebaseline) and at T12.,"CSF (and serum) concentration of specific markers of activated meningeal inflammation (CXCL12, TNF-a, IFN-¿) (ng/ml/mgPro) measured before starting ozanimod treatment (Prebaseline) and at T12., CSF (and serum) concentration of specific makers of activated microglia/macrophages (Chitinase 3-like1, Osteopontin, sCD163, CX3CL1) (ng/ml/mgPro) measured before starting ozanimod treatment (Prebaseline) and at T12., CSF (and serum) concentration of specific markers of neuronal/axonal damage (neurofilamentlight chains, parvalbumin) (ng/ml/mgPro) measured before starting ozanimod treatment (Prebaseline) and at T12, Number and volume of cortical lesions measured before starting ozanimod treatment (Prebaseline) and at T12, Number and susceptibility of of paramagnetic rim lesions measured before starting ozanimod treatment (Prebaseline), at baseline (T0) and after 1 year of ozanimod treatment (T12), Variation of the volume of white matter lesions before starting ozanimod treatment (¿ prebaseline-T0) and after 1 year of ozanimod treatment (¿ T0-T12), Variation global and regional cortical thickness change before starting ozanimod treatment (¿prebaseline-T0) and after 1 year of ozanimod treatment (¿ T0-T12), Significant linear relationship between the variation of the above-mentioned cytokines (¿ T0-T12) and the EDSS change (¿ T0-T12) or the relapse number by the end of the follow-up (T12)",11/11/2024,06/07/2023,N/A,N/A,No,Azienda Ospedaliera Universitaria Integrata Verona,Hospital/Clinic/Other health care facility,11/11/2024
2023-506515-18-00,BN42083,"A Phase IIIB Multicenter, Randomized, Double-Blind, Controlled Study to Evaluate the Efficacy, Safety and Pharmacokinetics of a Higher Dose of Ocrelizumab in Adults with Primary Progressive Multiple Sclerosis","Ongoing, recruitment ended","Greece:Ongoing, recruitment ended, Hungary:Ongoing, recruitment ended, Italy:Ongoing, recruitment ended, Spain:Ongoing, recruitment ended, France:Ongoing, recruitment ended, Bulgaria:Ongoing, recruitment ended, Belgium:Ongoing, recruitment ended, Portugal:Ongoing, recruitment ended, Poland:Ongoing, recruitment ended, Denmark:Ongoing, recruitment ended, Germany:Ongoing, recruitment ended",18-64 years,N/A,"Female, Male",310,In both EEA and non-EEA,Primary Progressive Multiple Sclerosis (PPMS),"[""Diseases [C] - Nervous System Diseases [C10]""]",Therapeutic confirmatory  (Phase III),"Methylprednisolone 500 mg powder and solvent for solution for injection/infusion, Paracetamol 500mg Tablets, Placebo Ocrelizumab, Ocrevus 300 mg concentrate for solution for infusion, Ocrevus 300 mg concentrate for solution for infusion, Diphenhydramine Hydrochloride Tablets 50 mg","1. Time to onset of cCDP sustained for at least 12 weeks. Time to onset of cCDP is defined as the first occurrence of a predefined confirmed progression event measured by EDSS, T25FWT or 9-HPT","1. Time to onset of 24 week cCDP (cCDP24), 2. Time to onset of cCDP12 independent of protocol-defined relapses (PDR), also termed progression independent of relapse activity (PIRA) as per Kappos et al.2020, 3. Time to onset of 12-week CDP (CDP12), 4. Time to ≥ 20% increase in 12 week confirmed T25FWT, 5. Annual rate of percent change from baseline in total brain volume, 6. Annual rate of percent change from baseline in thalamic volume, 7. Time to 12-week confirmed 4-point worsening in Symbol Digit Modalities Test (SDMT), 8. Change in NfL (i.e. ratio to baseline) at Week 96, 9.Time to 12-week confirmed 8-point increase in 12-Item Multiple Sclerosis Walking Scale (MSWS12), 10. Change in NfL (i.e. ratio to baseline) at Week 96 for patients in the higher dose ocrelizumab group, 11. Change in NfL (i.e. ratio to baseline) at Week 96 for patients in the approved dose ocrelizumab group, 12. Incidence and severity of adverse events, with severity determined according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 5.0, 13. Change from baseline in clinical laboratory test results (including hematology, chemistry, and Ig levels), 14. Change from baseline in vital signs (including systolic and diastolic blood pressure, and pulse rate) following study treatment administration, 15. Serum concentration of ocrelizumab at specified timepoints, 16. B-cell levels in blood (including comparing the degree of B-cell depletion between the doses), 17. Proportion of participants achieving 5 or less B-cells per microliter of blood, 18. Proportion of participants achieving 5 or less B-cells per microliter of blood in participants with the high versus low affinity Fcgamma Receptor 3A (FcγR3A) genotype per arm, 19. Change from Baseline in the anti-drug antibodies (ADAs) levels, 20. Levels of Neurofilament Light Chain (NfL) in blood, 21. Levels of Interleukin-6 (IL-6) in blood, 22. Levels of blood B-cells, 23. Levels of Lymphocytes in blood, 24. Proportion of participants with different DNA genotypes",08/02/2024,23/10/2020,N/A,N/A,No,F. Hoffmann-La Roche AG,Pharmaceutical company,26/03/2025
2024-513960-24-00,N/A,"Effects of ozanimod on myelin dynamics and neurodegeneration in patients with relapsingremitting multiple sclerosis: correlation with disease activity, cognition, fatigue,depression and quality of life","Ongoing, recruiting","Italy:Ongoing, recruiting",18-64 years,N/A,"Female, Male",30,EEA only,Multiple sclerosis patients in relapse and remission form,"[""Diseases [C] - Nervous System Diseases [C10]""]",Therapeutic use (Phase IV),-,"The primary endpoints of this study are to assess, in RRMS patients treated with ozanimod, the changes from baseline over 2 years of: • Global brain atrophy (i.e., percent brain volume change [PBVC]); • Regional GM volume; • Regional WM volume; • Thalamic volume; • Cortical volume.",N/A,01/07/2024,22/06/2022,N/A,N/A,No,Ospedale San Raffaele S.r.l.,Hospital/Clinic/Other health care facility,01/07/2024
2024-520287-34-01,BLCL-THC/CBD-01,"A phase II randomized, double-blind, placebo-controlled trial to evaluate the efficacy, safety, and tolerability of an oral solution of 9-Δ tetrahydrocannabinol/cannabidiol (THC/CBD) in multiple sclerosis patients with chronic neuropathic pain","Authorised, recruiting","Portugal:Authorised, recruiting","18-64 years, 65+ years",N/A,"Female, Male",68,EEA only,Chronic neuropathic pain due to multiple sclerosis (MS),"[""Diseases [C] - Nervous System Diseases [C10]""]",Therapeutic exploratory (Phase II),"Satalliv, Delta-9-tetrahydrocannabinol/cannabidiol (THC:CBD) 25 mg + 25 mg/mL, oral solution, Matching placebo oral solution",Efficacy: Change in pain intensity as measured by the Numeric Rating Scale (NRS 0-10) between baseline (Day 1) and 4 weeks of optimized treatment (corresponding to Week 6 visit); the average of the pain intensity measured over the period of 7 days prior to a study visit will be considered,"Efficacy: Proportion of patients who achieved at least a 30% reduction in their pain NRS 0-10 score after 4 weeks of optimized treatment, Efficacy: Proportion of patients who achieved at least a 50% reduction in their pain NRS 0-10 score after 4 weeks of optimized treatment, Efficacy: Change in pain intensity as measured by the NRS 0-10 between baseline (Day 1) and 12 weeks of optimized treatment, Efficacy: Proportion of patients who achieved at least a 30% reduction in their pain NRS 0-10 score after 12 weeks of optimized treatment, Efficacy: Proportion of patients who achieved at least a 50% reduction in their pain NRS 0-10 score after 12 weeks of optimized treatment, Efficacy: Proportion of patients who achieved at least a 30% reduction in spasticity NRS 0-10 score after 4 weeks of optimized treatment., Efficacy: Proportion of patients who achieved at least a 30% reduction in spasticity NRS 0-10 score after 12 weeks of optimized treatment., Efficacy: Change in spasticity symptom measured by the NRS 0-10 between baseline (Day 1) and 4 weeks of optimized treatment and baseline and 12 weeks of optimized treatment (0: No spasticity - The patient experiences no increase in muscle tone or involuntary muscle spasms; 10: Worst possible spasticity - The patient experiences extreme muscle stiffness, severe spasms, and significant difficulty with movement), Efficacy: Change in Pittsburgh Sleep Quality Index (PSQI) component scores and global score between baseline (Day 1) and 4 weeks of optimized treatment and baseline and 12 weeks of optimized treatment, Efficacy: Change in EuroQol 5-Dimensions, 5-Levels (EQ-5D-5L) index score between baseline (Day 1) and 12 weeks of optimized treatment, Efficacy: Change in EQ-5D-5L visual analogue scale (VAS) score between baseline (Day 1) and 12 weeks of optimized treatment, Efficacy: Proportion of patients reporting improvement in their condition with Patient Global Impression of Change (PGIC) scale after 4 and 12 weeks of optimized treatment, Efficacy: Change in the Expanded Disability Status Scale (EDSS) score between baseline (Day 1) and 4 weeks of optimized treatment and from baseline and 12 weeks of optimized treatment, Efficacy: Change in the Nine-Hole Peg test (NHPT) completion time from baseline (Day 1) and 4 weeks of optimized treatment and between baseline and 12 weeks of optimized treatment., Efficacy: Reduction of at least a 30% Neuropathic Pain Symptom Inventory (NPSI) score after 4 and 12 weeks of optimized treatment., Safety: Incidence of treatment-emergent adverse events (TEAEs), serious adverse events (SAEs), and adverse events (AE) leading to study discontinuation. Clinically relevant abnormalities in vital signs, 12-lead electrocardiogram (ECG) and laboratory parameters will be reported as AEs.",24/06/2025,12/09/2025,N/A,N/A,No,Ferraz Lynce Especialidades Farmaceuticas S.A.,Pharmaceutical company,15/09/2025
2023-510488-36-01,18870,PsyPal; Psilocybin Therapy for Psychological Distress in Palliative Patients,"Authorised, recruiting","Portugal:Authorised, recruitment pending, Czechia:Authorised, recruitment pending, Netherlands:Authorised, recruiting, Denmark:Authorised, recruitment pending","65+ years, 18-64 years",65-84 years,"Female, Male",108,EEA only,"Chronic obstructive pulmonary disease (COPD), amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), and atypical Parkinson disorder (APD), particularly multiple system atrophy (MSA), progressive supranuclear palsy (PSP), and corticobasal syndrome (CBS).","[""Diseases [C] - Respiratory Tract Diseases [C08]"",""Diseases [C] - Pathological Conditions, Signs and Symptoms [C23]"",""Psychiatry and Psychology [F] - Mental Disorders [F03]"",""Psychiatry and Psychology [F] - Behavior and Behavior Mechanisms [F01]"",""Diseases [C] - Musculoskeletal Diseases [C05]"",""Psychiatry and Psychology [F] - Psychological Phenomena [F02]"",""Phenomena and Processes [G] - Biological Phenomena [G16]"",""Diseases [C] - Nervous System Diseases [C10]"",""Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Therapeutics [E02]""]",Therapeutic exploratory (Phase II),"Psilocybin capsules 15 mg, Psilocybin capsules 25 mg, Psilocybin capsules 1 mg",The primary endpoint is the change in depressive symptoms from baseline to 6 weeks after the second dose of psilocybin (high dose session) compared low-dose control..,"To assess change in clinical functioning, end-of-life anxiety, psychological/existential distress, health-related quality of life, and how it impacts caregiver ’s health- and economic burden.",20/11/2024,03/07/2025,N/A,N/A,No,Universitair Medisch Centrum Groningen,Hospital/Clinic/Other health care facility,29/07/2025
2024-518374-13-00,SIPO20,Effect of siponimod on relevant imaging and immunological hallmarks of progressive multiple sclerosis,"Ongoing, recruiting","Italy:Ongoing, recruiting","18-64 years, 65+ years",N/A,"Female, Male",60,EEA only,Active progressive multiple sclerosis course after an initial relapse clinical course,"[""Diseases [C] - Nervous System Diseases [C10]""]",Therapeutic use (Phase IV),"Mayzent 0.25 mg film-coated tablets, Mayzent 2 mg film-coated tablets, Mayzent 1 mg film-coated tablets, BAF312, BAF312, BAF312","The study endpoint is the change (assumed to be a reduction) of the susceptibility of the rim lesions after treatment with siponimod in comparison to the “natural” change of this parameter during a recent period-time preceding treatment (no later than two years before) with siponimod, so that for each patient an internal comparison will be available.","To evaluate the effect of siponimod in reducing the number of SEL comparing to the period prior the treatment (retrospective phase) with the study phase (T3 vs T12 and T3 vs T24)., To describe the individual changes in CSF levels of specific makers of activated microglia/macrophages (sCD14, sCD163, TNF, sTNFR1, sTNFR2, Chitinase 3-1like) and of neuronal/axonal damage (neurofilament-light chains, parvalbumin) from baseline to T24, To evaluate the changes of sCD14, sCD163, TNF, sTNFR1, sTNFR2, Chitinase 3-1like, neurofilament-light chains, and parvalbumin in serum of patients at baseline and at T6, T12, T18, T24, To evaluate the EDSS change between the retrospective phase and the study phase (T0 vs T12 and T12 vs T24, To evaluate changes in cognitive functioning during the two-year study phase (T0-T24), Treatment emergent adverse effect (TEAE) and serious adverse event (SAE) at each follow-up visit",05/11/2024,28/02/2022,N/A,N/A,No,Azienda Ospedaliera Universitaria Integrata Verona,Hospital/Clinic/Other health care facility,05/11/2024
2024-512319-40-00,CCYB704A12301,An efficacy and safety study with integrated PK and PD assessment to compare the proposed ocrelizumab biosimilar CYB704 and Ocrevus in participants with relapsing multiple sclerosis,"Ongoing, recruiting","Croatia:Ongoing, recruiting, Bulgaria:Ongoing, recruiting, Poland:Ongoing, recruiting",18-64 years,N/A,"Female, Male",163,In both EEA and non-EEA,Subjects with relapsing multiple sclerosis (relapsing remitting MS and active secondary progressive MS),"[""Diseases [C] - Nervous System Diseases [C10]""]",Therapeutic confirmatory  (Phase III),N/A,N/A,N/A,01/06/2025,01/07/2025,N/A,N/A,No,H e x a l AG,Pharmaceutical company,02/06/2025
2024-510974-25-00,MN42988,"A Phase IV, Multicenter, Open-Label Study Evaluating B-Cell Levels in Infants Potentially Exposed to Ocrelizumab During Pregnancy – The MINORE Study",Ended,"Spain:Ended, Germany:Ended",18-64 years,N/A,"Female, Male",10,In both EEA and non-EEA,Multiple Sclerosis (MS) or Clinically Isolated Syndrome (CIS) [in line with the locally approved indications],"[""Diseases [C] - Nervous System Diseases [C10]""]",Therapeutic use (Phase IV),Ocrevus 300 mg concentrate for solution for infusion,"1. Proportion of infants with B-cell levels (CD19+ cells, absolute counts) below the lower limit of normal (LLN), measured at week 6 of life","1. B-cell levels (CD19+ cells, absolute counts and percentage of lymphocytes) measured at week 6 of life, 2. Serum concentration of ocrelizumab in the umbilical cord blood at birth, 3. Serum concentration of ocrelizumab in the infant at week 6 of life, 4. Mean titers of antibody immune response(s) to vaccination to common childhood vaccinations with full or partial doses given prior to 1 year, which include responses to diphtheria, tetanus, pertussis, Hib, PCV-13, MMR, and HBV, 5. Proportion of infants with positive humoral response (seroprotective titers; as defined for the individual vaccine) to vaccines, 6. Serum concentration of ocrelizumab in the mother during pregnancy (time frame of blood sampling: Week 24-30, Week 35) and at delivery (time frame of blood sampling: within 24 hours after delivery), 7. Rate and nature of adverse events (AEs) in the mother throughout the study, including changes in clinical and laboratory results, 8.Rate and nature of AEs in the infant throughout the study, including infections and hospitalizations, 9. Proportion of pregnancies resulting in live births (term and preterm, with and without congenital anomalies), therapeutic abortions, or stillbirths, 10. Infant characteristics at birth, including but not limited to body weight, head circumference and length",23/04/2024,10/11/2021,15/05/2025,14/07/2025,No,F. Hoffmann-La Roche AG,Pharmaceutical company,26/09/2024
2023-508656-19-00,CPO23001,Bioequivalence of Cladribine 10 mg from two different products,Ended,Bulgaria:Ended,18-64 years,N/A,Male,76,EEA only,"No therapeutic indication in the current trial with healthy volunteers.
The intended indication is for treatment of adult patients with highly active relapsing multiple sclerosis (MS).","[""Diseases [C] - Nervous System Diseases [C10]""]",Human Pharmacology (Phase I)- Bioequivalence Study,N/A,N/A,N/A,06/02/2024,01/03/2024,02/05/2024,N/A,No,"CCDRD Cooperative Clinical Drug Research and Development AG, Pharos Pharmaceutical Oriented Services Ltd.","Pharmaceutical company, Pharmaceutical company",06/02/2024
2024-519235-42-00,MSGLP/GAMS,Effects of GLP-1 analogue in multiple sclerosis,"Authorised, recruitment pending","Slovakia:Authorised, recruitment pending",18-64 years,N/A,"Female, Male",1,EEA only,"Patients with confirmed multiple sclerosis (MS), with worse prognosis given the higher disease activity, in productive age between 18 and 60 years, with EDSS<5, who at the time of investigation are on baseline therapy of the disease for at least 3 months","[""Diseases [C] - Nervous System Diseases [C10]""]",Therapeutic exploratory (Phase II),"Rybelsus 3 mg tablets, Trulicity 0.75 mg solution for injection in pre-filled pen, Rybelsus 7 mg tablets, Rybelsus 14 mg tablets",Primary endpoint: Annualized change in brain volume and gray matter volume. Serum neurofilament L level.,"Secondary end points: Insulin sensitivity through ISI Cederholm, ISI Matsuda, HOMA-IR and HOMA-IR2.  Scores in Symbol Digit Modalities Test (SDMT) and Stroop Test.",07/11/2024,N/A,N/A,N/A,No,Comenius University Bratislava,Educational Institution,07/11/2024